



DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of Health
Freedom of Information Office
Building 31, Room 5B-35
31 Center Drive, MSC 2107
Bethesda, Maryland 20892-2107
phone: (301) 496-5633
fax: (301) 402-4541

Via Email: foia@americanoversight.org

December 10, 2021

Austin Evers
American Oversight
1030 15th Street NW, B255
Washington, DC 20005

Re: NIH FOIA Case No.: 53694; American Oversight v. NIH, 20-cv-01063

Dear Mr. Evers:

This is a complete response to the third of several Freedom of Information Act (FOIA) requests that are the subject of the Complaint filed in American Oversight v. NIH, 20-cv-01063, now pending in the U.S. District Court for the District of Columbia. Your FOIA request 53694, dated March 5, 2020, was received by the National Institutes of Health (NIH) on the same day.

You requested all email communications between Dr. Fauci or anyone serving as White House Liaison or agency point of contact for the coronavirus task force, and the following Executive Office of the President officials: Mike Pence, Robert O'Brien, Matthew Pottinger, Robert Blair, Joseph Grogan, Christopher Liddell, Larry Kudlow, Deborah Birx, Katie Miller and Kelvin Droegemeier.

In response to your request, we identified 312 responsive pages. I have determined to withhold portions of the enclosed pages under FOIA exemptions (b)(3)(a), (b)(4), (b)(5), (b)(5) – Presidential Communications Privilege, and (b)(6). The information being withheld is protected from release pursuant to Exemptions 5, and 6 of the FOIA, 5 U.S.C. § 552 (b)(5) and (b)(6); and sections 5.31(e), (f) of the HHS FOIA Regulations, 45 CFR Part 5. Exemption 3 incorporates nondisclosure provisions that are contained in other federal statutes. In this case, Exemption 3 incorporates 42 USC 247d-6b(c)(3)(B) and (d) which prohibits federal agencies from disclosing certain information regarding the national stockpile. Exemption 4 protects from disclosure trade secrets and commercial or financial information that is privileged and confidential. Exemption 5 permits the withholding of internal government records which are pre-decisional and contain staff advice, opinion, and recommendations, as well as documents solicited and received by the President or his immediate White House advisers who have broad and significant responsibility for investigating and formulating the advice to be given to the President. Exemption 6 permits the withholding of privacy information, the release of which would constitute a clearly unwarranted invasion of personal privacy.

Please direct any questions regarding this response to Amy Powell of the Department of Justice, at Amy.Powell@usdoj.gov.

Sincerely,

for
Gorka Garcia-Malene
Freedom of Information Officer, NIH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 17:52:36 +0000
To: Policy Coordinator; (b) (6) (OS/IOS); Blair, Robert; Pottinger, Matthew F. EOP/WHO; Redfield, Robert R. (CDC/OD) (b) (6); (b) (6); Kan, Derek T. EOP/OMB; (b) (6); Liddell, Christopher P. EOP/WHO; Grogan, Joseph
Cc: Pataki, Tim A. EOP/WHO; Williams, Michael B. EOP/WHO; Hoelscher, Douglas L. EOP/WHO; McKenna, Michael A. EOP/WHO; Kadlec, Robert (OS/ASPR/IO); Kellogg, Joseph Keith K. Jr. EOP/OVP; McGowan, Robert (Kyle) (CDC/OD/OCS); Harrison, Brian (HHS/IOS); Ruggiero, Anthony J. EOP/NSC; Ferro, Phil J. EOP/NSC; FERRARA, WILLIAM; Cetron, Marty (CDC/DDID/NCEZID/DGMQ); Mango, Paul (HHS/IOS)
Subject: RE: FYA: (b) (5)

NIAID/NIH concurs

From: Policy Coordinator <PolicyCoordinator@who.eop.gov>
Sent: Sunday, February 2, 2020 12:30 PM
To: (b) (6) (OS/IOS) (b) (6); Blair, Robert <(b) (6)>; Pottinger, Matthew F. EOP/WHO <(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); (b) (6) (b) (6); Kan, Derek T. EOP/OMB (b) (6); Liddell, Christopher P. EOP/WHO <(b) (6)>; Grogan, Joseph (b) (6)>
Cc: Policy Coordinator <PolicyCoordinator@who.eop.gov>; Pataki, Tim A. EOP/WHO <(b) (6)>; Williams, Michael B. EOP/WHO (b) (6); Hoelscher, Douglas L. EOP/WHO (b) (6); McKenna, Michael A. EOP/WHO (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Kellogg, Joseph Keith K. Jr. EOP/OVP (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Ruggiero, Anthony J. EOP/NSC (b) (6); Ferro, Phil J. EOP/NSC <(b) (6)>; FERRARA, WILLIAM <(b) (6)>; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b) (6); Mango, Paul (HHS/IOS) (b) (6)>
Subject: FYA: (b) (5)

Members of the Coronavirus Task Force:

(b) (5)

We plan to formalize this plan at **1:00 PM today**, so please reply-all immediately if you have concerns.

NOTE: This is deliberative information and **should not be shared externally at this time**. Beginning at 1:00 PM, IGA, OPL, and OLA will begin coordinated engagement with the outside stakeholders. Please contact Tim Pataki or Doug Hoelscher (copied) if you have questions about this engagement.

Thank you,
Policy Coordinator

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 16:03:47 +0000
To: Ferro, Phil J. EOP/NSC (b) (6) (OS/IOS); AS2KTC; Biegun, Stephen E; Bigley, Mark C. EOP/OMB; Blair, Robert B. EOP/WHO; Harrison, Brian (HHS/IOS); Butterfield, Nicholas W. EOP/WHO; Campana, Alexandra D. EOP/WHO; Cetron, Marty (CDC/DDID/NCEZID/DGMQ); Chafin, Kelly B. EOP/NSC; Conant, Ann M. EOP/OMB; Conley, Sean P. CDR USN WHMO/WHMU; Conrad, Patricia (NIH/NIAID) [E]; Davis, May M. EOP/WHO; Ditto, Jessica E. EOP/WHO; DL Chief of Staff Office; (b) (6); Duffey, Michael P. EOP/OMB; Eisenberg, John A. EOP/WHO; Fabina, Lauren C. EOP/NSC; Grogan, Joseph J. EOP/WHO; Hemme, Jake W. EOP/NSC; Hennessey, Millicent S. EOP/NSC; Hoelscher, Douglas L. EOP/WHO; Kan, Derek T. EOP/OMB; (b) (6); Liddell, Christopher P. EOP/WHO; Miller, Julie L. EOP/OMB; Mulvaney, Mick M. EOP/WHO; OS Saleses, Robert; Pataki, Tim A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; Riggs, Charlotte R. EOP/WHO; Redfield, Robert R. (CDC/OD); Kadlec, Robert (OS/ASPR/IO); Ruggiero, Anthony J. EOP/NSC; Scher, Adam A. EOP/OMB; Shellooe, Ryan P. EOP/NSC; Sinclair, Michael R. EOP/NSC; Szabat, Joel (OST); Troye, Olivia EOP/NSC; Williams, Michael B. EOP/WHO; Woolfolk, Jon J. EOP/OVP
Subject: RE: nCoV WHTF Call Today February 15, 12:00-1:00 P.M.

Sorry, Phil, but when is the WHTF call today (Saturday)? Is it 12:00 noon or 1:00 PM?

From: Ferro, Phil J. EOP/NSC (b) (6) >
Sent: Saturday, February 15, 2020 9:43 AM
To: (b) (6) (OS/IOS) (b) (6) >; (b) (6) (b) (6); Biegun, Stephen E (b) (6) >; Bigley, Mark C. EOP/OMB <(b) (6)>; Blair, Robert B. EOP/WHO (b) (6) >; Harrison, Brian (HHS/IOS) (b) (6) >; Butterfield, Nicholas W. EOP/WHO (b) (6) >; Campana, Alexandra D. EOP/WHO (b) (6) >; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b) (6) >; Chafin, Kelly B. EOP/NSC (b) (6); Conant, Ann M. EOP/OMB (b) (6) >; Conley, Sean P. CDR USN WHMO/WHMU (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Davis, May M. EOP/WHO (b) (6) >; Ditto, Jessica E. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; (b) (6) (b) (6); Duffey, Michael P. EOP/OMB (b) (6); Eisenberg, John A. EOP/WHO <(b) (6)>; Fabina, Lauren C. EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Grogan, Joseph J. EOP/WHO <(b) (6)>; Hemme, Jake W. EOP/NSC (b) (6); Hennessey, Millicent S. EOP/NSC (b) (6) >; Hoelscher, Douglas L. EOP/WHO (b) (6) >; Kan, Derek T. EOP/OMB (b) (6) >; Liddell, Christopher P. EOP/WHO (b) (6) >; Miller, Julie L. EOP/OMB <(b) (6)>; Mulvaney, Mick M. EOP/WHO <(b) (6)>; OS Saleses, Robert (b) (6); Pataki, Tim A. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); Riggs, Charlotte R. EOP/WHO (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Kadlec, Robert (OS/ASPR/IO) <(b) (6)>; Ruggiero, Anthony J. EOP/NSC

(b) (6); Scher, Adam A. EOP/OMB (b) (6)
Shellooe, Ryan P. EOP/NSC (b) (6); Sinclair, Michael R. EOP/NSC
(b) (6); Szabat, Joel (OST) <(b) (6)>; Troye, Olivia EOP/NSC
(b) (6) Williams, Michael B. EOP/WHO <(b) (6)>;
Woolfolk, Jon J. EOP/OVP <(b) (6)>
Subject: RE: nCoV WHTF Call Today February 15, 12:00-1:00 P.M.

WHTF,

Sincere Apologies for multiple messages.

The time of the call is from 12:00-1:00. The body of the previous email stated 1:00-2:00 that is incorrect, please find the corrected information below.

Best Regards,

Phil

Good Morning WHTF,

Per the request of several TF members, there will be a **White House Task Force on Coronavirus UNCLASSIFIED CONFERENCE CALL TODAY, Saturday, February 15, 2020, from 12:00 – 1:00 p.m.** The requested participation is **Task Force Member ONLY**.

Please find attached the agenda for the call.

In order to access the conference as a participant, dial the number below and enter the Participant Code:

Participant Dial-In: (b) (6)

Participant Code: (b) (6)

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council

(b) (6) (O) (b) (6) (cell)
(b) (6)

From: Ferro, Phil J. EOP/NSC (b) (6)>
Sent: Saturday, February 15, 2020 9:32 AM
To: (b) (6) (OS/IOS) (b) (6)>; (b) (6)<(b) (6)>; Biegun, Stephen E
(b) (6)>; Bigley, Mark C. EOP/OMB <(b) (6)>; Blair, Robert B.
EOP/WHO <(b) (6)>; Brian Harrison (b) (6)
(b) (6)>; Butterfield, Nicholas W. EOP/WHO (b) (6);
Campana, Alexandra D. EOP/WHO (b) (6)>; Cetron, Marty
(CDC/DDID/NCEZID/DGMQ) (b) (6)>; Chafin, Kelly B. EOP/NSC
(b) (6)>; Conant, Ann M. EOP/OMB (b) (6)>; Conley,
Sean P. CDR USN WHMO/WHMU (b) (6)>; conradpa (b) (6)

(b) (6); Davis, May M. EOP/WHO < (b) (6)>; Ditto, Jessica E. EOP/WHO (b) (6)>; DL Chief of Staff Office (b) (6)>; donna.o'berry (b) (6)>; Duffey, Michael P. EOP/OMB (b) (6)>; Eisenberg, John A. EOP/WHO < (b) (6)>; Fabina, Lauren C. EOP/NSC (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Ferro, Phil J. EOP/NSC (b) (6)>; Grogan, Joseph J. EOP/WHO (b) (6)>; Hemme, Jake W. EOP/NSC (b) (6)>; Hennessey, Millicent S. EOP/NSC (b) (6)>; Hoelscher, Douglas L. EOP/WHO (b) (6)>; Kan, Derek T. EOP/OMB (b) (6)>; Liddell, Christopher P. EOP/WHO (b) (6)>; Miller, Julie L. EOP/OMB < (b) (6)>; Mulvaney, Mick M. EOP/WHO (b) (6)>; OS Saleses, Robert (b) (6)>; Pataki, Tim A. EOP/WHO (b) (6)>; Pottinger, Matthew F. EOP/WHO (b) (6)>; Riggs, Charlotte R. EOP/WHO (b) (6)>; Robert R. Redfield (b) (6)>; Ruggiero, Anthony J. EOP/NSC < (b) (6)>; Scher, Adam A. EOP/OMB (b) (6)>; Shellooe, Ryan P. EOP/NSC (b) (6)>; Sinclair, Michael R. EOP/NSC (b) (6)>; Szabat, Joel (OST) (b) (6)>; Troye, Olivia EOP/NSC (b) (6)>; Williams, Michael B. EOP/WHO (b) (6)>; Woolfolk, Jon J. EOP/OVP (b) (6)>

Subject: nCoV WHTF Call Today February 15, 12:00-1:00 P.M.

Good Morning WHTF,

Per the request of several TF members, there will be a **White House Task Force on Coronavirus UNCLASSIFIED CONFERENCE CALL TODAY, Saturday, February 15, 2020, from 1:00 – 2:00 p.m.** The requested participation is **Task Force Member ONLY.**

Please find attached the agenda for the call.

In order to access the conference as a participant, dial the number below and enter the Participant Code:

Participant Dial-In: (b) (6)

Participant Code: (b) (6)

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council

(b) (6) (O) (b) (6) (cell)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:38:30 +0000
To: Ferro, Phil J. EOP/NSC; (b) (6)
 Droegemeier, Kelvin K. EOP/OSTP; Daravi, Kamran S. EOP/WHO; Grewe, Brenda L. EOP/NSC; Deere, Judd P. EOP/WHO; Ditto, Jessica E. EOP/WHO; Yanick, Brittany M. EOP/WHO; Hayes, Bradley F. EOP/OMB; Smith, Gregory L. EOP/WHO; Doster, Kim M. EOP/OSTP; Gastfriend, Daniel Z. EOP/OMB; Baum, Kristina R. EOP/OSTP; Bicket, Mark C. EOP/OSTP; Blair, Robert B. EOP/WHO; Bonyun, Sean C. EOP/OSTP; Butterfield, Nicholas W. EOP/WHO; Campana, Alexandra D. EOP/WHO; Grogan, Joseph J. EOP/WHO; Hudson, Renee R. EOP/WHO; Jack, Brian T. EOP/WHO; Kan, Derek T. EOP/OMB; Kratsios, Michael J. EOP/OSTP; Lattimore, Tracie B. EOP/OSTP; Lin, Merry S. EOP/WHO; McKenna, Michael A. EOP/WHO; Merkel, Theo W. EOP/WHO; Miles, Aaron R. EOP/OSTP; Olmem, Andrew J. EOP/WHO; Pataki, Tim A. EOP/WHO; Ray, Paul J. EOP/OMB; Wong, Anna W. EOP/CEA; Walters, William; Bonner, Maria K. EOP/WHO; Sinclair, Michael R. EOP/NSC; DL NSC WMD; Cetron, Marty (CDC/DDID/NCEZID/DGMQ); (b) (6); Naar, Alex (FAA); Firoved, Aaron; Limage, Julia; Seffel, Gary A. EOP/NSC; Redfield, Robert R. (CDC/OD); Waterman, Paige E. EOP/OSTP; Waterman, Elijah J. EOP/NSC; Watson, Ian D. EOP/OSTP; (b) (6) OSD OUSD POLICY (USA); Marston, Hilary (NIH/NIAID) [E]; Marks, Peter (FDA/CBER); Mair, Michael (FDA/OC); Kadlec, Robert (OS/ASPR/IO) (b) (6) Grigsby, Garrett (HHS/OS/OGA); Disbrow, Gary (OS/ASPR/BARDA); (b) (6)
 (b) (6)
 (b) (6); Redd, John (OS/ASPR/SPPR); (b) (6) CIV (USA); (b) (6) OSD OUSD POLICY (USA); (b) (6); Liebschutz, Jennifer E. EOP/OMB; Farquharson, Christine E. EOP/OMB (b) (6); Kendra Chittenden; Boney, Virginia M. EOP/WHO; Tully, Ryan M. EOP/NSC (b) (6); Christ, Katelyn E. EOP/NSC; Weinberger, Collin (OS/OGA); Landrum, Ryan P. EOP/NSC; Rault, Nick M. EOP/NSC; Hanna, Cory M. EOP/NSC; Burton, Nicholas S. EOP/OMB; Garufi, Marc A. EOP/OMB; Mroz, Sara K. EOP/NSC; Wade, Dave S. EOP/NSC; Troye, Olivia EOP/NSC; (b) (6)
 (b) (6) McGowan, Robert (Kyle) (CDC/OD/OCS); Lowry, Patrick J. EOP/NSC; Cartin, Josh M. EOP/NSC; Kanapathy, Ivan J. EOP/NSC; Elvander, Erika (OS/OGA); Cavanaugh, Brian J. EOP/NSC; (b) (6); Thomas, Gloria (HHS/OS/OGA); Butler, Jay C. (CDC/DDID/OD); Bright, Rick (OS/ASPR/BARDA); Ruggiero, Anthony J. EOP/NSC; Brett Armstrong - D1R; (b) (6) (b) (6); Hassell, David (Chris) (OS/ASPR/IO); McMillin, Virginia D. EOP/WHO; Telle, Adam R. EOP/WHO; Sugarman, AJ J. EOP/WHO; Planning, David M. EOP/WHO; Feddersen, Brett (FAA); (b) (6); Greene Richard S. (GH/HIDN) [USAID] (b) (6); Baehr, James S. EOP/WHO; Magrino, Christopher; (b) (6); Tobin, Elizabeth D. EOP/NSC; Jonas, Seth H. EOP/NSC; (b) (6); Music, Chris G. EOP/OMB; (b) (6); Burris, Meghan K. EOP/WHO; Henning, Alexa A. EOP/WHO; Daravi, Roma S. EOP/WHO; Horstman, John H. EOP/WHO (b) (6) OSD OUSD POLICY (USA); Wilson, John Mark M. EOP/NSC; Martin, Michael E. EOP/NSC (b) (6) (b) (6); Sadat, Mir H. EOP/NSC; Gray, Alexander B. EOP/NSC; Rubini, Jeffrey H. EOP/NSC (b) (6) OSD OUSD POLICY (USA); Ulliot, John L. EOP/NSC; Stuft, Julie M. EOP/NSC; Stimson, Brian (HHS/OGC); Browne, Lisa Y. EOP/NSC; Davis, May M. EOP/WHO; Lekan, Scott (ACF); Chafin, Kelly B. EOP/NSC; Bailey, Drew M. EOP/OMB; Thallam, Satya P. EOP/OMB; Allen, Ronald G. EOP/NSC; Schuchat, Anne MD (CDC/OD); Bain, Ally P. EOP/OMB; Schmoyer, Michael (OS/ONS); Lepore, Loretta (CDC/OD/OCS); (b) (6); Hinton, Denise (FDA/OC); Champagne, Joshua D. EOP/NSC; (b) (6) OSD OUSD POLICY (USA); DL Chief of Staff Office (b) (6); Ash, Deborah J. EOP/NSC; Reilly, Tom M. EOP/OMB; Havranek, John; (b) (6); FORET, VERNON T; Ellis, Michael J. EOP/WHO; Blue, Matthew (ODAG); Decker, Matthew G. EOP/NSC; JACKSTA, LINDA L (b) (6); Carter, Hillary H.

EOP/NSC; Galkowski, James J. EOP/WHO; (b) (6); Doyle, Emma K. EOP/WHO; Lason, Adam J. EOP/NSC; (b) (6); (b) (6) (Geneva); Bibo, David; (b) (6); (b) (6) OSD OUSD POLICY (USA); Gile, Robertson S. EOP/NSC; Berrios, Isalen (CTR) (b) (6); Dozor, Joshua; (b) (6); Williams, Michael B. EOP/WHO; Harvard, Hope M. EOP/WHO; (b) (6)

Subject: RE: FLASH Clearance Needed Regarding DIAMOND PRINCESS

Fauci/NIAID clears

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ferro, Phil J. EOP/NSC (b) (6)
Sent: Monday, February 17, 2020 11:54 AM
To: (b) (6); Droegemeier, Kelvin K. EOP/OSTP <(b) (6)>; Daravi, Kamran S. EOP/WHO <(b) (6)>; Grewe, Brenda L. EOP/NSC <(b) (6)>; Deere, Judd P. EOP/WHO <(b) (6)>; Ditto, Jessica E. EOP/WHO <(b) (6)>; Yanick, Brittany M. EOP/WHO <(b) (6)>; Hayes, Bradley F. EOP/OMB <(b) (6)>; Smith, Gregory L. EOP/WHO <(b) (6)>; Doster, Kim M. EOP/OSTP <(b) (6)>; Gastfriend, Daniel Z. EOP/OMB <(b) (6)>; Baum, Kristina R. EOP/OSTP <(b) (6)>; Bicket, Mark C. EOP/OSTP <(b) (6)>; Blair, Robert B. EOP/WHO <(b) (6)>; Bonyun, Sean C. EOP/OSTP <(b) (6)>; Butterfield, Nicholas W. EOP/WHO <(b) (6)>; Campana, Alexandra D. EOP/WHO <(b) (6)>; Grogan, Joseph J. EOP/WHO <(b) (6)>; Hudson, Renee R. EOP/WHO <(b) (6)>; Jack, Brian T. EOP/WHO <(b) (6)>; Kan, Derek T. EOP/OMB <(b) (6)>; Kratsios, Michael J. EOP/OSTP <(b) (6)>; Lattimore, Tracie B. EOP/OSTP <(b) (6)>; Lin, Merry S. EOP/WHO <(b) (6)>; McKenna, Michael A. EOP/WHO <(b) (6)>; Merkel, Theo W. EOP/WHO <(b) (6)>; Miles, Aaron R. EOP/OSTP

(b) (6); Olmem, Andrew J. EOP/WHO (b) (6)
Pataki, Tim A. EOP/WHO < (b) (6); Ray, Paul J. EOP/OMB
(b) (6); Wong, Anna W. EOP/CEA (b) (6) Walters, William
(b) (6); Bonner, Maria K. EOP/WHO (b) (6); Sinclair,
Michael R. EOP/NSC (b) (6) (b) (6) Cetron,
Marty (CDC/DDID/NCEZID/DGMQ) (b) (6)
Naar, Alex (FAA) (b) (6); Firoved, Aaron
(b) (6); Limage, Julia (b) (6); Seffel, Gary A. EOP/NSC
(b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Waterman, Paige E.
EOP/OSTP (b) (6); Waterman, Elijah J. EOP/NSC
(b) (6); Watson, Ian D. EOP/OSTP (b) (6); (b) (6)
OSD OUSD POLICY (USA) (b) (6); Fauci, Anthony (NIH/NIAID)
[E] (b) (6); Marston, Hilary (NIH/NIAID) [E] < (b) (6); Marks, Peter
(FDA/CBER) (b) (6) Mair, Michael (FDA/OC) (b) (6); Kadlec,
Robert (OS/ASPR/IO) (b) (6); Grigsby, Garrett
(HHS/OS/OGA) (b) (6); Disbrow, Gary (OS/ASPR/BARDA)
(b) (6); (b) (6) < (b) (6); (b) (6)
(b) (6); (b) (6) < (b) (6); (b) (6)

Redd, John
(OS/ASPR/SPPR) (b) (6); (b) (6) (USA)
(b) (6); (b) (6) OSD OUSD POLICY (USA)
(b) (6); (b) (6) (b) (6); Liebschutz, Jennifer E.
EOP/OMB (b) (6) Farquharson, Christine E. EOP/OMB
(b) (6); Kendra Chittenden
(b) (6) Boney, Virginia M. EOP/WHO < (b) (6); Tully, Ryan
M. EOP/NSC (b) (6); (b) (6) (b) (6); Christ, Katelyn E.
EOP/NSC < (b) (6); Weinberger, Collin (OS/OGA) (b) (6);
Landrum, Ryan P. EOP/NSC (b) (6); Rault, Nick M. EOP/NSC
< (b) (6); Hanna, Cory M. EOP/NSC (b) (6); Burton,
Nicholas S. EOP/OMB (b) (6); Garufi, Marc A. EOP/OMB
(b) (6) Mroz, Sara K. EOP/NSC (b) (6); Wade, Dave S.
EOP/NSC (b) (6); Troye, Olivia EOP/NSC (b) (6); (b) (6)
(b) (6) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Lowry, Patrick
J. EOP/NSC < (b) (6); Cartin, Josh M. EOP/NSC (b) (6);
Kanapathy, Ivan J. EOP/NSC (b) (6); Elvander, Erika (OS/OGA)
(b) (6); Cavanaugh, Brian J. EOP/NSC < (b) (6); (b) (6)
(b) (6) (b) (6); Thomas, Gloria (HHS/OS/OGA) < (b) (6); Butler,
Jay C. (CDC/DDID/OD) (b) (6); Bright, Rick (OS/ASPR/BARDA) < (b) (6) Ruggiero,
Anthony J. EOP/NSC (b) (6); Brett Armstrong - D1R
(b) (6); (b) (6) (b) (6);
(b) (6) (b) (6); Hassell, David (Chris) (OS/ASPR/IO)
(b) (6); McMillin, Virginia D. EOP/WHO (b) (6); Telle,
Adam R. EOP/WHO (b) (6); Sugarman, AJ J. EOP/WHO
(b) (6); Planning, David M. EOP/WHO < (b) (6);
Feddersen, Brett (FAA) (b) (6); (b) (6) (b) (6); Greene
Richard S. (GH/HIDN) [USAID] (b) (6) Baehr, James S. EOP/WHO

(b) (6); Magrino, Christopher < (b) (6);
(b) (6) Tobin, Elizabeth D. EOP/NSC
(b) (6); Jonas, Seth H. EOP/NSC (b) (6); (b) (6)
(b) (6); Music, Chris G. EOP/OMB (b) (6); (b) (6)
(b) (6); Burris, Meghan K. EOP/WHO (b) (6); Henning, Alexa A.
EOP/WHO (b) (6); Daravi, Roma S. EOP/WHO
< (b) (6); Horstman, John H. EOP/WHO < (b) (6);
(b) (6) OSD OUSD POLICY (USA) (b) (6); Wilson,
John Mark M. EOP/NSC < (b) (6); Martin, Michael E. EOP/NSC
(b) (6) S60.Policy@dot.gov; Sadat, Mir H. EOP/NSC
(b) (6) Gray, Alexander B. EOP/NSC (b) (6) Rubini,
Jeffrey H. EOP/NSC (b) (6); (b) (6) OSD OUSD POLICY (USA)
(b) (6); Ulyot, John L. EOP/NSC < (b) (6); Stuftt,
Julie M. EOP/NSC < (b) (6), Brian (HHS/OGC) (b) (6)
Browne, Lisa Y. EOP/NSC (b) (6); Davis, May M. EOP/WHO
(b) (6); Lekan, Scott (ACF) (b) (6); Chafin, Kelly B. EOP/NSC
(b) (6); Bailey, Drew M. EOP/OMB < (b) (6); Thallam,
Satya P. EOP/OMB (b) (6); Allen, Ronald G. EOP/NSC
(b) (6); Schuchat, Anne MD (CDC/OD) < (b) (6) Bain, Ally P.
EOP/OMB (b) (6); Schmoyer, Michael (OS/ONS)
(b) (6); Lepore, Loretta (CDC/OD/OCS) (b) (6);
(b) (6) Hinton, Denise (FDA/OC) (b) (6); Champagne,
Joshua D. EOP/NSC (b) (6); (b) (6)
< (b) (6); (b) (6) OSD OUSD POLICY (USA)
(b) (6); DL Chief of Staff Office (b) (6)
(b) (6); Ash, Deborah J. EOP/NSC < (b) (6); Reilly,
Tom M. EOP/OMB (b) (6); Havranek, John
(b) (6); (b) (6) (b) (6); FORET, VERNON T
(b) (6); Ellis, Michael J. EOP/WHO (b) (6); Blue,
Matthew (ODAG) (b) (6); Decker, Matthew G. EOP/NSC
(b) (6); JACKSTA, LINDA L (b) (6); (b) (6)
(b) (6); Carter, Hillary H. EOP/NSC (b) (6) Galkowski, James
J. EOP/WHO (b) (6); (b) (6)
(b) (6); Doyle, Emma K. EOP/WHO (b) (6); Lason, Adam
J. EOP/NSC < (b) (6); (b) (6) (Geneva)
< (b) (6); Bibo, David (b) (6); (b) (6) OSD OUSD
POLICY (USA) (b) (6); Gile, Robertson S. EOP/NSC
(b) (6); Berrios, Isalen (CTR) (b) (6);
(b) (6); Dozor, Joshua (b) (6); (b) (6)
(b) (6); (b) (6) < (b) (6); (b) (6)
(b) (6); Williams, Michael B. EOP/WHO (b) (6)
Harvard, Hope M. EOP/WHO (b) (6); (b) (6) (b) (6)
>

Subject: FLASH Clearance Needed Regarding DIAMOND PRINCESS

Importance: High

Colleagues,

The attached document has already been circulated and departments and agencies have already provided comments and edits. Please provide critical edits only and note at what level that your department or agency is clearing the document.

DHS—please provide justification for what we understand is your [REDACTED] (b) (5)

Please provide clearance **NLT 1315 today** in preparation for a WHTF call.

We are very appreciative of your dedication and flexibility regarding this issue.

All the best,

Phil

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council

(b) (6) (O) [REDACTED] (b) (6) (cell)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 00:57:34 +0000
To: Wilson, John Mark M. EOP/NSC; Ferro, Phil J. EOP/NSC; (b) (6) (OS/IOS); (b) (6); Biegun, Stephen E; Bigley, Mark C. EOP/OMB; Blair, Robert B. EOP/WHO; Harrison, Brian (HHS/IOS); Butterfield, Nicholas W. EOP/WHO; Campana, Alexandra D. EOP/WHO; Cetron, Marty (CDC/DDID/NCEZID/DGMQ); Chafin, Kelly B. EOP/NSC; Conant, Ann M. EOP/OMB; Conley, Sean P. CDR USN WHMO/WHMU; Conrad, Patricia (NIH/NIAID) [E]; Davis, May M. EOP/WHO; Ditto, Jessica E. EOP/WHO; DL Chief of Staff Office; donna.o'berry (b) (6); Duffey, Michael P. EOP/OMB; Eisenberg, John A. EOP/WHO; Fabina, Lauren C. EOP/NSC; Grogan, Joseph J. EOP/WHO; Hemme, Jake W. EOP/NSC; Hennessey, Millicent S. EOP/NSC; Hoelscher, Douglas L. EOP/WHO; Kan, Derek T. EOP/OMB (b) (6); Liddell, Christopher P. EOP/WHO; Miller, Julie L. EOP/OMB; Mulvaney, Mick M. EOP/WHO; OS Saleses, Robert; Pataki, Tim A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; Riggs, Charlotte R. EOP/WHO; Redfield, Robert R. (CDC/OD); Kadlec, Robert (OS/ASPR/IO); Ruggiero, Anthony J. EOP/NSC; Scher, Adam A. EOP/OMB; Shellooe, Ryan P. EOP/NSC; Sinclair, Michael R. EOP/NSC; Szabat, Joel (OST); Tignor, Beth (HHS/IOS); Troye, Olivia EOP/NSC; Ulyot, John L. EOP/NSC; Williams, Michael B. EOP/WHO; Woolfolk, Jon J. EOP/OVP
Subject: RE: PROPOSED TRAVEL ALERT FOR CRUISE SHIPS - Clearance Requested NLT 7:30 P.M. this Evening

Fauci clears with minor edit in red

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Wilson, John Mark M. EOP/NSC (b) (6)
Sent: Wednesday, February 19, 2020 7:14 PM
To: Ferro, Phil J. EOP/NSC (b) (6) (OS/IOS) (b) (6); (b) (6); (b) (6); Biegun, Stephen E <(b) (6)>; Bigley, Mark C. EOP/OMB (b) (6); Blair, Robert B. EOP/WHO (b) (6); Harrison, Brian (HHS/IOS) <(b) (6)>; Butterfield, Nicholas W. EOP/WHO (b) (6); Campana, Alexandra D. EOP/WHO (b) (6); Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b) (6); Chafin, Kelly B. EOP/NSC <(b) (6)>; Conant, Ann M. EOP/OMB

(b) (6); Conley, Sean P. CDR USN WHMO/WHMU (b) (6);
Conrad, Patricia (NIH/NIAID) [E] (b) (6); Davis, May M. EOP/WHO
(b) (6); Ditto, Jessica E. EOP/WHO (b) (6); DL Chief of
Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; donna.o'berry (b) (6)
(b) (6); Duffey, Michael P. EOP/OMB (b) (6); Eisenberg,
John A. EOP/WHO (b) (6); Fabina, Lauren C. EOP/NSC
(b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Grogan,
Joseph J. EOP/WHO (b) (6); Hemme, Jake W. EOP/NSC
(b) (6); Hennessey, Millicent S. EOP/NSC
(b) (6); Hoelscher, Douglas L. EOP/WHO
(b) (6); Kan, Derek T. EOP/OMB (b) (6);
(b) (6); Liddell, Christopher P. EOP/WHO
(b) (6); Miller, Julie L. EOP/OMB (b) (6)
Mulvaney, Mick M. EOP/WHO (b) (6); OS Salesses, Robert
(b) (6); Pataki, Tim A. EOP/WHO <(b) (6);
Pottinger, Matthew F. EOP/WHO (b) (6); Riggs, Charlotte R. EOP/WHO
(b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Kadlec, Robert
(OS/ASPR/IO) (b) (6); Ruggiero, Anthony J. EOP/NSC
(b) (6); Scher, Adam A. EOP/OMB <(b) (6);
Shellooe, Ryan P. EOP/NSC (b) (6); Sinclair, Michael R. EOP/NSC
(b) (6); Szabat, Joel (OST) (b) (6); Tignor, Beth (HHS/IOS)
(b) (6); Troye, Olivia EOP/NSC (b) (6); Ulliyot, John L. EOP/NSC
(b) (6); Williams, Michael B. EOP/WHO <(b) (6);
Woolfolk, Jon J. EOP/OVP <(b) (6)

Subject: RE: PROPOSED TRAVEL ALERT FOR CRUISE SHIPS - Clearance Requested NLT 7:30 P.M. this Evening

From NSC Stratcom Clear with suggested edits based upon the guidance received from the TF re: messaging focus



John Mark Wilson
Office of Strategic Communications
National Security Council

(b) (6)
Office (b) (6)
Cell: (b) (6)

From: Ferro, Phil J. EOP/NSC (b) (6) >
Sent: Wednesday, February 19, 2020 5:49 PM
To: (b) (6) (OS/IOS) (b) (6) >; (b) (6) (b) (6) >; Biegun, Stephen E (b) (6) >; Bigley, Mark C. EOP/OMB (b) (6) >; Blair, Robert B. EOP/WHO (b) (6) >; Brian Harrison (b) (6) (b) (6) >; Butterfield, Nicholas W. EOP/WHO < (b) (6) >; Campana, Alexandra D. EOP/WHO (b) (6) >; Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b) (6) Chafin, Kelly B. EOP/NSC (b) (6) >; Conant, Ann M. EOP/OMB (b) (6) >; Conley, Sean P. CDR USN WHMO/WHMU (b) (6) >; conradpa (b) (6) (b) (6) >; Davis, May M. EOP/WHO < (b) (6) >; Ditto, Jessica E. EOP/WHO < (b) (6) >; DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; donna.o'berry (b) (6) (b) (6) >; Duffey, Michael P. EOP/OMB (b) (6) >; Eisenberg, John A. EOP/WHO < (b) (6) >; Fabina, Lauren C. EOP/NSC (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) < (b) (6) >; Ferro, Phil J. EOP/NSC (b) (6) >; Grogan, Joseph J. EOP/WHO (b) (6) >; Hemme, Jake W. EOP/NSC

(b) (6); Hennessey, Millicent S. EOP/NSC
(b) (6); Hoelscher, Douglas L. EOP/WHO
(b) (6); Kan, Derek T. EOP/OMB (b) (6);
(b) (6); Liddell, Christopher P. EOP/WHO
(b) (6); Miller, Julie L. EOP/OMB (b) (6);
Mulvaney, Mick M. EOP/WHO (b) (6); OS Salesses, Robert
(b) (6); Pataki, Tim A. EOP/WHO (b) (6);
Pottinger, Matthew F. EOP/WHO < (b) (6); Riggs, Charlotte R. EOP/WHO
(b) (6); Robert R. Redfield (b) (6);
(b) (6); Ruggiero, Anthony J. EOP/NSC < (b) (6); Scher,
Adam A. EOP/OMB (b) (6); Shellooe, Ryan P. EOP/NSC
(b) (6); Sinclair, Michael R. EOP/NSC (b) (6);
Szabat, Joel (OST) < (b) (6); Tignor, Beth (HHS/IOS) (b) (6); Troye, Olivia
EOP/NSC (b) (6); Ulyot, John L. EOP/NSC < (b) (6);
Williams, Michael B. EOP/WHO < (b) (6); Wilson, John Mark M. EOP/NSC
(b) (6); Woolfolk, Jon J. EOP/OVP (b) (6)

Subject: PROPOSED TRAVEL ALERT FOR CRUISE SHIPS - Clearance Requested NLT 7:30 P.M. this Evening
Importance: High

Dear WHTF,

Please find below the proposed travel alert for cruise ships. We respectfully request clearance by **7:30 p.m. this evening.**

State is targeting a rollout time of 11:00 a.m. tomorrow NSC is coordinating with State, DHS and NSC elements to conduct industry, Hill and press engagement.

Best Regards,

Phil

(b) (5)

(b) (5)

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council

(b) (6) (O) (b) (6) (cell)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 17:54:47 +0000
To: Fabina, Lauren C. EOP/NSC; (b) (6)
(b) (6) Droegemeier, Kelvin K. EOP/OSTP; Daravi, Kamran S. EOP/WHO; Grewe, Brenda L. EOP/NSC; Deere, Judd P. EOP/WHO; Ditto, Jessica E. EOP/WHO; Yanick, Brittany M. EOP/WHO; Hayes, Bradley F. EOP/OMB; Smith, Gregory L. EOP/WHO; Doster, Kim M. EOP/OSTP; Gastfriend, Daniel Z. EOP/OMB; Baum, Kristina R. EOP/OSTP; Bicket, Mark C. EOP/OSTP; Blair, Robert B. EOP/WHO; Bonyun, Sean C. EOP/OSTP; Butterfield, Nicholas W. EOP/WHO; Campana, Alexandra D. EOP/WHO; Grogan, Joseph J. EOP/WHO; Hudson, Renee R. EOP/WHO; Jack, Brian T. EOP/WHO; Kan, Derek T. EOP/OMB; Kratsios, Michael J. EOP/OSTP; Lattimore, Tracie B. EOP/OSTP; Lin, Merry S. EOP/WHO; McKenna, Michael A. EOP/WHO; Merkel, Theo W. EOP/WHO; Miles, Aaron R. EOP/OSTP; Olmem, Andrew J. EOP/WHO; Pataki, Tim A. EOP/WHO; Ray, Paul J. EOP/OMB; Wong, Anna W. EOP/CEA; Walters, William; Bonner, Maria K. EOP/WHO; Sinclair, Michael R. EOP/NSC; (b) (6); Cetron, Marty (CDC/DDID/NCEZID/DGMQ); (b) (6); Naar, Alex (FAA); Firoved, Aaron; Limage, Julia; Seffel, Gary A. EOP/NSC; Redfield, Robert R. (CDC/OD); Waterman, Paige E. EOP/OSTP; Waterman, Elijah J. EOP/NSC; Watson, Ian D. EOP/OSTP; (b) (6) OSD OUSD POLICY (USA); Marston, Hilary (NIH/NIAID) [E]; Marks, Peter (FDA/CBER); Mair, Michael (FDA/OC); Kadlec, Robert (OS/ASPR/IO); (b) (6); Grigsby, Garrett (HHS/OS/OGA); Disbrow, Gary (OS/ASPR/ (b) (6)
(b) (6); Redd, John (OS/ASPR/SPPR); (b) (6) (USA); (b) (6) OSD OUSD POLICY (USA); (b) (6); Liebschutz, Jennifer E. EOP/OMB; Farquharson, Christine E. EOP/OMB; (b) (6); Kendra Chittenden; Boney, Virginia M. EOP/WHO; Tully, Ryan M. EOP/NSC; (b) (6) Christ, Katelyn E. EOP/NSC; Weinberger, Collin (OS/OGA); Landrum, Ryan P. EOP/NSC; Rault, Nick M. EOP/NSC; Hanna, Cory M. EOP/NSC; Burton, Nicholas S. EOP/OMB; Garufi, Marc A. EOP/OMB; Mroz, Sara K. EOP/NSC; Troye, Olivia EOP/NSC; (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS); Lowry, Patrick J. EOP/NSC; Cartin, Josh M. EOP/NSC; Kanapathy, Ivan J. EOP/NSC; Elvander, Erika (OS/OGA); Cavanaugh, Brian J. EOP/NSC; (b) (6); Thomas, Gloria (HHS/OS/OGA); Butler, Jay C. (CDC/DDID/OD); Bright, Rick (OS/ASPR/BARDA); Ruggiero, Anthony J. EOP/NSC; Brett Armstrong - D1R; (b) (6); (b) (6); Hassell, David (Chris) (OS/ASPR/IO); McMillin, Virginia D. EOP/WHO; Telle, Adam R. EOP/WHO; Sugarman, AJ J. EOP/WHO; Planning, David M. EOP/WHO; Feddersen, Brett (FAA); (b) (6); Greene Richard S. (GH/HIDN) [USAID] (b) (6); Baehr, James S. EOP/WHO; Magrino, Christopher; (b) (6); Tobin, Elizabeth D. EOP/NSC; Jonas, Seth H. EOP/NSC; (b) (6); Music, Chris G. EOP/OMB; (b) (6); Burris, Meghan K. EOP/WHO; Henning, Alexa A. EOP/WHO; Daravi, Roma S. EOP/WHO; Horstman, John H. EOP/WHO; (b) (6) OSD OUSD POLICY (USA); Wilson, John Mark M. EOP/NSC; Martin, Michael E. EOP/ (b) (6); S60.Policy@dot.gov; Sadat, Mir H. EOP/NSC; Gray, Alexander B. EOP/NSC; Rubini, Jeffrey H. EOP/NSC; Ulyot, John L. EOP/NSC; Stuftt, Julie M. EOP/NSC; Stimson, Brian (HHS/OGC); Browne, Lisa Y. EOP/NSC; Davis, May M. EOP/WHO; Lekan, Scott (ACF); Chafin, Kelly B. EOP/NSC; Bailey, Drew M. EOP/OMB; Thallam, Satya P. EOP/OMB; Allen, Ronald G. EOP/NSC; Schuchat, Anne MD (CDC/OD); Bain, Ally P. EOP/OMB; Schmoyer, Michael (OS/ONS); Lepore, Loretta (CDC/OD/OCS); Hinton, Denise (FDA/OC); Champagne, Joshua D. EOP/ (b) (6)
(b) (6), (b) (6) OSD OUSD POLICY (USA); DL Chief of Staff Office; (b) (6); Ash, Deborah J. EOP/NSC; Reilly, Tom M. EOP/OMB; Havranek, John; (b) (6); FORET, VERNON T; Ellis, Michael J. EOP/WHO; Blue, Matthew (ODAG); Decker, Matthew G. EOP/NSC; JACKSTA, LINDA L; (b) (6); Carter, Hillary H.

EOP/NSC;Galkowski, James J. EOP/WHO; (b) (6) Doyle, Emma K.
EOP/WHO;Lason, Adam J. EOP/NSC; (b) (6) (b) (6) (Geneva);Bibo,
David;Dorko, Jeffrey;Hughes, William C. (ODAG); (b) (6) OSD OUSD POLICY
(USA); (b) (6); (b) (6) OSD OUSD POLICY
(USA); (b) (6) (Beijing);De La Riva, Etienne EOP/NSC;Morgan, Jameson A. EOP/NSC;Smith,
Jason S. EOP/NSC;Durie, Troy M. EOP/CEA;Chang, William (HHS/OGC); (b) (6)
A;Eisenberg, John A. EOP/WHO;Bai, Sue J. EOP/WHO;Hennessey, Millicent S. EOP/ (b) (6)
(b) (6);Maycock, Brett (OS/ONS); (b) (6)
Subject: RE: FOR REVIEW: Revised - Phases of USG nCoV Response

Fauci concurs with 1 edit. On the bottom of page 2: (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fabina, Lauren C. EOP/NSC (b) (6) >

Sent: Thursday, February 20, 2020 12:29 PM

To: (b) (6)

(b) (6) >; Droegemeier,
Kelvin K. EOP/OSTP (b) (6) >; Daravi, Kamran S. EOP/WHO

(b) (6) >; Grewe, Brenda L. EOP/NSC < (b) (6) >; Deere,
Judd P. EOP/WHO (b) (6); Ditto, Jessica E. EOP/WHO

< (b) (6) >; Yanick, Brittany M. EOP/WHO (b) (6)

Hayes, Bradley F. EOP/OMB (b) (6) >; Smith, Gregory L. EOP/WHO

< (b) (6) >; Doster, Kim M. EOP/OSTP (b) (6)

Gastfriend, Daniel Z. EOP/OMB (b) (6); Baum, Kristina R. EOP/OSTP
(b) (6); Bicket, Mark C. EOP/ (b) (6); Blair,
Robert B. EOP/WHO (b) (6); Bonyun, Sean C. EOP/OSTP
(b) (6); Butterfield, Nicholas W. EOP/WHO
(b) (6); Campana, Alexandra D. EOP/WHO
(b) (6); Grogan, Joseph J. EOP/WHO
(b) (6); Hudson, Renee R. EOP/WHO (b) (6); Jack,
Brian T. EOP/WHO < (b) (6); Kan, Derek T. EOP/OMB
< (b) (6); Kratsios, Michael J. EOP/OSTP (b) (6);
Lattimore, Tracie B. EOP/OSTP < (b) (6) Lin, Merry S. EOP/WHO
(b) (6); McKenna, Michael A. EOP/WHO (b) (6);
Merkel, Theo W. EOP/WHO < (b) (6); Miles, Aaron R. EOP/OSTP
< (b) (6); Olmem, Andrew J. EOP/WHO (b) (6);
Pataki, Tim A. EOP/WHO < (b) (6); Ray, Paul J. EOP/OMB
(b) (6); Wong, Anna W. EOP/CEA (b) (6); (b) (6)
(b) (6) (b) (6); Bonner, Maria K. EOP/WHO < (b) (6);
Sinclair, Michael R. EOP/NSC (b) (6); (b) (6)
Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b) (6); (b) (6)
(b) (6) 'Naar, Alex (FAA)'
(b) (6); 'Firoved, Aaron' (b) (6); 'Limage, Julia'
(b) (6); Seffel, Gary A. EOP/NSC (b) (6); Redfield, Robert R.
(CDC/OD) (b) (6); Waterman, Paige E. EOP/OSTP (b) (6);
Waterman, Elijah J. EOP/NSC (b) (6) Watson, Ian D. EOP/OSTP
(b) (6); (b) (6) OSD OUSD POLICY (USA)'
(b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marston, Hilary
(NIH/NIAID) [E] (b) (6); Marks, Peter (FDA/CBER) (b) (6); Mair,
Michael (FDA/OC) (b) (6); Kadlec, Robert (OS/ASPR/IO)
(b) (6) Grigsby, Garrett
(HHS/OS/OGA) (b) (6); Disbrow, Gary (OS/ASPR/BARDA)
(b) (6); (b) (6) (b) (6); (b) (6)
(b) (6); (b) (6) (b) (6); (b) (6)
>; Redd, John
(OS/ASPR/SPPR) (b) (6); (b) (6) (USA)'
(b) (6) (b) (6) OSD OUSD POLICY (USA)'
(b) (6) (b) (6)' (b) (6); Liebschutz, Jennifer E.
EOP/OMB (b) (6); Farquharson, Christine E. EOP/OMB
< (b) (6)
>; 'Kendra Chittenden' (b) (6); Boney, Virginia M. EOP/WHO
(b) (6); Tully, Ryan M. EOP/NSC < (b) (6); (b) (6)
(b) (6); Christ, Katelyn E. EOP/NSC (b) (6); Weinberger,
Collin (OS/OGA) < (b) (6); Landrum, Ryan P. EOP/NSC
< (b) (6); Rault, Nick M. EOP/NSC (b) (6); Hanna,
Cory M. EOP/NSC (b) (6); Burton, Nicholas S. EOP/OMB
(b) (6); Garufi, Marc A. EOP/OMB (b) (6); Mroz,
Sara K. EOP/NSC < (b) (6); Troye, Olivia EOP/NSC (b) (6);
(b) (6) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6);

Lowry, Patrick J. EOP/NSC (b) (6); Cartin, Josh M. EOP/NSC (b) (6); Kanapathy, Ivan J. EOP/NSC (b) (6);
 Elvander, Erika (OS/OGA) (b) (6); Cavanaugh, Brian J. EOP/NSC (b) (6); Thomas, Gloria
 (HHS/OS/OGA) (b) (6); Butler, Jay C. (CDC/DDID/OD) (b) (6); Bright, Rick
 (OS/ASPR/BARDA) (b) (6); Ruggiero, Anthony J. EOP/NSC (b) (6); 'Brett Armstrong - D1R' (b) (6);
 (b) (6) ' (b) (6) < (b) (6);
 (b) (6) (b) (6); Hassell, David (Chris) (OS/ASPR/IO) (b) (6) McMillin, Virginia D. EOP/WHO < (b) (6); Telle,
 Adam R. EOP/WHO (b) (6); Sugarman, AJ J. EOP/WHO (b) (6); Planning, David M. EOP/WHO (b) (6);
 'Feddersen, Brett (FAA)' (b) (6); (b) (6) (b) (6); Greene
 Richard S. (GH/HIDN) [USAID] (b) (6) Baehr, James S. EOP/WHO
 (b) (6) v>; 'Magrino, Christopher' < (b) (6);
 (b) (6)
 Tobin, Elizabeth D. EOP/NSC (b) (6); Jonas,
 Seth H. EOP/NSC (b) (6); ' (b) (6) (b) (6); Music, Chris
 G. EOP/OMB (b) (6); (b) (6) (b) (6); Burris, Meghan K.
 EOP/WHO (b) (6); Henning, Alexa A. EOP/WHO
 < (b) (6); Daravi, Roma S. EOP/WHO < (b) (6)
 Horstman, John H. EOP/WHO < (b) (6); (b) (6) OSD
 OUSD POLICY (USA)' (b) (6); Wilson, John Mark M. EOP/NSC
 (b) (6); Martin, Michael E. EOP/NSC (b) (6)
 (b) (6) 'S60.Policy@dot.gov' <S60.Policy@dot.gov>; Sadat,
 Mir H. EOP/NSC (b) (6); Gray, Alexander B. EOP/NSC
 (b) (6); Rubini, Jeffrey H. EOP/NSC (b) (6) Ulliyot,
 John L. EOP/NSC (b) (6); Stuftt, Julie M. EOP/NSC
 (b) (6); Stimson, Brian (HHS/OGC) (b) (6); Browne, Lisa Y.
 EOP/NSC (b) (6); Davis, May M. EOP/WHO (b) (6); Lekan,
 Scott (ACF) (b) (6); Chafin, Kelly B. EOP/NSC (b) (6); Bailey,
 Drew M. EOP/OMB (b) (6); Thallam, Satya P. EOP/OMB
 (b) (6); Allen, Ronald G. EOP/NSC (b) (6); Schuchat,
 Anne MD (CDC/OD) (b) (6) Bain, Ally P. EOP/OMB (b) (6)
 Schmoyer, Michael (OS/ONS) (b) (6); Lepore, Loretta (CDC/OD/OCS)
 (b) (6); Hinton, Denise (FDA/OC) (b) (6); Champagne, Joshua D.
 EOP/NSC (b) (6) (b) (6) (b) (6)
 (b) (6) OSD OUSD POLICY (USA)' (b) (6); DL
 Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; (b) (6)
 ; Ash, Deborah J. EOP/NSC (b) (6);
 Reilly, Tom M. EOP/OMB (b) (6); 'Havranek, John'
 (b) (6) ' (b) (6) (b) (6); 'FORET, VERNON T'
 (b) (6); Ellis, Michael J. EOP/WHO < (b) (6); 'Blue,
 Matthew (ODAG)' (b) (6); Decker, Matthew G. EOP/NSC
 (b) (6); 'JACKSTA, LINDA L' (b) (6); (b) (6)
 < (b) (6); Carter, Hillary H. EOP/NSC < (b) (6)
 Galkowski, James J. EOP/WHO (b) (6); ' (b) (6)
 < (b) (6); Doyle, Emma K. EOP/WHO < (b) (6); Lason, Adam

J. EOP/NSC < (b) (6)>; (b) (6)
(Geneva) < (b) (6) Bibo, David (b) (6)>; Dorko, Jeffrey
(b) (6)>; Hughes, William C. (ODAG) < (b) (6)>; (b) (6)
OSD OUSD POLICY (USA) (b) (6)>; (b) (6)
< (b) (6) (b) (6) OSD OUSD
POLICY (USA) (b) (6)>; (b) (6) (Beijing) (b) (6) De
La Riva, Etienne EOP/NSC (b) (6)>; Morgan, Jameson A. EOP/NSC
(b) (6)>; Smith, Jason S. EOP/NSC < (b) (6)>; Durie, Troy
M. EOP/CEA < (b) (6)>; Chang, William (HHS/OGC) (b) (6);
(b) (6) (b) (6); Eisenberg, John A. EOP/WHO
(b) (6)>; Bai, Sue J. EOP/WHO (b) (6)>; Hennessey,
Millicent S. EOP/NSC (b) (6); (b) (6) (b) (6);
Maycock, Brett (OS/ONS) (b) (6)>; (b) (6) (b) (6)>
Subject: FOR REVIEW: Revised - Phases of USG nCoV Response

Good Afternoon Colleagues –

Per this morning's (b) (6) discussion, please find attached the proposed revised language for the phases of USG nCoV response. Please provide concurrence or substantive edits for your department/agency by **1500 TODAY.**

Thank you,
Lauren

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 23:12:54 +0000
To: Ferro, Phil J. EOP/NSC (b) (6) (OS/IOS); (b) (6) Biegun, Stephen E; Bigley, Mark C. EOP/OMB; Blair, Robert B. EOP/WHO; Harrison, Brian (HHS/IOS); Butterfield, Nicholas W. EOP/WHO; Campana, Alexandra D. EOP/WHO; Cetron, Marty (CDC/DDID/NCEZID/DGMQ); Chafin, Kelly B. EOP/NSC; Conant, Ann M. EOP/OMB; Conley, Sean P. CDR USN WHMO/WHMU; Conrad, Patricia (NIH/NIAID) [E]; Davis, May M. EOP/WHO; Ditto, Jessica E. EOP/WHO; DL Chief of Staff Office; donna.o'berry (b) (6); Duffey, Michael P. EOP/OMB; Eisenberg, John A. EOP/WHO; Fabina, Lauren C. EOP/NSC; Grogan, Joseph J. EOP/WHO; Hemme, Jake W. EOP/NSC; Hennessey, Millicent S. EOP/NSC; Hoelscher, Douglas L. EOP/WHO; (b) (6); Kan, Derek T. EOP/OMB (b) (6); Liddell, Christopher P. EOP/WHO; Miller, Julie L. EOP/OMB; Mulvaney, Mick M. EOP/WHO; OS Salesses, Robert; Pataki, Tim A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; Riggs, Charlotte R. EOP/WHO; (b) (6); Redfield, Robert R. (CDC/OD); Kadlec, Robert (OS/ASPR/IO); Ruggiero, Anthony J. EOP/NSC; Scher, Adam A. EOP/OMB; Shellooe, Ryan P. EOP/NSC; Sinclair, Michael R. EOP/NSC; Szabat, Joel (OST); Tignor, Beth (HHS/IOS); Troye, Olivia EOP/NSC; Ulyot, John L. EOP/NSC; Williams, Michael B. EOP/WHO; Wilson, John Mark M. EOP/NSC; Woolfolk, Jon J. EOP/OVP
Subject: RE: ACTION: Please Review by 6:30 P.M.

Fauci concurs with CDC proposal

From: Ferro, Phil J. EOP/NSC (b) (6)
Sent: Sunday, February 23, 2020 5:48 PM
To: (b) (6) (OS/IOS) (b) (6); (b) (6) Biegun, Stephen E (b) (6); Bigley, Mark C. EOP/OMB (b) (6); Blair, Robert B. EOP/WHO (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Butterfield, Nicholas W. EOP/WHO (b) (6); Campana, Alexandra D. EOP/WHO (b) (6); Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b) (6); Chafin, Kelly B. EOP/NSC (b) (6); Conant, Ann M. EOP/OMB (b) (6); Conley, Sean P. CDR USN WHMO/WHMU (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Davis, May M. EOP/WHO (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; donna.o'berry (b) (6) (b) (6); Duffey, Michael P. EOP/OMB (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Fabina, Lauren C. EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Ferro, Phil J. EOP/NSC (b) (6); Grogan, Joseph J. EOP/WHO (b) (6); Hemme, Jake W. EOP/NSC (b) (6); Hennessey, Millicent S. EOP/NSC (b) (6); Hoelscher, Douglas L. EOP/WHO (b) (6); Kan, Derek T. EOP/OMB (b) (6); Liddell, Christopher P. EOP/WHO (b) (6); Miller, Julie L. EOP/OMB (b) (6); Mulvaney, Mick M. EOP/WHO (b) (6); OS Salesses, Robert (b) (6); Pataki, Tim A. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); Riggs, Charlotte R. EOP/WHO (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Kadlec,

Robert (OS/ASPR/IO) <(b) (6)>; Ruggiero, Anthony J. EOP/NSC
(b) (6)>; Scher, Adam A. EOP/OMB <(b) (6)>;
Shellooe, Ryan P. EOP/NSC (b) (6)>; Sinclair, Michael R. EOP/NSC
(b) (6); Szabat, Joel (OST) <(b) (6)>; Tignor, Beth (HHS/IOS)
(b) (6)>; Troye, Olivia EOP/NSC <(b) (6)>; Ulliyot, John L. EOP/NSC
(b) (6); Williams, Michael B. EOP/WHO (b) (6)>;
Wilson, John Mark M. EOP/NSC <(b) (6)>; Woolfolk, Jon J. EOP/OVP
(b) (6)>

Subject: ACTION: Please Review by 6:30 P.M.

Importance: High

Good Evening WHTF,

(b) (5)

If you have an objection or concern with this course of action please let me know by 6:45 P.M. Pending any objections by the WHTF by 6:45 P.M. this evening, (b) (5)

Thank you,

Phil

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council
(b) (6) (O) (b) (6) (cell)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 02:53:03 +0000
To: Grogan, Joseph J. EOP/WHO; Birx, Deborah L. EOP/NSC
Subject: RE: This week

(b) (5)

-----Original Message-----

From: Grogan, Joseph J. EOP/WHO (b) (6)
Sent: Sunday, March 8, 2020 10:12 PM
To: Birx, Deborah L. EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Subject: This week

(b) (5)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 10 Mar 2020 17:40:33 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Gastfriend, Daniel Z. EOP/OMB
Subject: RE: If possible - connect Daniel to your science screening group for COVID 19

Will do today.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Tuesday, March 10, 2020 1:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Gastfriend, Daniel Z. EOP/OMB (b) (6) >
Subject: If possible - connect Daniel to your science screening group for COVID 19

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 02:58:28 +0000
To: Redfield, Robert R. (CDC/OD); Birx, Deborah L. EOP/NSC
Subject: RE: County specific guidance
Attachments: Seattle_Community_Mitigation_3_10 as version final with minor Fauci edits..docx, Santa Clara_Community_Mitigation_3_10 as (002) - with Fauci minor edits.docx

Bob:

They look pretty good. I have made a few minor changes that are tracked in the attached documents.

Best regards,
Tony

From: Redfield, Robert R. (CDC/OD) (b) (6)
Sent: Tuesday, March 10, 2020 6:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Birx, Deborah L. EOP/NSC
<(b) (6)>
Subject: Fwd: County specific guidance

Draft I am reviewing now but wanted you both now so not delay
Get [Outlook for iOS](#)

From: Schuchat, Anne MD (CDC/OD) (b) (6)
Sent: Tuesday, March 10, 2020 5:58:15 PM
To: Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Cohn, Amanda (CDC/DDID/NCIRD/OD) (b) (6); Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6); Redd, Stephen (CDC/DDPHSIS/OD) (b) (6); Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Schuchat, Anne MD (CDC/OD) <(b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Berger, Sherri (CDC/OCOO/OD) (b) (6); Warner, Agnes (CDC/OD/OCS) (b) (6)
Subject: FW: County specific guidance

Dr Redfield: (b) (5)
(b) (5)

Note that if you are trying to send to Debbi Birx she mentioned that things going to her CDC email will not reach her so you may want to include Olivia Troye to make sure to meet your deadline.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 11:55:14 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Do you have a min. I don't have your number.

Office - (b) (6)
Cell (b) (6)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Wednesday, March 11, 2020 7:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Do you have a min. I don't have your number.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 11 Mar 2020 12:02:03 +0000
To: Birx, Deborah L. EOP/NSC
Cc: 'Dieffenbach, Carl (NIH/NIAID) [E]'; Redd, Stephen (CDC/DDPHSIS/OD); Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Do you have a min. I don't have your number.

The contact person for COVID-19 RNA high throughput tests is Carl Dieffenbach. I am connecting him here with Steve Redd. THANKS.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Wednesday, March 11, 2020 7:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Do you have a min. I don't have your number.

Sent from my iPhone

From: (b) (6)
Sent: Wed, 11 Mar 2020 09:06:25 -0400
To: Liddell, Christopher P. EOP/WHO
Subject: Re: do you have time for a very quick call between 9.00 and 10.00 ?

Am on way to Hearing. Can you call now at (b) (6)

On Mar 11, 2020, at 8:30 AM, Liddell, Christopher P. EOP/WHO
(b) (6) wrote:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 14 Mar 2020 12:26:23 +0000
To: Staff Secretary; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Harrison, Brian (HHS/IOS); Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Kushner, Jared C. EOP/WHO; Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC; Pottinger, Matthew F. EOP/WHO; Vought, Russell T. EOP/OMB; Kan, Derek T. EOP/OMB (b) (6); Hicks, Hope C. EOP/WHO; 'Mizelle, Chad'; (b) (6); Levi, William (OAG); Moran, John (OAG); Blyth, Jonathan J.; (b) (6); Ornato, Tony M. EOP/WHO; Liddell, Christopher P. EOP/WHO; Ueland, Eric M. EOP/WHO; Grogan, Joseph J. EOP/WHO; McEntee, John D. II EOP/WHO; White House Clearances; Puesan, Cesar (HHS/OS/IOS); Pataki, Tim A. EOP/WHO; Hoelscher, Douglas L. EOP/WHO; Grisham, Stephanie A. EOP/WHO; Ditto, Jessica E. EOP/WHO; Gidley, Hogan H. EOP/WHO
Subject: RE: QUICK Review: Coronavirus TF - Travel Guidance

Looks fine to me. Clear and precise.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Saturday, March 14, 2020 8:03 AM
To: Short, Marc T. EOP/OVP <(b) (6)>; Miller, Katie R. EOP/OVP <(b) (6)>; Harrison, Brian (HHS/IOS) <(b) (6)>; Philbin, Patrick F. EOP/WHO <(b) (6)>; Eisenberg, John A. EOP/WHO <(b) (6)>; Kushner, Jared C. EOP/WHO <(b) (6)>; Birx, Deborah L. EOP/NSC <(b) (6)>; Troye, Olivia EOP/NSC <(b) (6)>; Pottinger, Matthew F. EOP/WHO <(b) (6)>; Vought, Russell T. EOP/OMB <(b) (6)>; Kan, Derek T. EOP/OMB <(b) (6)>; Hicks, Hope C. EOP/WHO <(b) (6)>; 'Mizelle, Chad' <(b) (6)>; Levi, William (OAG <(b) (6)>; Moran, John (OAG <(b) (6)>; Blyth, Jonathan J. <(b) (6)>; Ornato, Tony M. EOP/WHO <(b) (6)>; Liddell, Christopher P. EOP/WHO <(b) (6)>; Ueland, Eric M. EOP/WHO <(b) (6)>; Grogan, Joseph J. EOP/WHO <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; McEntee, John D. II EOP/WHO <(b) (6)>; White House Clearances <WhiteHouseClearances@state.gov>; Puesan, Cesar (HHS/OS/IOS) <(b) (6)>; Pataki, Tim A. EOP/WHO <(b) (6)>; Hoelscher, Douglas L. EOP/WHO <(b) (6)>; Grisham, Stephanie A. EOP/WHO <(b) (6)>; Ditto, Jessica E. EOP/WHO <(b) (6)>; Gidley, Hogan H. EOP/WHO <(b) (6)>
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: QUICK Review: Coronavirus TF - Travel Guidance

All,

Attached is draft travel guidance that OMB would like to release this afternoon. Please send any comments you may have by noon today.

Thank you,

Staff Secretary

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 01:44:31 +0000
To: Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: RE: Updated document on social distancing recommendations

This looks fine.

(b) (5)
(b) (5)

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Saturday, March 14, 2020 9:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD)
(b) (6)>
Subject: Updated document on social distancing recommendations

Bob I know you are working on (b) (5). Can you both review these to see if they sync up with your thoughts. Deb

Sent from my iPhone

Begin forwarded message:

From: Nat Turner (b) (6)>
Date: March 14, 2020 at 9:13:34 PM EDT
To: "Birx, Deborah L. EOP/NSC" (b) (6)>
Cc: "Kushner, Jared C. EOP/WHO" (b) (6), Adam Boehler (b) (6)
Subject: [EXTERNAL] Updated document on social distancing recommendations

Dr. Birx- please see attached. I updated the document to incorporate your feedback.

Let me know what you think. Thanks

-Nat

Nat Turner
Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 17:57:02 +0000
To: Birx, Deborah L. EOP/NSC;Staff Secretary
Cc: Short, Marc T. EOP/OVP;Miller, Katie R. EOP/OVP;Harrison, Brian (HHS/IOS);Redfield, Robert R. (CDC/OD);Philbin, Patrick F. EOP/WHO;Eisenberg, John A. EOP/WHO;Kushner, Jared C. EOP/WHO;Troye, Olivia EOP/NSC;Pottinger, Matthew F. EOP/WHO;Vought, Russell T. EOP/OMB; (b) (6); Hicks, Hope C. EOP/WHO;Mizelle, Chad (b) (6); Levi, William (OAG;Ornato, Tony M. EOP/WHO;Rinat, Ory S. EOP/WHO;Liddell, Christopher P. EOP/WHO;Ueland, Eric M. EOP/WHO;Grogan, Joseph J. EOP/WHO;McEntee, John D. II EOP/WHO;Pataki, Tim A. EOP/WHO;Hoelscher, Douglas L. EOP/WHO;Grisham, Stephanie A. EOP/WHO;Ditto, Jessica E. EOP/WHO;Gidley, Hogan H. EOP/WHO
Subject: RE: QUICK Review: Coronavirus TF - Post Card

OK and I agree with Debbie's comment.

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Sunday, March 15, 2020 8:07 AM
To: Staff Secretary <staffsecretary@who.eop.gov>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Philbin, Patrick F. EOP/WHO <(b) (6)>; Eisenberg, John A. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Troye, Olivia EOP/NSC (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); Vought, Russell T. EOP/OMB (b) (6); Hicks, Hope C. EOP/WHO <(b) (6)>; Mizelle, Chad <(b) (6)>; (b) (6); Levi, William (OAG (b) (6); Ornato, Tony M. EOP/WHO (b) (6); Rinat, Ory S. EOP/WHO (b) (6); Liddell, Christopher P. EOP/WHO (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO (b) (6); McEntee, John D. II EOP/WHO (b) (6); Pataki, Tim A. EOP/WHO (b) (6); Hoelscher, Douglas L. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO <(b) (6)>
Subject: Re: QUICK Review: Coronavirus TF - Post Card

Would add (b) (5)

Sent from my iPhone

On Mar 14, 2020, at 10:17 PM, Staff Secretary <staffsecretary@who.eop.gov> wrote:

All,

Attached is an updated post card, revised to reflect the comments received. In order to meet the USPS deadline, **please send any further comments or concerns by 8:30am tomorrow morning, Sunday, March 15.** In particular, we would appreciate Dr. Fauci, Dr. Birx, and CDC's review of this updated version. Note as well two additional questions/flags received below for feedback:

(b) (5)

From: Staff Secretary <staffsecretary@who.eop.gov>

Sent: Saturday, March 14, 2020 5:00 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Birx, Deborah L. EOP/NSC (b) (6); Troye, Olivia EOP/NSC (b) (6); Pottinger, Matthew F. EOP/WHO < (b) (6); Vought, Russell T. EOP/OMB (b) (6); Kan, Derek T. EOP/OMB (b) (6); Hicks, Hope C. EOP/WHO < (b) (6); 'Mizelle, Chad' (b) (6); Levi, William (OAG) (b) (6); Moran, John (OAG) (b) (6); Blyth, Jonathan J. (b) (6); Ornato, Tony M. EOP/WHO (b) (6); Rinat, Ory S. EOP/WHO (b) (6); Liddell, Christopher P. EOP/WHO (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO (b) (6); McEntee, John D. II EOP/WHO (b) (6); White House Clearances < (b) (6); Puesan, Cesar (HHS/OS/IOS) (b) (6); Pataki, Tim A. EOP/WHO (b) (6); Hoelscher, Douglas L. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6)

Cc: Staff Secretary (b) (6)

Subject: QUICK Review: Coronavirus TF - Post Card

Importance: High

All,

Attached is a draft mass-mailing postcard from the President with information on how to protect yourself from COVID-19 and what to do if you have symptoms. Please review and send any critical comments, being mindful to the limited ability to make large structural changes. Please also let us know if you believe any recommendations are miscategorized or mischaracterize the guidance. To meet the

USPS deadline, please send any comments you have **by 7pm tonight.** If you need more time, please let us know so we can see if your request can be accommodated.

Thank you,

Staff Secretary

<USPS_postcard-mockup_v5_with-stamp.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 18:03:49 +0000
To: Keller, Catherine B. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Harrison, Brian (HHS/IOS); Redfield, Robert R. (CDC/OD); Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Kushner, Jared C. EOP/WHO; Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC; Pottinger, Matthew F. EOP/WHO; Vought, Russell T. EOP/OMB; (b) (6); Hicks, Hope C. EOP/WHO; 'Mizelle, Chad' (b) (6); Levi, William (OAG; Ornato, Tony M. EOP/WHO; Rinat, Ory S. EOP/WHO; Liddell, Christopher P. EOP/WHO; Grogan, Joseph J. EOP/WHO; McEntee, John D. II EOP/WHO; Pataki, Tim A. EOP/WHO; Hoelscher, Douglas L. EOP/WHO; Grisham, Stephanie A. EOP/WHO; Ditto, Jessica E. EOP/WHO; Ueland, Eric M. EOP/WHO
Cc: Staff Secretary
Subject: RE: QUICK Review: Coronavirus TF - Social Distancing Recs
Attachments: Social Distancing v3 -with Fauci minor edit.pptx

See minor edit in red

From: Keller, Catherine B. EOP/WHO <(b) (6)>
Sent: Sunday, March 15, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6)>; Harrison, Brian (HHS/IOS) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6)>; Kushner, Jared C. EOP/WHO (b) (6)>; Birx, Deborah L. EOP/NSC (b) (6)>; Troye, Olivia EOP/NSC <(b) (6)>; Pottinger, Matthew F. EOP/WHO (b) (6); Vought, Russell T. EOP/OMB (b) (6); Hicks, Hope C. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6); Levi, William (OAG (b) (6)>; Ornato, Tony M. EOP/WHO <(b) (6)>; Rinat, Ory S. EOP/WHO (b) (6); Liddell, Christopher P. EOP/WHO (b) (6)>; Grogan, Joseph J. EOP/WHO (b) (6)>; McEntee, John D. II EOP/WHO (b) (6)>; Pataki, Tim A. EOP/WHO (b) (6)>; Hoelscher, Douglas L. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Ueland, Eric M. EOP/WHO <(b) (6)>
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: QUICK Review: Coronavirus TF - Social Distancing Recs
Importance: High

All,

Please see attached for draft recommendations on Social Distancing. Please send any feedback you have by **11:15am today**. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 18:08:26 +0000
To: Birx, Deborah L. EOP/NSC;AMA2 (OS/IOS)
Cc: Kadlec, Robert (OS/ASPR/IO);Redfield, Robert R. (CDC/OD);Harrison, Brian (HHS/IOS)
Subject: RE: WHO debrief

I have discussed all this in detail with Cliff and (b) (5)

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Sunday, March 15, 2020 10:21 AM
To: (b) (6) (OS/IOS) (b) (6) >
Cc: Kadlec, Robert (OS/ASPR/IO) (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Harrison, Brian (HHS/IOS) (b) (6)
Subject: Re: WHO debrief

A great summary. (b) (5)

Sent from my iPhone

On Mar 15, 2020, at 10:17 AM, (b) (6) (OS/IOS) (b) (6) wrote:

Privileged and Confidential Predecisional Draft Deliberative Process Material

(b) (5)

(b) (5)

AMA

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 18:25:26 +0000
To: Birx, Deborah L. EOP/NSC; Schuchat, Anne MD (CDC/OD)
Cc: Kadlec, Robert (OS/ASPR/IO); Giroir, Brett (HHS/OASH); AMA2 (OS/IOS); Redfield, Robert R. (CDC/OD); Cohn, Amanda (CDC/DDID/NCIRD/OD); CDC IMS 2019 NCOV Response Incident Manager; Messonnier, Nancy (CDC/DDID/NCIRD/OD); McGowan, Robert (Kyle) (CDC/OD/OCS)
Subject: RE: US Social Distancing Recommendations - CDC 11 am_3_15_2020

This looks really good. Thanks!

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Sunday, March 15, 2020 11:16 AM
To: Schuchat, Anne MD (CDC/OD) <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Giroir, Brett (HHS/OASH) (b) (6); (b) (6) (OS/IOS) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Cohn, Amanda (CDC/DDID/NCIRD/OD) (b) (6); CDC IMS 2019 NCOV Response Incident Manager (b) (6); Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)
Subject: Re: US Social Distancing Recommendations - CDC 11 am_3_15_2020


Thank you. Great team work down there. Please thank your staff for their around the clock work. I am very grateful. Deb

Sent from my iPhone

On Mar 15, 2020, at 11:13 AM, Schuchat, Anne MD (CDC/OD) (b) (6) wrote:

Dr Redfield wanted to provide this version of the recommendations on social distancing which incorporates CDC guidance and evidence-review in plain language for all Americans. The team is also working to revise the slide deck you just sent Dr Redfield to assure plain language with shorter wording, but this is so your team sees the critical content we recommend.

<US Social Distancing Recommendations - CDC 11 am_3_15_2020.docx>



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 10:30:29 +0000
To: Birx, Deborah L. EOP/NSC; Hicks, Hope C. EOP/WHO
Cc: Boehler, Adam; Nat Turner; Short, Marc T. EOP/OVP; Lyons, Derek S. EOP/WHO; Kushner, Jared C. EOP/WHO; Liddell, Christopher P. EOP/WHO; Keller, Catherine B. EOP/WHO; Miller, Katie R. EOP/OVP; Berkowitz, Avraham J. EOP/WHO
Subject: RE: Guidance

This is really good now. Excellent improvements. (b) (5)

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Monday, March 16, 2020 5:26 AM
To: Hicks, Hope C. EOP/WHO (b) (6)
Cc: Boehler, Adam <(b) (6)>; Nat Turner (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP (b) (6)>; Lyons, Derek S. EOP/WHO (b) (6); Kushner, Jared C. EOP/ (b) (6); Liddell, Christopher P. EOP/WHO <(b) (6)>; Keller, Catherine B. EOP/WHO (b) (6)>; Miller, Katie R. EOP/OVP (b) (6); Berkowitz, Avraham J. EOP/WHO (b) (6)>
Subject: Re: Guidance

That is much better. (b) (5)

Sent from my iPhone

On Mar 16, 2020, at 4:42 AM, Hicks, Hope C. EOP/WHO <(b) (6)> wrote:

In my opinion, (b) (5)

Sent from my iPhone

On Mar 15, 2020, at 11:48 PM, Boehler, Adam <(b) (6)> wrote:

Thanks — agree with the feedback. Jared caught up with Derek, Nat, and me earlier this evening and his thoughts were similar. As a next step, we caucused with a few experts (including Gottlieb)...attaching a revised draft for the group's review that we modified based on the feedback.
<Short GuidanceRev DL JK.docx>

Adam

On Mar 15, 2020, at 10:46 PM, Nat Turner (b) (6) > wrote:

+Adam Boehler

On Sun, Mar 15, 2020, 10:38 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

(b) (5)

Sent from my iPad

On Mar 15, 2020, at 10:24 PM, Short, Marc T. EOP/OVP (b) (6) > wrote:

Thanks to everyone for the diligent work on the new guidelines

(b) (5)

Sent from my iPhone

On Mar 15, 2020, at 7:22 PM, Lyons, Derek S. EOP/WHO (b) (6) > wrote:

Please provide feedback as soon as you can.

(b) (5)

<Short GuidanceRev DL.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 10:45:00 +0000
To: Staff Secretary; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Harrison, Brian (HHS/IOS); Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Kushner, Jared C. EOP/WHO; Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC; Pottinger, Matthew F. EOP/WHO; Vought, Russell T. EOP/OMB; (b) (6); Hicks, Hope C. EOP/WHO; 'Mizelle, Chad'; (b) (6); Levi, William (OAG; Moran, John (OAG; Ornato, Tony M. EOP/WHO; Liddell, Christopher P. EOP/WHO; Ueland, Eric M. EOP/WHO; Grogan, Joseph J. EOP/WHO; McEntee, John D. II EOP/WHO; Hoelscher, Douglas L. EOP/WHO; White House Clearances; Puesan, Cesar (HHS/OS/IOS); Pataki, Tim A. EOP/WHO; Hoelscher, Douglas L. EOP/WHO; Grisham, Stephanie A. EOP/WHO; Ditto, Jessica E. EOP/WHO; Gidley, Hogan H. EOP/WHO; Hahn, Julia A. EOP/WHO; 'Young, Joby - OSEC, Washington, DC'; Pataki, Tim A. EOP/WHO; Grogan, Joseph J. EOP/WHO
Subject: RE: Quick Review - POTUS Remarks, 11:00 am Call with Governors
Attachments: Call with Governors_1100 0316 - with Fauci edits.docx

See minor suggested edits in attached document.

From: Staff Secretary (b) (6) >
Sent: Sunday, March 15, 2020 10:47 PM
To: Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6) >; Harrison, Brian (HHS/IOS) (b) (6); Philbin, Patrick F. EOP/WHO (b) (6) >; Eisenberg, John A. EOP/WHO (b) (6) >; Kushner, Jared C. EOP/WHO < (b) (6) >; Birx, Deborah L. EOP/NSC < (b) (6) >; Troye, Olivia EOP/NSC (b) (6) >; Pottinger, Matthew F. EOP/WHO (b) (6) >; Vought, Russell T. EOP/OMB < (b) (6) >; Hicks, Hope C. EOP/WHO (b) (6) >; 'Mizelle, Chad' (b) (6); Levi, William (OAG (b) (6) >; Moran, John (OAG (b) (6) >; Ornato, Tony M. EOP/WHO (b) (6); Liddell, Christopher P. EOP/WHO (b) (6) >; Ueland, Eric M. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; McEntee, John D. II EOP/WHO (b) (6) >; Hoelscher, Douglas L. EOP/WHO (b) (6); White House Clearances <WhiteHouseClearances@state.gov>; Puesan, Cesar (HHS/OS/IOS) (b) (6) >; Pataki, Tim A. EOP/WHO (b) (6); Hoelscher, Douglas L. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6) >; Ditto, Jessica E. EOP/WHO (b) (6) >; Gidley, Hogan H. EOP/WHO < (b) (6) >; Hahn, Julia A. EOP/WHO (b) (6) >; 'Young, Joby - OSEC, Washington, DC' (b) (6) >; Pataki, Tim A. EOP/WHO (b) (6) >; Grogan, Joseph J. EOP/WHO (b) (6)
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: Quick Review - POTUS Remarks, 11:00 am Call with Governors

Attached for your review are draft POTUS remarks for tomorrow's 11:00 am call with Governors.

Please let Staff Sec know by **8:30 am tomorrow, March 16**, if you have any edits or feedback.

Thank you,

Staff Sec

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 23:28:41 +0000
To: Miller, Katie R. EOP/OVP
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: PSA tomorrow

No problem at all. Happy to do so.

From: Miller, Katie R. EOP/OVP [REDACTED] (b) (6) >
Sent: Monday, March 16, 2020 6:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Rinat, Ory S. EOP/WHO [REDACTED] (b) (6)
Subject: PSA tomorrow

Could you stick around tomorrow until you film PSA with Ory? Thanks

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Mar 2020 18:27:08 +0000
To: Redfield, Robert R. (CDC/OD); Stephen Hahn; Birx, Deborah L. EOP/NSC
Cc: (b) (6); Troye, Olivia EOP/NSC; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Hicks, Hope C. EOP/WHO; kellyanne conway
Subject: Follow-up of today's conversation

Folks:

(b) (5)

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 19 Mar 2020 02:33:41 +0000
To: Redfield, Robert R. (CDC/OD);Stephen Hahn;Birx, Deborah L. EOP/NSC
Cc: (b) (6);Troye, Olivia EOP/NSC;Short, Marc T. EOP/OVP;Miller, Katie R. EOP/OVP;Hicks, Hope C. EOP/WHO;kellyanne conway
Subject: FW: NEJM: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 <http://bit.ly/2x9IJI0>

As per my prior e-mail. The medical people likely are aware of this. It just came out tonight. But for the others, see yellow highlight. (b) (5)

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, March 18, 2020 10:14 PM
Subject: NEJM: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
<http://bit.ly/2x9IJI0>

Access provided by NIH Library

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

List of authors.

- Bin Cao, M.D., et al.

Abstract

Background

No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.

Methods

We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao_2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao_2) to the fraction of inspired oxygen (Fio_2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.

Results

A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir–ritonavir group, and 100 to the standard-care group. Treatment with lopinavir–ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72).

Mortality at 28 days was similar in the lopinavir–ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, –5.8 percentage points; 95% CI, –17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir–ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir–ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir–ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.

Conclusions

In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308. [opens in new tab.](#))




Figure 2. Time to Clinical Improvement in the Intention-to-Treat Population.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 22:45:24 +0000
To: Stephen Hahn; Redfield, Robert R. (CDC/OD); Birx, Deborah L.
EOP/NSC; (b) (6)
Subject: Treatment Document
Attachments: dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked changes showing.docx, dbInformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and Lane tracked Clean copy.docx

Team:

As per my discussion with Steve a few minutes ago, I have made some changes in the document. (b) (5)

I am attaching a tracked version of the document that was your FINAL as well as a clean copy with all of the changes accepted. Please take a look and Steve said that he would like to set up a quick call to discuss after you have had a look. I am very sorry to come in with these changes at this late point, but I really did not get a chance to have a good look at the document as I was in a car.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 23:23:40 +0000
To: (b) (6) (OS/IOS);Kadlec, Robert (OS/ASPR/IO);Deborah Birx;Redfield, Robert R. (CDC/OD);Giroir, Brett (HHS/OASH)
Cc: (b) (6)
Subject: RE: Tedros Call

(b) (5)

-----Original Message-----

From: (b) (6) (OS/IOS) (b) (6) >
Sent: Saturday, March 21, 2020 4:27 PM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >; Deborah Birx (b) (6); Redfield, Robert R. (CDC/OD)
(b) (6) Giroir, Brett (HHS/OASH) (b) (6)
Subject: Tedros Call

(b) (5)

Wanted to pass this along for your consideration.
AMA

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 16:26:38 +0000
To: Staff Secretary; Kushner, Jared C. EOP/WHO; Hicks, Hope C. EOP/WHO; Grisham, Stephanie A. EOP/WHO; Miller, Stephen EOP/WHO; Eisenberg, John A. EOP/WHO; Philbin, Patrick F. EOP/WHO; Moore, Caroline E. EOP/WHO; Hutchinson, Cassidy J. EOP/WHO; Pottinger, Matthew F. EOP/WHO; Hughes, Andrew; Birx, Deborah L. EOP/NSC; Conway, Kellyanne E. EOP/WHO (b) (6); Kudlow, Larry A. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Harrison, Brian (HHS/IOS); Bailey, Nathan; White House Clearances; Grogan, Joseph J. EOP/WHO; Levi, William (OAG; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Vought, Russell T. EOP/OMB; Nevins, Kristan K. EOP/WHO; Ueland, Eric M. EOP/WHO; 'Mizelle, Chad'; Liddell, Christopher P. EOP/WHO
Subject: RE: FLASH Review: Remarks for Today's Press Conference
Attachments: Press Conference Open 3-22 - with Fauci edits.docx

Please see my tracked suggested edits in the attached document.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Sunday, March 22, 2020 12:09 PM
To: Kushner, Jared C. EOP/WHO <(b) (6)>; Hicks, Hope C. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Miller, Stephen EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Moore, Caroline E. EOP/WHO (b) (6); Hutchinson, Cassidy J. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); Hughes, Andrew (b) (6); Birx, Deborah L. EOP/NSC (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Bailey, Nathan (b) (6); White House Clearances <WhiteHouseClearances@state.gov>; Grogan, Joseph J. EOP/WHO (b) (6); Levi, William (OAG

(b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A.
EOP/WHO <(b) (6)>; Vought, Russell T. EOP/OMB
(b) (6); Nevins, Kristan K. EOP/WHO (b) (6)
Ueland, Eric M. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6);
Liddell, Christopher P. EOP/WHO (b) (6)
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: FLASH Review: Remarks for Today's Press Conference
Importance: High

All,

Please see attached for draft remarks for today's press conference. Affirmative clearance is requested from **WHCO, DHS, OVP, and IGA**. Please send any feedback **by 2pm today**.

Thank you,
Staff Secretary

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 18:49:22 +0000
To: Staff Secretary; Kushner, Jared C. EOP/WHO; Hicks, Hope C. EOP/WHO; Grisham, Stephanie A. EOP/WHO; Miller, Stephen EOP/WHO; Eisenberg, John A. EOP/WHO; Philbin, Patrick F. EOP/WHO; Moore, Caroline E. EOP/WHO; Hutchinson, Cassidy J. EOP/WHO; Pottinger, Matthew F. EOP/WHO; Hughes, Andrew; Birx, Deborah L. EOP/NSC; Conway, Kellyanne E. EOP/WHO; (b) (6); Kudlow, Larry A. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Harrison, Brian (HHS/IOS); Bailey, Nathan; White House Clearances; Grogan, Joseph J. EOP/WHO; Levi, William (OAG; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Vought, Russell T. EOP/OMB; Nevins, Kristan K. EOP/WHO; Ueland, Eric M. EOP/WHO; 'Mizelle, Chad'; Liddell, Christopher P. EOP/WHO; Navarro, Peter K. EOP/WHO; Syrek, Christopher D. (Chris)
Subject: RE: FLASH Review: Remarks for Today's Press Conference
Attachments: Press Conference Open 3-22 - with minor edits.docx

Please see very minor edits in attached document.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Sunday, March 22, 2020 2:37 PM
To: Kushner, Jared C. EOP/WHO (b) (6); Hicks, Hope C. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Miller, Stephen EOP/WHO <(b) (6)>; Eisenberg, John A. EOP/WHO <(b) (6)>; Philbin, Patrick F. EOP/WHO (b) (6); Moore, Caroline E. EOP/WHO <(b) (6)>; Hutchinson, Cassidy J. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); Hughes, Andrew (b) (6); Birx, Deborah L. EOP/NSC (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Bailey, Nathan (b) (6); White House Clearances <WhiteHouseClearances@state.gov>; Grogan, Joseph J. EOP/WHO (b) (6); Levi, William (OAG (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Vought, Russell T. EOP/OMB <(b) (6)>; Nevins, Kristan K. EOP/WHO <(b) (6)>; Ueland, Eric M. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6); Liddell, Christopher P. EOP/WHO <(b) (6)>; Navarro, Peter K. EOP/WHO (b) (6); Syrek, Christopher D. (Chris) (b) (6)>
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: RE: FLASH Review: Remarks for Today's Press Conference

Updated remarks are attached. Please send any critical edits by 3pm today.

From: Staff Secretary
Sent: Sunday, March 22, 2020 12:09 PM
To: Kushner, Jared C. EOP/WHO (b) (6); Hicks, Hope C. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Miller, Stephen EOP/WHO

(b) (6); Eisenberg, John A. EOP/WHO (b) (6);
Philbin, Patrick F. EOP/WHO (b) (6); Moore, Caroline E. EOP/WHO
(b) (6); Hutchinson, Cassidy J. EOP/WHO
(b) (6); Pottinger, Matthew F. EOP/WHO < (b) (6);
'Hughes, Andrew' (b) (6); Bix, Deborah L. EOP/NSC
(b) (6); Conway, Kellyanne E. EOP/WHO (b) (6);
(b) (6); 'Fauci, Anthony (NIH/NIAID) [E]' (b) (6); Kudlow, Larry A. EOP/WHO
(b) (6); Short, Marc T. EOP/OVP (b) (6); Miller,
Katie R. EOP/OVP (b) (6); 'Harrison, Brian (HHS/IOS)' (b) (6);
'Bailey, Nathan' (b) (6); 'White House Clearances'
<WhiteHouseClearances@state.gov>; Grogan, Joseph J. EOP/WHO < (b) (6);
'Levi, William (OAG)' (b) (6); Ditto, Jessica E. EOP/WHO
(b) (6); Hahn, Julia A. EOP/WHO < (b) (6); Vought, Russell
T. EOP/OMB < (b) (6) Nevins, Kristan K. EOP/WHO
(b) (6); Ueland, Eric M. EOP/WHO < (b) (6) 'Mizelle,
Chad' < (b) (6); Liddell, Christopher P. EOP/WHO
(b) (6)

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: FLASH Review: Remarks for Today's Press Conference

Importance: High

All,

Please see attached for draft remarks for today's press conference. Affirmative clearance is requested from **WHCO, DHS, OVP, and IGA**. Please send any feedback **by 2pm today**.

Thank you,
Staff Secretary

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 20:54:20 +0000
To: Birx, Deborah L. EOP/NSC;Schuchat, Anne MD (CDC/OD)
Cc: Redfield, Robert R. (CDC/OD);Warner, Agnes (CDC/OD/OCS);Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID);Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)
Subject: RE: additional data on exposure to symptom onset (incubation period) beyond what we sent previously

Thanks, Anne.

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Sunday, March 22, 2020 4:39 PM
To: Schuchat, Anne MD (CDC/OD) (b) (6) >
Cc: Redfield, Robert R. (CDC/OD) (b) (6); Warner, Agnes (CDC/OD/OCS) (b) (6) >; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <(b) (6)>
Subject: Re: additional data on exposure to symptom onset (incubation period) beyond what we sent previously

Thank you Anne. I appreciate all the work you are doing on this. Deb

From: "Schuchat, Anne MD (CDC/OD)" (b) (6) >
Date: Sunday, March 22, 2020 at 4:31 PM
To: "Birx, Deborah L. EOP/NSC" (b) (6) >
Cc: "Redfield, Robert R. (CDC/OD)" (b) (6), "Warner, Agnes (CDC/OD/OCS)" (b) (6), "Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID)" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>, "Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)" <(b) (6)>
Subject: additional data on exposure to symptom onset (incubation period) beyond what we sent previously

(b) (5)

Happy to discuss if you need more details.

Anne Schuchat, MD cell (b) (6)
Principal Deputy Director
Centers for Disease Control and Prevention
Rear Admiral, US Public Health Service (Retired)



(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 21:41:05 +0000
To: Birx, Deborah L. EOP/NSC
Subject: Re: (b) (5)
(b) (5)
Attachments: image001.png, image002.png

Thanks

On Mar 22, 2020, at 2:14 PM, Birx, Deborah L. EOP/NSC (b) (6) wrote:

(b) (5)

From: "Birx, Deborah L. EOP/NSC" (b) (6) >
Date: Sunday, March 22, 2020 at 2:10 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >, "Redfield, Robert R. (CDC/OD)" (b) (6) >
Subject: (b) (5)

<image001.png>

<image002.png>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 22 Mar 2020 22:44:45 +0000
To: Birx, Deborah L. EOP/NSC; McGuffee, Tyler A. EOP/OVP
Cc: Hahn, Stephen; Redfield, Robert R. (CDC/OD); Rom, Colin (FDA/OC); Lenihan, Keagan (FDA/OC); McGowan, Robert (Kyle) (CDC/OD/OCS)
Subject: RE: Genentech and COVID-19

(b) (5)

I agree with Dr. Birx

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Sunday, March 22, 2020 6:38 PM
To: McGuffee, Tyler A. EOP/OVP <(b) (6)>
Cc: Hahn, Stephen (b) (6); Redfield, Robert R. (CDC/OD) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Rom, Colin (FDA/OC) <(b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>
Subject: Re: Genentech and COVID-19

It's fine. (b) (5).

Sent from my iPhone

On Mar 22, 2020, at 6:37 PM, McGuffee, Tyler A. EOP/OVP
(b) (6) > wrote:

Flagging – Genentech just followed with an advanced copy of a Genentech Press Release for 9:00am tomorrow morning acknowledging “FDA’s rapid approval of a clinical study for Actemra as well as recognizes our strong partnership with BARDA. It also announces our intention to provide 10,000 units of Actemra to the Strategic National Stockpile.

From: McGuffee, Tyler A. EOP/OVP (b) (6) >
Sent: Sunday, March 22, 2020 5:16 PM
To: Hahn, Stephen (b) (6); Redfield, Robert R (CDC) (b) (6); Fauci, Anthony S (NIH) (b) (6) >
Cc: Birx, Deborah L. EOP/NSC (b) (6); Rom, Colin <(b) (6)>
Lenihan, Keagan <(b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)
Subject: Genentech and COVID-19

Dr. Hahn, Dr. Redfield, Dr. Fauci,
Per Dr. Birx – please see the highlighted note below from Dr. Birx.
Two attachments from Genentech are provided for additional context.

I am on standby, as always, and stand ready to help coordinate if/when you are all ready to meet/discuss internally and/or with Genentech. Let me know how I can be helpful.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D.
Office of the White House Coronavirus Response Coordinator
Associate Advisor to the Office of the Vice President
C: [REDACTED] (b) (6) [no text]

From: Birx, Deborah L. EOP/NSC [REDACTED] (b) (6)
Sent: Sunday, March 22, 2020 11:30 AM
To: McGuffee, Tyler A. EOP/OVP [REDACTED] (b) (6)
Subject: Fwd: [EXTERNAL] Fwd: Fwd: Genentech and COVID-19

[REDACTED] (b) (5)

Sent from my iPhone

Ambassador Birx, I look forward to connecting with you as soon as possible. [REDACTED] (b) (4)

[REDACTED] Additionally, I'd like to detail our extensive efforts to contribute to COVID-19 response, specifically relating to our medicine Actemra (tocilizimab).

Specifically, I would like to update you on:

- Our submission of an IND for a randomized controlled trial of Actemra (tocilizimab) in severely ill COVID-19 patients
- Our intent to donate 10,000 vials of Actemra to the Strategic National Stockpile for future use at the discretion of the USG
- Our experience globally in China, Italy, and other countries relating to the use and demand
- Our thinking around distribution of product to best ensure patient access
- Our initial thinking on key supply issues including increased global demand and our thinking around our domestic infrastructure

----- Forwarded message -----

From: Frederick Bittenbender [REDACTED] (b) (6)

Date: Tuesday, March 17 2020 at 8:27 AM EDT
Subject: Fwd: Genentech and COVID-19
To: [REDACTED] (b) (6)
Cc: Alexander Hardy [REDACTED] (b) (6) >

Nat:

After much internal discussion, we finalized the attached memo. I sent this to Joe Grogan as he asked for something as well. This is ripe for the White House Coronavirus Task Force as there must be coordination across multiple agencies. Roche/Genentech stands ready to do everything we can to support the US Government's efforts during this pandemic. Both FDA and BARDA have been incredible partners to date. The 4,000 units is an initial donation to treat approximately 1,000-1250 patients. More supply will be donated if needed.

Let's discuss when you have a free moment.

Best

Fritz

Sent from my iPad

Begin forwarded message:

From: Fritz Bittenbender [REDACTED] (b) (6) >
Date: March 16, 2020 at 10:01:15 PM EDT
To: [REDACTED] (b) (6)
Cc: David Burt [REDACTED] (b) (6) >
Subject: Genentech and COVID-19

Dear Joe:

Attached is the memo that we discussed. Genentech has had very productive on-going conversations with both FDA and BARDA regarding possible usage of Actemra to treat a sub-set of very ill COVID-19 patients.

[REDACTED] (b) (4)

We stand ready to discuss this further at anytime.

Best regards,

Fritz Bittenbender

Senior Vice President
Genentech

<mime-attachment>
<2020-03-16_Genentech_WH Memo-Actemra-COVID-19_FINAL.docx>
<mime-attachment>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 12:54:22 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Ueland, Eric M. EOP/WHO (b) (6); 'Mizelle, Chad'; Liddell, Christopher P. EOP/WHO; Moore, Caroline E. EOP/WHO; Hutchinson, Cassidy J. EOP/WHO; Birx, Deborah L. EOP/NSC; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Conway, Kellyanne E. EOP/WHO; Miller, Stephen EOP/WHO; Vought, Russell T. EOP/OMB; Miller, Katie R. EOP/OVP; Pottinger, Matthew F. EOP/WHO; Short, Marc T. EOP/OVP; Grogan, Joseph J. EOP/WHO; Lewis, Oliver CAPT SD; Levi, William (OAG)
Subject: RE: Quick Review: Press Conference Open - March 23
Attachments: Press Conference Open - March 23 - with Fauci edits.docx

Please see attached document with tracked suggested edits and comments.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Monday, March 23, 2020 8:02 AM
To: Hicks, Hope C. EOP/WHO <(b) (6)>; Kushner, Jared C. EOP/WHO (b) (6)>; Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6)>; Ueland, Eric M. EOP/WHO (b) (6)>; 'Mizelle, Chad' (b) (6)>; Liddell, Christopher P. EOP/WHO (b) (6)>; Moore, Caroline E. EOP/WHO (b) (6)>; Hutchinson, Cassidy J. EOP/WHO (b) (6)>; Birx, Deborah L. EOP/NSC (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6)>; Conway, Kellyanne E. EOP/WHO (b) (6)>; Miller, Stephen EOP/WHO (b) (6)>; Vought, Russell T. EOP/OMB (b) (6); Miller, Katie R. EOP/OVP (b) (6)>; Pottinger, Matthew F. EOP/WHO (b) (6)>; Short, Marc T. EOP/OVP (b) (6); Grogan, Joseph J. EOP/WHO (b) (6)>; Lewis, Oliver CAPT SD (b) (6); Levi,

William (OAG) [REDACTED] (b) (6)>

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: Quick Review: Press Conference Open - March 23

All,

Please see attached for draft remarks for today's press conference. Affirmative clearance is requested from **WHCO, HHS, DHS, and DOJ**. All others welcome to comment as well. Please send all comments and clearances to Staff Secretary by 1pm today.

Thank you,
Staff Secretary

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 02:41:39 +0000
To: Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Fox Town Hall

Thanks, Marc. Much appreciated.

From: Short, Marc T. EOP/OVP <(b) (6)>
Sent: Monday, March 23, 2020 10:32 PM
To: Miller, Katie R. EOP/OVP <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Fox Town Hall

Thanks, Dr Fauci. I am on same page. (b) (5)
(b) (6). Thanks for your continued good counsel

Sent from my iPhone

On Mar 23, 2020, at 10:24 PM, Miller, Katie R. EOP/OVP (b) (6) wrote:

The email I sent to Patricia pre-dated your phone conversation with Marc.

Sent from my iPhone

On Mar 23, 2020, at 10:21 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Marc:

As per our conversation this evening, (b) (5)

(b) (5)

Best,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Tue, 24 Mar 2020 07:47:49 -0400
To: Pottinger, Matthew F. EOP/WHO
Subject: Re: regarding masks and Covid-19

Very good point.

On Mar 24, 2020, at 6:38 AM, Pottinger, Matthew F. EOP/WHO
(b) (6) wrote:

(b) (5)

Matt

Sent from my iPhone

On Mar 24, 2020, at 6:27 AM, Pottinger, Matthew F. EOP/WHO
(b) (6) wrote:

Dr. KY Yuen, a leading member of the COVID response in Hong Kong, bcc'ed me on his response to a reporter's query.

(b) (5)
(b) (5)

Best
Matt Pottinger
Deputy National Security Advisor.
Sent from my iPhone

Begin forwarded message:

From: KY Yuen (b) (6)
Date: March 23, 2020 at 10:39:53 PM EDT
To: "Lyons, John" <john.lyons@wsj.com>
Subject: [EXTERNAL] Wall Street Journal question regarding masks and Covid-19

Dear John,

Thanks for your message.

- i. Studies have shown that wearing a mask with frequent hand hygiene significantly reduced transmission of influenza virus (also an enveloped respiratory virus with high transmissibility) in a community setting. But once the use of surgical mask is removed, the effect of hand hygiene becomes insignificant. (see attached)
- ii. Moreover, besides protecting yourself from this novel coronavirus or other respiratory viruses by wearing a mask, for those who are infected with this novel coronavirus asymptomatically (subclinical) or symptomatically, this will markedly reduce the amount of virus shedding in the saliva and respiratory droplet. This will therefore markedly reduce the community transmission. But the wearers must wear it correctly, learn to avoid touching the mask involuntarily and still observe good hand hygiene. This is not easy.
- iii. Except for the rich people, millions of HK people are living in very small housing estate or subdivided flat of 60 square feet. Advice has to be pragmatic. We go out to work, exercise or hiking. The first thing is to go into a VERY crowded elevator, then into very crowded MTR or bus, then going up a crowded elevator to our office OR to the place of hiking and exercise, and the reverse order happens when we go home. If we take off a mask and throw it away every time when not in a crowded environment and put up a new mask when entering a crowded environment, we need to use at least 8 mask per day when lunch and dinner outside are counted. Thus all these advice by many authorities may not be pragmatic.

HK is the most densely populated city in the world. Before the epidemic, at least 0.1 million HK residents or tourists cross our mainland border every day carrying the virus with them into HK. If not for universal masking once we depart from our home every day and wearing it correctly with hand hygiene, HK would be like Korea and Italy LONG ago. We now achieve 250 confirmed cases per 7.5 million population. This is really a record and is BETTER than other countries with a HOT weather and much less epidemic pressure from Chinese mainlanders.

Hope that this message will explain clearly why most medical colleagues in HK advocate universal masking once leaving their home. Note that the logistic of mask availability is another issue that requires other ways to work on.

Warm regards.
KY

From: Lyons, John [mailto:john.lyons@wsj.com]
Sent: Tuesday, March 24, 2020 10:16 AM
To: (b) (6)
Subject: Wall Street Journal question regarding masks and Covid-19

Dear Professor Yuen,

I am a senior reporter at the WSJ based here in Hong Kong.

I am interested in your perspective for a story I am writing on whether "to mask or not to mask" in the fight against the new Coronavirus.

On the one hand, the WHO has said healthy people need not wear masks on the grounds that they are not effective if not properly used; may lead to a false sense of security; and could use up scarce supplies.

On the other hand, many people, especially in Asia, see it as common sense a barrier will help contain the spread, especially when some carriers are asymptomatic. In Hong Kong, the experience of successfully fighting SARS seems to add evidence that masks are a good idea.

I can be reached at (b) (6) I am trying to finish the story today. It will run in the newspaper and on our website globally.

Best,

John

--

John Lyons

The Wall Street Journal.

Hong Kong Cell: (b) (6)

<hand_hygiene_and_risk_of_influenza_virus_infections_in_the_community_a_systematic_review_and_metaanalysis.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 14:12:54 +0000
To: Miller, Katie R. EOP/OVP
Cc: Short, Marc T. EOP/OVP; Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; O'Malley, Devin M. EOP/OVP
Subject: RE: Please advise

I called the reporter and she was very receptive to my corrections of the record and presentation of the facts.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
(b) (6)

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Miller, Katie R. EOP/OVP (b) (6) >
Sent: Tuesday, March 24, 2020 9:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Short, Marc T. EOP/OVP <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >; O'Malley, Devin M. EOP/OVP (b) (6) >
Subject: Re: Please advise

If you want to call her we would appreciate it.

Sent from my iPhone

On Mar 24, 2020, at 9:27 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Marc/Katie:

Please see below an e-mail from a Washington Post reporter (Yasmeen Abutaleb) to my Special Assistant, Patty Conrad. There are more than one of

these types of inquiries coming in. Clearly, people are feeding total lies to the media trying to create a rift between me and the POTUS and ultimately hurt him. See the first bullet saying that "Fauci was apoplectic about Trump's tweet yesterday saying the cure.....". This is total nonsense. I have not spoken to anyone about any of this and I certainly am not apoplectic about anything. I told you last night how I felt about this, being respectful of the difficult position the POTUS is in having to balance multiple issues in his decisions. Should I call this reporter and try to smash this story or just leave it alone? Thanks.

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Abutaleb, Yasmeen <Yasmeen.Abutaleb@washpost.com>

Sent: Tuesday, March 24, 2020 9:05 AM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >

Cc: Parker, Ashley <Ashley.Parker@washpost.com>

Subject: Washington Post fact check on Fauci/scientists story

Hi Patty,

Thanks very much for your help yesterday and hope you're doing well. We're working on a story today about Trump's relationship with the scientific and medical experts in the coronavirus response, including Dr. Fauci. We're reporting this out today but wanted to send you what we've been hearing as we get it so there's ample time to fact check everything today. Here are some points we'd love to discuss with the best person in your office or, better yet, Dr. Fauci himself.

- Fauci was apoplectic about Trump's tweet yesterday saying the cure couldn't be worse than the virus and indicating that he wants to reopen businesses soon.
- Fauci has been forceful privately that unproven drugs should not be advertised to Americans as a panacea (and he of course has publicly spoken about these drugs).

- We are also reporting in a separate story that Larry Ellison is building a website for the federal government that will collect data on the efficacy of remdesivir, chloroquine and hydroxychloroquine. Our understanding is Fauci is vehemently opposed to this idea and has pushed back on it, citing patient privacy concerns with the website and collecting data in this way outside of an approved FDA trial.

Again, we'd love to speak with Dr. Fauci and any others in your office who may have insight into these particular issues and other aspects of the coronavirus response. Please feel free to give me a call on my cell at any time at (b) (6)

Thanks very much,

Yasmeen Abutaleb
The Washington Post
Health policy reporter

o: 202-334-8387 c: (b) (6)
@yabutaleb7

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 25 Mar 2020 14:41:31 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Ueland, Eric M. EOP/WHO; (b) (6); 'Mizelle, Chad'; Liddell, Christopher P. EOP/WHO; Moore, Caroline E. EOP/WHO; Hutchinson, Cassidy J. EOP/WHO; Birx, Deborah L. EOP/NSC; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Conway, Kellyanne E. EOP/WHO; Miller, Stephen EOP/WHO; Vought, Russell T. EOP/OMB; Miller, Katie R. EOP/OVP; Pottinger, Matthew F. EOP/WHO; Short, Marc T. EOP/OVP; Grogan, Joseph J. EOP/WHO; (b) (6); Levi, William (OAG); (b) (6)
Subject: RE: Quick Review: Press Conference Open - March 25
Attachments: Press Conference Open - March 25 - with suggested edits.docx

See minor suggested edits in attached document.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary (b) (6) >
Sent: Wednesday, March 25, 2020 10:24 AM
To: Hicks, Hope C. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO <(b) (6)>; Eisenberg, John A. EOP/WHO (b) (6)>; Ueland, Eric M. EOP/WHO (b) (6); (b) (6) Mizelle, Chad' (b) (6); Liddell, Christopher P. EOP/WHO (b) (6)>; Moore, Caroline E. EOP/WHO (b) (6)>; Hutchinson, Cassidy J. EOP/WHO (b) (6)>; Birx, Deborah L. EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6)>; Conway, Kellyanne E. EOP/WHO (b) (6)>; Miller, Stephen EOP/WHO (b) (6)>; Vought, Russell T. EOP/OMB <(b) (6)>; Miller, Katie R. EOP/OVP (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6)>; Short, Marc T. EOP/OVP (b) (6)>; Grogan, Joseph J. EOP/WHO (b) (6)>; (b) (6) (b) (6)>; Levi,

William (OAG) <[REDACTED]> (b) (6)

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: Quick Review: Press Conference Open - March 25

All,

Please see attached for draft remarks for today's press conference. Affirmative clearance requested from **WHCO, OLA, OVP, DHS, and HHS**. Please send any critical comments and feedback to Staff Secretary **by 2pm today.**

Thank you,
Staff Secretary

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 02:32:15 +0000
To: Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC
Cc: Redfield, Robert R. (CDC/OD)
Subject: RE: Follow up to today's task force meeting

(b) (5)

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Wednesday, March 25, 2020 8:22 PM
To: Troye, Olivia EOP/NSC <(b) (6)>
Cc: Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Re: Follow up to today's task force meeting

Thank you helpful.

Sent from my iPhone

On Mar 25, 2020, at 7:38 PM, Troye, Olivia EOP/NSC (b) (6) > wrote:

Hello to my favorite doctors!
Just wanted to follow up to today's task force meeting.

(b) (5)

Let me know how I can help!
Olivia

Olivia Troye
Special Advisor to the Vice President for
Homeland Security and Counterterrorism
Office of the Vice President, National Security Affairs
White House Coronavirus Task Force
O: (b) (6) | M: (b) (6) (Does not receive texts)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 17:50:30 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Gidley, Hogan H. EOP/WHO; Grisham, Stephanie A. EOP/WHO; DL Chief of Staff Office; Birx, Deborah L. EOP/NSC; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Deere, Judd P. EOP/WHO (b) (6); Conway, Kellyanne E. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; 'Mizelle, Chad'; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Grogan, Joseph J. EOP/WHO; Vought, Russell T. EOP/OMB; Ueland, Eric M. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Miller, Stephen EOP/WHO; (b) (6) (b) (6); Hoelscher, Douglas L. EOP/WHO; Pataki, Tim A. EOP/WHO
Subject: RE: FLASH REVIEW: Thursday Press Conference
Attachments: Press Conference Open - March 26 REVISED - with additional edits.docx

Please see minor tracked edits in attached document.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Thursday, March 26, 2020 1:37 PM
To: Hicks, Hope C. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Birx, Deborah L. EOP/NSC <(b) (6)>; Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Deere, Judd P. EOP/WHO (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO <(b) (6)>; Vought, Russell T. EOP/OMB (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6); Miller, Stephen

EOP/WHO (b) (6); (b) (6) < (b) (6) Hoelscher,
Douglas L. EOP/WHO (b) (6); Pataki, Tim A. EOP/WHO
(b) (6)>

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: FLASH REVIEW: Thursday Press Conference

Importance: High

All,

Attached are draft remarks for today's press conference. Affirmative clearance is requested from **WHCO, DHS, and HHS**. All others are welcome to comment as well. Please send all comments and clearances to Staff Secretary **by 2:30pm today.**

Thank you,
Staff Secretary

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 16:13:42 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Gidley, Hogan H. EOP/WHO; Grisham, Stephanie A. EOP/WHO; DL Chief of Staff Office; Birx, Deborah L. EOP/NSC; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Deere, Judd P. EOP/WHO; (b) (6) Conway, Kellyanne E. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; O'Brien, Robert C. EOP/WHO; 'Mizelle, Chad'; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Grogan, Joseph J. EOP/WHO; Vought, Russell T. EOP/OMB; Ueland, Eric M. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Miller, Stephen EOP/WHO; (b) (6); Hoelscher, Douglas L. EOP/WHO; Pataki, Tim A. EOP/WHO; Berkowitz, Avraham J. EOP/WHO; Howerton, Jonathan E. BG USA WHMO/HQ; Ornato, Tony M. EOP/WHO
Subject: RE: QUICK REVIEW: POTUS Remarks - Norfolk, VA
Attachments: USNS Comfort_16pt_1126 - with tracked minor edits.docx

See attachment with minor tracked edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Saturday, March 28, 2020 11:28 AM
To: Hicks, Hope C. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO <(b) (6)>; Grisham, Stephanie A. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Birx, Deborah L. EOP/NSC (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Deere, Judd P. EOP/WHO (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO <(b) (6)>; O'Brien, Robert C. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO (b) (6); Vought, Russell T. EOP/OMB (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP (b) (6); Miller, Katie R.

EOP/OVP (b) (6)>; Miller, Stephen EOP/WHO (b) (6)>;
(b) (6) (b) (6)>; Hoelscher, Douglas L. EOP/WHO
(b) (6) Pataki, Tim A. EOP/WHO (b) (6);
Berkowitz, Avrahm J. EOP/ (b) (6); Howerton, Jonathan E. BG USA WHMO/HQ
(b) (6) Ornato, Tony M. EOP/WHO (b) (6)

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: RE: QUICK REVIEW: POTUS Remarks - Norfolk, VA

Attached is an updated version of POTUS' remarks for today. Please review and provide any critical feedback to Staff Sec before 11:50 am today.

Thank you,

Staff Sec

From: Staff Secretary

Sent: Friday, March 27, 2020 9:42 PM

To: Hicks, Hope C. EOP/WHO (b) (6)>; Kushner, Jared C. EOP/WHO (b) (6)
Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO
(b) (6)>; DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>;
Birn, Deborah L. EOP/NSC (b) (6); Ditto, Jessica E. EOP/WHO
(b) (6)>; Hahn, Julia A. EOP/ (b) (6)>; Deere, Judd P.
EOP/WHO (b) (6) Conway, Kellyanne E. EOP/WHO
(b) (6) Philbin, Patrick F. EOP/WHO (b) (6)>; Eisenberg, John A.
EOP/WHO (b) (6)>; O'Brien, Robert C. EOP/WHO (b) (6)>;
'Mizelle, Chad' (b) (6); 'Harrison, Brian (HHS/IOS)' (b) (6)
Kudlow, Larry A. EOP/WHO < (b) (6)>; Grogan, Joseph J. EOP/WHO
(b) (6)>; Vought, Russell T. EOP/OMB < (b) (6)>
Ueland, Eric M. EOP/WHO < (b) (6)>; 'Fauci, Anthony (NIH/NIAID) [E]'
(b) (6)>; Short, Marc T. EOP/OVP (b) (6)>; Miller, Katie R.
EOP/OVP (b) (6)>; Miller, Stephen EOP/WHO (b) (6)>;
(b) (6) (b) (6) Hoelscher, Douglas L. EOP/WHO
(b) (6)>; Pataki, Tim A. EOP/WHO < (b) (6)>;
Berkowitz, Avrahm J. EOP/WHO (b) (6)>; Howerton, Jonathan E. BG USA WHMO/HQ
(b) (6)>; Ornato, Tony M. EOP/WHO < (b) (6)>

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: QUICK REVIEW: POTUS Remarks - Norfolk, VA

Attached for your expedited review are draft remarks prepared for the President's trip to Norfolk.

Staff Secretary will assume your component clears unless we receive feedback or a request for a brief extension by 8:30 am tomorrow, March 28.

Thank you,

Staff Sec

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 29 Mar 2020 01:59:58 +0000
To: Birx, Deborah L. EOP/NSC; Ferrer Piran Basualdo, Austin G. EOP/WHO
Cc: Staff Secretary; Lyons, Derek S. EOP/WHO
Subject: RE: For Review: Seattle Curve

(b) (5)

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Saturday, March 28, 2020 9:20 PM
To: Ferrer Piran Basualdo, Austin G. EOP/WHO <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Staff Secretary <staffsecretary@who.eop.gov>; Lyons, Derek S. EOP/WHO (b) (6)
Subject: Re: For Review: Seattle Curve

(b) (5)

From: "Ferrer Piran Basualdo, Austin G. EOP/WHO" <(b) (6)>
Date: Saturday, March 28, 2020 at 9:00 PM
To: "Birx, Deborah L. EOP/NSC" (b) (6) "Fauci, Anthony (NIH/NIAID)
[E]" (b) (6)>
Cc: Staff Secretary <staffsecretary@who.eop.gov>, "Lyons, Derek S. EOP/WHO"
(b) (6)>
Subject: For Review: Seattle Curve

Dr. Fauci and Dr. Birx --

Please see the below note from the WH Speechwriting team regarding information for the President's press conference tomorrow. Will you please review and provide feedback by **11:30 am tomorrow, March 29?**

Thank you,

Austin

Austin G. Ferrer
Assistant Staff Secretary

(b) (6)

FROM DR. BIRX/FAUCI

(b) (5)

From: (b) (6)
Sent: Sun, 29 Mar 2020 10:06:07 -0400
To: Birx, Deborah L. EOP/NSC
Cc: Grogan, Joseph J. EOP/WHO; CMS (b) (6); Short, Marc T. EOP/OVP; Kushner, Jared C. EOP/WHO; Giroir, Brett (HHS/OASH)
Subject: Re: AMA Statement FYI

As I have stressed at the TF, (b) (5).

On Mar 29, 2020, at 9:53 AM, Birx, Deborah L. EOP/NSC

<(b) (6)> wrote:

Agree – (b) (5)

From: "Grogan, Joseph J. EOP/WHO" (b) (6) >
Date: Sunday, March 29, 2020 at 9:52 AM
To: CMS (b) (6)
Cc: "Short, Marc T. EOP/OVP" (b) (6) >, "Kushner, Jared C. EOP/WHO" (b) (6) >, "Giroir, Brett (HHS/OASH)" (b) (6) >, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >, "Birx, Deborah L. EOP/NSC" (b) (6)
Subject: Re: AMA Statement FYI

Consistent with the conversations at TF, I think (b) (5)
(b) (5)

Sent from my iPhone

On Mar 29, 2020, at 9:11 AM, CMS (b) (6) (b) (6):

FYI..statement from hospitals and doctors on PPE.

Sent from my iPhone

Begin forwarded message:

From: "Pollackc, Rick" <rpollack@aha.org>
Date: March 28, 2020 at 7:37:32 PM EDT

To: "Seema Verma [REDACTED] (b) (6)>

Subject: AMA Statement FYI

With Inadequate Supply of PPE, AMA Urges Critical Steps to Protect Frontline Health Care Workers During COVID-19

March 28, 2020

><https://www.ama-assn.org/press-center/ama-statements/ama-urges-critical-steps-protect-frontline-health-care-workers><

Statement Attributed To:

Patrice A. Harris, M.D., M.A.

President, American Medical Association

"Physicians and front-line health care workers across the country are pleading for more personal protective equipment (PPE), doing everything they can to raise awareness of this crisis. Those on the front lines of the COVID-19 pandemic are concerned that the lack of adequate PPE endangers not only themselves, but their patients and families as well.

"It is vital that our health care workforce is equipped with a sufficient supply of personal protective equipment, including using their own PPE in order to protect themselves and their patients when no other PPE is available.

"At this critical moment, a unified effort is urgently needed to identify gaps in the supply of and lack of access to PPE necessary to fight COVID-19. The AMA continues to urge the Administration to ensure manufacturing of PPE is operating at maximum possible capacity and create a national tracking system of acquisition and distribution of critical PPE supplies.

Federal coordination is necessary to ensure adequate supply and will limit situations where states compete against each other at inflated prices for limited essential supplies.

"Physicians stand ready to provide urgent medical care on the front lines in a pandemic crisis. But their need for protective gear is equally urgent and necessary."

###

RICK POLLACK

President & Chief Executive Officer
American Hospital Association
800 10th Street NW – Suite 400
Two CityCenter
Washington, D.C. 20001-4956
(202) 626-4625 – Telephone
(202) 253-4068 – Fax
rpollack@aha.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 29 Mar 2020 15:44:59 +0000
To: Troye, Olivia EOP/NSC;Hoelscher, Douglas L. EOP/WHO;Birx, Deborah L. EOP/NSC;Obenshain, Tucker T. EOP/OVP
Cc: Pottebaum, Nic D. EOP/WHO
Subject: RE: For your consideration

OK. Let us discuss today.

From: Troye, Olivia EOP/NSC <(b) (6)>
Sent: Sunday, March 29, 2020 10:48 AM
To: Hoelscher, Douglas L. EOP/WHO <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Birx, Deborah L. EOP/NSC <(b) (6)>; Obenshain, Tucker T. EOP/OVP <(b) (6)>
Cc: Pottebaum, Nic D. EOP/WHO <(b) (6)>
Subject: RE: For your consideration

We're going to be inundated with these in the coming days so we'll have to triage and figure out how to be responsive to all these groups.

From: Hoelscher, Douglas L. EOP/WHO <(b) (6)>
Sent: Sunday, March 29, 2020 10:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Birx, Deborah L. EOP/NSC <(b) (6)>; Troye, Olivia EOP/NSC <(b) (6)> Obenshain, Tucker T. EOP/OVP <(b) (6)>
Cc: Pottebaum, Nic D. EOP/WHO <(b) (6)>
Subject: FW: For your consideration

Dr. Fauci and Dr. Birx – please see below which is a fair request. At the right time, we can set up such an interaction on your behalf.

Sincerely,
Doug

From: Michael Fraser <mfraser@astho.org>
Sent: Sunday, March 29, 2020 10:13 AM
To: Pottebaum, Nic D. EOP/WHO <(b) (6)>; Hoelscher, Douglas L. EOP/WHO <(b) (6)>
Subject: [EXTERNAL] For your consideration

Gentlemen – if you think the task force will issue any changes to current community mitigation guidance in the next week, I respectfully request on behalf of our entire membership that at least someone advising on those changes engage with us in a pre-decisional conversation to avoid any further confusion about what may be said at task force press briefings and what governors and health officials

are doing in their states especially if these include partial easement of community mitigation efforts in some states and not others. If decisions have already been made, sharing those in an embargoed manner to advise the states and territories involved is critical to allow our health officials time to plan for those changes. Thank you. Mike

Michael Fraser, PhD MS CAE FCPP

Chief Executive Officer, Association of State and Territorial Health Officials

National Headquarters: 2231 Crystal Drive, Suite 450, Arlington, VA 22202

Regional Office: 600 Peachtree Street NE, Suite 100, Atlanta, GA 30308

Tel: (202) 371-9090 | Asst: (571) 527-3142 | 24/7 S/THO Help Line (571) 527-3131

Mobile: (b) (6)

Pronouns: he, him, his

Follow me on Twitter @mfraserdc1 astho.org | [Facebook](#) | [Twitter](#) | [Blog](#)

Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd**, an innovator in Software as a Service (SaaS) for business. Providing a **safer** and **more useful** place for your human generated data. Specializing in; Security, archiving and compliance. To find out more [Click Here](#).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 29 Mar 2020 17:01:32 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Gidley, Hogan H. EOP/WHO; Grisham, Stephanie A. EOP/WHO; DL Chief of Staff Office; Birx, Deborah L. EOP/NSC; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Deere, Judd P. EOP/WHO; (b) (6) Conway, Kellyanne E. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; O'Brien, Robert C. EOP/WHO; 'Mizelle, Chad'; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Grogan, Joseph J. EOP/WHO; Vought, Russell T. EOP/OMB; Ueland, Eric M. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Miller, Stephen EOP/WHO; (b) (6); Hoelscher, Douglas L. EOP/WHO; Pataki, Tim A. EOP/WHO; Berkowitz, Avraham J. EOP/WHO; Howerton, Jonathan E. BG USA WHMO/HQ; Ornato, Tony M. EOP/WHO
Subject: RE: QUICK REVIEW: POTUS Remarks - 3/29 Press Conference
Attachments: Press Conference 3.29_V1 - with tracked edits.docx

See attached document with minor tracked edits.

From: Staff Secretary (b) (6) >
Sent: Sunday, March 29, 2020 12:42 PM
To: Hicks, Hope C. EOP/WHO (b) (6) >; Kushner, Jared C. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6) >; Grisham, Stephanie A. EOP/WHO (b) (6) >; DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Birx, Deborah L. EOP/NSC (b) (6) >; Ditto, Jessica E. EOP/WHO (b) (6) Hahn, Julia A. EOP/WHO (b) (6) >; Deere, Judd P. EOP/WHO (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6) Eisenberg, John A. EOP/WHO (b) (6) >; O'Brien, Robert C. EOP/WHO (b) (6) 'Mizelle, Chad' (b) (6); Harrison, Brian (HHS/IOS) (b) (6) >; Kudlow, Larry A. EOP/WHO (b) (6) >; Grogan, Joseph J. EOP/WHO (b) (6) >; Vought, Russell T. EOP/OMB <(b) (6) >; Ueland, Eric M. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP <(b) (6) >; Miller, Katie R. EOP/OVP <(b) (6) >; Miller, Stephen EOP/WHO <(b) (6) >; (b) (6) (b) (6) >; Hoelscher, Douglas L. EOP/WHO (b) (6) >; Pataki, Tim A. EOP/WHO (b) (6) Berkowitz, Avraham J. EOP/WHO (b) (6); Howerton, Jonathan E. BG USA WHMO/HQ (b) (6) >; Ornato, Tony M. EOP/WHO (b) (6)
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: QUICK REVIEW: POTUS Remarks - 3/29 Press Conference

Corrected subject line

Attached for your expedited review are draft remarks prepared for the President's press conference this afternoon.

Affirmative clearance is requested from **HHS, DHS, SBA, and WHCO**. All others are welcome to comment. Please review and provide feedback to Staff Sec by **2:00 pm today, March 29.**

-
Thank you,

Staff Sec

From: (b) (6)
Sent: Tue, 31 Mar 2020 13:38:07 -0400
To: Pottinger, Matthew F. EOP/WHO
Cc: Bax, Adriaan (NIH/NIDDK) [E]
Subject: Re: Article

The scientist's name is Adriaan Bax. He is at NIH at NIDDK. I am copying him on this email

On Mar 31, 2020, at 12:15 PM, Pottinger, Matthew F. EOP/WHO
<(b) (6)> wrote:

Tony,
Do you have any info about the forthcoming NEJM article you mentioned in the TF meeting yesterday? The author or title, or any preview of the synopsis? I think you mentioned it had to do with aerosolization of the virus through speaking by asymptomatic and pre-symptomatic people (which masks could help mitigate).
Best,
Matt

From: Droegemeier, Kelvin K. EOP/OSTP (b) (6) >
Sent: Tuesday, March 31, 2020 10:29 AM
To: Pottinger, Matthew F. EOP/WHO (b) (6); Carter, Hillary H. EOP/NSC (b) (6)
Subject: Article

Hi Matt and Hillary,

I chatted with the NE Journal of Medicine Editorial Office and without at least the name of an author or some sense of the title, they can't track down the article. Can you reach out to Tony and see if he has more info, or if he just heard about this and doesn't know more?

Thanks!

Kelvin

Dr. Kelvin K. Droegemeier, Director
Office of Science and Technology Policy
The White House
Washington, DC 20502
(b) (6)
<http://www.ostp.gov>
@WHOSTP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 1 Apr 2020 15:58:34 +0000
To: Birx, Deborah L. EOP/NSC; Carlos del Rio
Subject: RE: [EXTERNAL] Messaging

Ditto.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Tuesday, March 31, 2020 9:11 PM
To: Carlos del Rio (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: [EXTERNAL] Messaging

That's how we presented.

Sent from my iPhone

> On Mar 31, 2020, at 9:08 PM, Del Rio, Carlos (b) (6) wrote:

>

> Dear Debbie & Tony:

> Let me give you a small piece of advice, I hear many wealthy people saying "so what is the big deal with 100,000 or even 200,000 deaths, every year 2.8 M die every year, is the economic pain worth it? The economic cost is too great". I think that we need to say "it's 100,000 - 200,000 deaths with EVERYTHING WE ARE DOING. If we had not done this the number of deaths could have been XX".

>

>

>

> Carlos del Rio, MD.

> Sent from my iPhone

>

>

>

> This e-mail message (including any attachments) is for the sole use of
> the intended recipient(s) and may contain confidential and privileged
> information. If the reader of this message is not the intended
> recipient, you are hereby notified that any dissemination,
> distribution or copying of this message (including any attachments) is

- > strictly prohibited.
- >
- > If you have received this message in error, please contact the sender
- > by reply e-mail message and destroy all copies of the original message
- > (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 16:43:52 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Gidley, Hogan H. EOP/WHO; Grisham, Stephanie A. EOP/WHO; DL Chief of Staff Office; Birx, Deborah L. EOP/NSC; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Deere, Judd P. EOP/WHO; (b) (6); Conway, Kellyanne E. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; Gountanis, John; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Grogan, Joseph J. EOP/WHO; Vought, Russell T. EOP/OMB; Ueland, Eric M. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Miller, Stephen EOP/WHO; (b) (6); (b) (6); Hoelscher, Douglas L. EOP/WHO; Pataki, Tim A. EOP/WHO; Nevins, Kristan K. EOP/WHO; Levi, William (OAG); Moran, John (OAG); Berkowitz, Avraham J. EOP/WHO; Rinat, Ory S. EOP/WHO; (b) (6)
Subject: RE: FLASH REVIEW: POTUS Remarks for Thursday's Press Conference
Attachments: Press Conference 4.2 - with tracked edits.docx

See attached document with tracked edits

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary (b) (6)
Sent: Thursday, April 2, 2020 12:33 PM
To: Hicks, Hope C. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Birx, Deborah L. EOP/NSC (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Deere, Judd P. EOP/WHO (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); Gountanis, John (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO (b) (6); Vought, Russell T. EOP/OMB (b) (6); Ueland, Eric M. EOP/WHO <(b) (6)>; Fauci,

Anthony (NIH/NIAID) [E] <(b) (6)>; Short, Marc T. EOP/OVP
(b) (6)>; Miller, Katie R. EOP/OVP (b) (6) Miller, Stephen
EOP/WHO <(b) (6)>; (b) (6) (b) (6)>; Hoelscher,
Douglas L. EOP/WHO (b) (6); Pataki, Tim A. EOP/WHO
<(b) (6)>; Nevins, Kristan K. EOP/WHO (b) (6)>; Levi,
William (OAG) (b) (6); Moran, John (OAG) (b) (6) Berkowitz,
Avraham J. EOP/WHO (b) (6); Rinat, Ory S. EOP/WHO (b) (6);
(b) (6)

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: FLASH REVIEW: POTUS Remarks for Thursday's Press Conference

Attached are draft remarks for the President for today's press conference.

Affirmative clearances are requested from WHCO, HHS, and DPC. All others are also welcome to comment.

Please review and send all edits and clearances to STAFF SEC by 1:30 p.m.

Thank you,

STAFF SEC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 23:52:52 +0000
To: Hughes, Andrew;Fetalvo, Ninio J. EOP/OVP;Henning, Alexa A. EOP/WHO;Love, Kelly A. EOP/OVP;Daravi, Roma S. EOP/WHO;O'Malley, Devin M. EOP/OVP;Gidley, Hogan H. EOP/WHO;Hahn, Julia A. EOP/WHO;Miller, Katie R. EOP/OVP;Schuck, Matthew J;Bishop, Bradley E;Baker, John C;Adams, Jerome (HHS/OASH);Sherman, Jennifer (HHS/OASH);Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Nevins, Kristan K. EOP/WHO;Naaden, Jennifer L;Vanvick, Caroline G;Lim, Evelyn
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Principal Media Prep: Primetime/Morning Shows

I am sorry, but I have a CNN Town Hall TV hit at 8:00 PM and will have to be in the chair at 8:00 PM and so will not be able to make the call.

From: Hughes, Andrew (b) (6) >
Sent: Thursday, April 2, 2020 7:43 PM
To: Fetalvo, Ninio J. EOP/OVP <(b) (6)>; Henning, Alexa A. EOP/WHO (b) (6)>; Love, Kelly A. EOP/OVP (b) (6)>; Daravi, Roma S. EOP/WHO (b) (6)>; O'Malley, Devin M. EOP/OVP (b) (6)>; Gidley, Hogan H. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO <(b) (6)>; Miller, Katie R. EOP/OVP (b) (6)>; Schuck, Matthew J (b) (6)>; Bishop, Bradley E <(b) (6)>; Baker, John C (b) (6); Adams, Jerome (HHS/OASH) (b) (6); Sherman, Jennifer (HHS/OASH) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Nevins, Kristan K. EOP/WHO (b) (6); Naaden, Jennifer L (b) (6); Vanvick, Caroline G <(b) (6); Lim, Evelyn (b) (6)
Subject: Re: Principal Media Prep: Primetime/Morning Shows

Thanks, we had Secretary Carson on the line twice waiting for people to join. If you could let us know with more advance notice that would be appreciated.

We know y'all are busy and dealing with a lot so thank you for your understanding.

Sincerely,

Andrew

Andrew D. Hughes
Chief of Staff
HUD

(b) (6)

From: Fetalvo, Ninio J. EOP/OVP <(b) (6)>

Sent: Thursday, April 2, 2020 7:37 PM

To: Henning, Alexa A. EOP/WHO; Love, Kelly A. EOP/OVP; Daravi, Roma S. EOP/WHO; O'Malley, Devin M. EOP/OVP; Gidley, Hogan H. EOP/WHO; Hahn, Julia A. EOP/WHO; Miller, Katie R. EOP/OVP; Schuck, Matthew J; Bishop, Bradley E; Hughes, Andrew; Baker, John C; Adams, Jerome (HHS/OASH); Sherman, Jennifer (HHS/OASH); Anthony Fauci; Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]

Subject: RE: Principal Media Prep: Primetime/Morning Shows

All—It looks like some of you may or may not have received the update. As of now, this will take place at **8pm tonight**.

Thank you,
Ninio

-----Original Appointment-----

From: Fetalvo, Ninio J. EOP/OVP

Sent: Thursday, April 2, 2020 7:15 PM

To: Henning, Alexa A. EOP/WHO; Love, Kelly A. EOP/OVP; Daravi, Roma S. EOP/WHO; O'Malley, Devin M. EOP/OVP; Gidley, Hogan H. EOP/WHO; Hahn, Julia A. EOP/WHO; Miller, Katie R. EOP/OVP; Schuck, Matthew J; 'Bishop, Bradley E'; Hughes, Andrew; Baker, John C; 'Adams, Jerome (HHS/OASH)'; 'Sherman, Jennifer (HHS/OASH)'; Anthony Fauci; 'Conrad, Patricia (NIH/NIAID) [E]'; Billet, Courtney (NIH/NIAID) [E]

Subject: Principal Media Prep: Primetime/Morning Shows

When: Thursday, April 2, 2020 8:00 PM-8:30 PM (UTC-05:00) Eastern Time (US & Canada).

Where: Dial-In: (b) (6) | Code: (b) (6)

Hi all—

This will be a media prep for any principals doing primetime/morning shows. Please forward this invite to your respective principal's scheduler.

Dr. Carson

- 9:00PM FNC Hannity
 - Topics: The White House's new announcement on wearing masks and then she said they will ask on our CARES Act funding.

Surgeon General Adams

- 11:00AM NBC Facebook Live w/ John Torres, Chief Medical Correspondent
 - Topics: What do we all need to do over the next 30 days? Guidance on face masks for the general population? What are we currently doing right in our response and what could use improvement? Is vaping a risk factor for complications from this virus?

Dr. Fauci

- 8:00PM CNN Town Hall
 - Topics:
- 8:00AM FNC Fox and Friends
 - Topics:

If you have any conflicts, please let us know asap.

Thank you,
Ninio

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 02:36:33 +0000
To: Birx, Deborah L. EOP/NSC; Kan, Derek T. EOP/OMB
Subject: RE: Nature pre-print - viral dynamics-2020.pdf

Derek:

(b) (5)

Best regards,
Tony

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Thursday, April 2, 2020 10:30 PM
To: Kan, Derek T. EOP/OMB (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Re: Nature pre-print - viral dynamics-2020.pdf

(b) (5) Deb

From: "Kan, Derek T. EOP/OMB" (b) (6)
Date: Thursday, April 2, 2020 at 10:20 PM
To: Anthony Fauci <(b) (6)>, "Birx, Deborah L. EOP/NSC"
(b) (6)
Subject: Nature pre-print - viral dynamics-2020.pdf

Debbie and Tony, not sure if you saw the attached paper.

Was published online yesterday and may be of use. I have no medical training but am a data guy.

(b) (5)

Keep fighting the good fight!

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 11:04:01 +0000
To: Short, Marc T. EOP/OVP; Adams, Jerome (HHS/OASH); Birx, Deborah (CDC/OD); Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Giroir, Brett (HHS/OASH); Stephen Hahn; Kadlec, Robert (OS/ASPR/IO)
Subject: RE: Mask

Look forward to discussing this.

-----Original Message-----

From: Short, Marc T. EOP/OVP (b) (6)>
Sent: Friday, April 3, 2020 7:03 AM
To: Adams, Jerome (HHS/OASH) (b) (6)>; Birx, Deborah (CDC/OD) (b) (6)
Birx, Deborah L. EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); Giroir, Brett (HHS/OASH)
(b) (6)>; Stephen Hahn (b) (6); Kadlec, Robert (OS/ASPR/IO)
(b) (6)
Subject: RE: Mask

(b) (5)

-----Original Message-----

From: Adams, Jerome (HHS/OASH) (b) (6)>
Sent: Friday, April 3, 2020 6:41 AM
To: Birx, Deborah (CDC/OD) (b) (6); Birx, Deborah L. EOP/NSC (b) (6)>;
Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6);
Giroir, Brett (HHS/OASH) (b) (6); Stephen Hahn (b) (6)>; Kadlec, Robert
(OS/ASPR/IO) (b) (6)>
Subject: Mask

I know this is going to sound self-serving/ self defending and I assure you it's not and apologize in advance- but as doctors and scientists I just want to have this discussion.

(b) (5)

(b) (5)

Thoughts?
Jerome

VADM Jerome Adams
20th US Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 3 Apr 2020 15:22:37 +0000
To: Staff Secretary;DL Chief of Staff Office;Philbin, Patrick F. EOP/WHO;Eisenberg, John A. EOP/WHO;Short, Marc T. EOP/OVP;Miller, Katie R. EOP/OVP;Miller, Stephen EOP/WHO;Birx, Deborah L. EOP/NSC;Pottinger, Matthew F. EOP/WHO;Troye, Olivia EOP/NSC;Liddell, Christopher P. EOP/WHO;Vought, Russell T. EOP/OM (b) (6);Blackwell, Juliana;Conway, Kellyanne E. EOP/WHO;Navarro, Peter K. EOP/WHO;Hicks, Hope C. EOP/WHO;Berkowitz, Avrahm J. EOP/WHO;Kushner, Jared C. EOP/WHO; (b) (6);Kudlow, Larry A. EOP/WHO;Olmem, Andrew J. EOP/WHO;Grogan, Joseph J. EOP/WHO;Rinat, Ory S. EOP/WHO;Ueland, Eric M. EOP/WHO;Hahn, Julia A. EOP/WHO;Ditto, Jessica E. EOP/WHO;Gidley, Hogan H. EOP/WHO;Grisham, Stephanie A. EOP/WHO;Hoelscher, Douglas L. EOP/WHO;Pataki, Tim A. EOP/WHO;Nevins, Kristan K. EOP/WHO;Harrison, Brian (HHS/IOS);Redfield, Robert R. (CDC/OD)
Subject: RE: FOR FLASH REVIEW: Draft Mask Guidance
Attachments: Mask Wearing REVISED v5 - with tracked edits.docx

Please see attached document with tracked edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Friday, April 3, 2020 11:13 AM
To: DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6); Miller, Stephen EOP/WHO (b) (6); Birx, Deborah L. EOP/NSC (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); Troye, Olivia EOP/NSC (b) (6); Liddell, Christopher P. EOP/WHO (b) (6); Vought, Russell T. EOP/OMB (b) (6); Blackwell, Juliana (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Navarro, Peter K. EOP/WHO (b) (6); Hicks, Hope C. EOP/WHO (b) (6); Berkowitz, Avrahm J. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); (b) (6); Kudlow, Larry A. EOP/WHO <(b) (6)>; Olmem, Andrew J.

EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO (b) (6); Rinat, Ory S. EOP/WHO (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Hoelscher, Douglas L. EOP/WHO (b) (6); Pataki, Tim A. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Nevins, Kristan K. EOP/WHO (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: RE: FOR FLASH REVIEW: Draft Mask Guidance
Importance: High

Updated guidance attached. Please let Staff Sec know **by Noon today** if you have any critical edits.

Thanks,

Staff Sec

From: Staff Secretary
Sent: Thursday, April 2, 2020 10:13 AM
To: DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO <(b) (6)>; Staff Secretary <staffsecretary@who.eop.gov>; Short, Marc T. EOP/OVP (b) (6); Miller, Katie R. EOP/OVP (b) (6); Miller, Stephen EOP/WHO (b) (6); Bix, Deborah L. EOP/NSC (b) (6); Pottinger, Matthew F. EOP/WHO <(b) (6)>; Troye, Olivia EOP/NSC (b) (6); Liddell, Christopher P. EOP/WHO <(b) (6)>; Vought, Russell T. EOP/OMB (b) (6); 'john.gountanis@hq.dhs.gov' (b) (6); 'Blackwell, Juliana' (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Navarro, Peter K. EOP/WHO (b) (6); Hicks, Hope C. EOP/WHO (b) (6); Berkowitz, Avrahm J. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Kudlow, Larry A. EOP/WHO <(b) (6)>; Olmem, Andrew J. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO (b) (6); Rinat, Ory S. EOP/WHO (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); Hoelscher, Douglas L. EOP/WHO (b) (6); Pataki, Tim A. EOP/WHO (b) (6); 'Fauci, Anthony (NIH/NIAID) [E]' (b) (6); Nevins, Kristan K. EOP/WHO (b) (6); 'Brian.Harrison@hhs.gov' (b) (6)
Cc: Staff Secretary <staffsecretary@who.eop.gov>
Subject: FOR FLASH REVIEW: Draft Mask Guidance
Importance: High

Attached for expedited review is draft guidance on the use of masks to be posted on the CDC website.

Please let Staff Sec know **by 11:00 am** if you have any edits or comments.

Thanks,

Staff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 5 Apr 2020 18:28:15 +0000
To: Birx, Deborah L. EOP/NSC; 'Birx, Deborah L'
Subject: FW: Alternate corona virus model: statistician (NIST) reaffirms your prediction results, Part 2
Attachments: corona_virus_korea_deaths_040220.pdf,
corona_virus_italy_deaths_040220.pdf, corona_virus_usa_deaths_040220.pdf,
corona_virus_new_york_city_deaths_040220.pdf,
corona_virus_montgomery_county_md_cases_040220.pdf

Attachments from prior e-mail

From: Filliben, James J. (Fed) (b) (6)
Sent: Saturday, April 4, 2020 8:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Filliben, James J. (Fed) <(b) (6)>
Subject: Alternate corona virus model: statistician (NIST) reaffirms your prediction results, Part 2

4/4/20 Sat 8pm

Dr. Fauci,

I herein attach the promised analyses for the 5 sites.

Jim Filliben

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 12:59:55 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Gidley, Hogan H. EOP/WHO; Grisham, Stephanie A. EOP/WHO; DL Chief of Staff Office; Birx, Deborah L. EOP/NSC; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Deere, Judd P. EOP/WHO; (b) (6); Conway, Kellyanne E. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; 'Mizelle, Chad'; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Grogan, Joseph J. EOP/WHO; Vought, Russell T. EOP/OMB; Ueland, Eric M. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Miller, Stephen EOP/WHO; (b) (6); Hoelscher, Douglas L. EOP/WHO; Pataki, Tim A. EOP/WHO; Berkowitz, Avraham J. EOP/WHO; DeBacker, Devin A. EOP/WHO; Sandoloski, Sean M. EOP/WHO; (b) (6)
Subject: RE: For Review: POTUS Remarks (video script) - Passover
Attachments: Pocket Card - Passover video - with suggested tracked edits.docx

Please see attachment with suggested tracked edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>

Sent: Monday, April 6, 2020 8:49 AM

To: Hicks, Hope C. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Birx, Deborah L. EOP/NSC (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Deere, Judd P. EOP/WHO <(b) (6)>; Conway, Kellyanne E. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO <(b) (6)>; Vought, Russell T. EOP/OMB (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP

(b) (6); Miller, Katie R. EOP/OVP (b) (6); Miller, Stephen
EOP/WHO (b) (6) (b) (6) (b) (6); Hoelscher,
Douglas L. EOP/WHO (b) (6); Pataki, Tim A. EOP/WHO
(b) (6); Berkowitz, Avrahm J. EOP/WHO (b) (6); DeBacker,
Devin A. EOP/WHO (b) (6); Sandoloski, Sean M. EOP/WHO
(b) (6); (b) (6);

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: For Review: POTUS Remarks (video script) - Passover

Attached for your awareness are draft POTUS remarks for a video recording on Passover.

Staff Secretary will assume your component clears unless we receive feedback or a request for an extension by **12:00 pm today, April 6.**

Thank you,

Staff Sec

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 13:04:46 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Gidley, Hogan H. EOP/WHO; Grisham, Stephanie A. EOP/WHO; DL Chief of Staff Office; Birx, Deborah L. EOP/NSC; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Deere, Judd P. EOP/WHO; (b) (6); Conway, Kellyanne E. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; 'Mizelle, Chad'; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Grogan, Joseph J. EOP/WHO; Vought, Russell T. EOP/OMB; Ueland, Eric M. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Miller, Stephen EOP/WHO; (b) (6); Hoelscher, Douglas L. EOP/WHO; Pataki, Tim A. EOP/WHO; Berkowitz, Avraham J. EOP/WHO; DeBacker, Devin A. EOP/WHO; Sandoloski, Sean M. EOP/WHO; (b) (6)
Subject: RE: For Review: POTUS Remarks (video script) - Easter
Attachments: Pocket Card - Easter video - with suggested edits.docx

Please see attachment with minor suggested tracked edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>
Sent: Monday, April 6, 2020 8:49 AM
To: Hicks, Hope C. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Birx, Deborah L. EOP/NSC (b) (6); Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Deere, Judd P. EOP/WHO (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO <(b) (6)>; Pottinger, Matthew F. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO <(b) (6)>; Vought, Russell T. EOP/OMB (b) (6); Ueland, Eric M. EOP/WHO <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP

(b) (6); Miller, Katie R. EOP/OVP (b) (6); Miller, Stephen
EOP/WHO (b) (6); (b) (6) (b) (6); Hoelscher,
Douglas L. EOP/WHO (b) (6); Pataki, Tim A. EOP/WHO
(b) (6); Berkowitz, Avrahm J. EOP/WHO (b) (6); DeBacker,
Devin A. EOP/WHO (b) (6); Sandomoski, Sean M. EOP/WHO
(b) (6); (b) (6)

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: For Review: POTUS Remarks (video script) - Easter

Attached for your awareness are draft POTUS remarks for a video recording on Easter.

Staff Secretary will assume your component clears unless we receive feedback or a request for an extension by **12:00 pm today, April 6.**

Thank you,

Staff Sec

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 13:17:35 +0000
To: Staff Secretary; Hicks, Hope C. EOP/WHO; Kushner, Jared C. EOP/WHO; Gidley, Hogan H. EOP/WHO; Grisham, Stephanie A. EOP/WHO; DL Chief of Staff Office; Birx, Deborah L. EOP/NSC; Ditto, Jessica E. EOP/WHO; Hahn, Julia A. EOP/WHO; Deere, Judd P. EOP/WHO; (b) (6); Conway, Kellyanne E. EOP/WHO; Philbin, Patrick F. EOP/WHO; Eisenberg, John A. EOP/WHO; Pottinger, Matthew F. EOP/WHO; 'Mizelle, Chad'; Harrison, Brian (HHS/IOS); Kudlow, Larry A. EOP/WHO; Grogan, Joseph J. EOP/WHO; Vought, Russell T. EOP/OMB; Ueland, Eric M. EOP/WHO; Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP; Miller, Stephen EOP/WHO; (b) (6); Hoelscher, Douglas L. EOP/WHO; Pataki, Tim A. EOP/WHO; Berkowitz, Avraham J. EOP/WHO; DeBacker, Devin A. EOP/WHO; Sandoloski, Sean M. EOP/WHO; (b) (6)
Subject: RE: For Review: Draft POTUS Remarks - Call with Governors
Attachments: Call with Governors 4-6-2020 - with minor tracked edits.docx

See attachment with minor tracked edits

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Staff Secretary <staffsecretary@who.eop.gov>

Sent: Monday, April 6, 2020 7:10 AM

To: Hicks, Hope C. EOP/WHO (b) (6); Kushner, Jared C. EOP/WHO (b) (6); Gidley, Hogan H. EOP/WHO (b) (6); Grisham, Stephanie A. EOP/WHO (b) (6); DL Chief of Staff Office <DLChiefofStaffOffice@WHO.eop.gov>; Birx, Deborah L. EOP/NSC <(b) (6)>; Ditto, Jessica E. EOP/WHO (b) (6); Hahn, Julia A. EOP/WHO (b) (6); Deere, Judd P. EOP/WHO (b) (6); Conway, Kellyanne E. EOP/WHO (b) (6); Philbin, Patrick F. EOP/WHO (b) (6); Eisenberg, John A. EOP/WHO (b) (6); Pottinger, Matthew F. EOP/WHO (b) (6); 'Mizelle, Chad' (b) (6); Harrison, Brian (HHS/IOS) (b) (6); Kudlow, Larry A. EOP/WHO (b) (6); Grogan, Joseph J. EOP/WHO <(b) (6)>; Vought, Russell T. EOP/OMB (b) (6); Ueland, Eric M. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP

(b) (6)>; Miller, Katie R. EOP/OVP (b) (6)>; Miller, Stephen
EOP/WHO (b) (6)>; (b) (6) < (b) (6) Hoelscher,
Douglas L. EOP/WHO (b) (6)>; Pataki, Tim A. EOP/WHO
(b) (6) Berkowitz, Avrahm J. EOP/WHO (b) (6)>; DeBacker,
Devin A. EOP/WHO (b) (6); Sandoloski, Sean M. EOP/WHO
(b) (6)>; (b) (6)>

Cc: Staff Secretary <staffsecretary@who.eop.gov>

Subject: For Review: Draft POTUS Remarks - Call with Governors

Attached for your review are draft POTUS remarks for today's call with Governors.

Please send all comments and clearances to Staff Sec by **10:00 am today, April 6.**

Thank you,

Staff Sec

From: (b) (6)
Sent: Mon, 6 Apr 2020 21:00:59 -0400
To: (b) (6); Deborah Birx
Subject: Fwd: Toward the new normal with COVID-19

Deb:

(b) (5)
Tony's

Begin forwarded message:

From: "Thomas R. Frieden" (b) (6)
Date: April 6, 2020 at 8:19:05 PM EDT
To: "Thomas R. Frieden" (b) (6) >
Subject: Toward the new normal with COVID-19

Dear Colleague,

Until there's a COVID-19 vaccine, we won't be able to return to the way things were. Reopening will have to be gradual—loosening a tap not opening a floodgate, and must be guided by data on specific benchmarks to be reached. Writing today for Think Global Health of CFR, [I outlined the key steps we must take](#) right now to re-open as soon and as safely as possible. This will require improving strategic intelligence, fortifying our health care system, and revolutionizing public health, including extensive testing and intensive contact tracing and support for people who are infected and their contacts.

Last week I shared [simple but high-value COVID-19 interventions](#) which require minimal cost and. The simple steps were adapted from a [great paper](#) from a team in Australia which we also summarized [here](#).

Our team analyzes the latest COVID-19 data, including a hugely important review of syndromic surveillance and clear scientific analysis of topics such as face masks and blood type. See the latest below and in our [Weekly Science Review](#).

If you would like to share, I've tweeted [here](#), [here](#), and [here](#).

Thank you for what you do to fight COVID-19.
Tom

Tom Frieden, MD, MPH
President and CEO
www.DrTomFrieden.net
tfrieden@rtsl.org





STAY CONNECTED

www.resolvetosavelives.org [facebook](#) [twitter](#)



Science Update: April 6, 2020

Covering articles published March 28 - April 3, 2020

Dear Colleague,

This week we're focusing on 'what's next?' Opening up society is about data, not a date. It's about easing a faucet not opening the floodgates and we must prepare to test, isolate, contact trace, and quarantine to avoid future peaks. Our team at [Resolve to Save Lives](#), an initiative of [Vital Strategies](#), has been analyzing the latest COVID-19 data on pressing topics, providing helpful summaries and insight.

We're now on our second week of sharing our data summaries every Monday. I hope you find this resource useful, and are staying informed and safe.

All the best,

Tom



Dr. Tom Frieden

President and CEO of Resolve to Save Lives, an Initiative of Vital Strategies

[Download a PDF version of the Weekly Science Review](#)

New Insights

Data insight: Syndromic surveillance should be explored as an early signal for COVID-19

Syndromic surveillance is an innovative surveillance technique designed to detect illness clusters early, before diagnoses are confirmed and reported to public health agencies, and to mobilize a rapid response, thereby reducing morbidity and mortality.


Two syndromes could be used to detect an increase in complaints associated with COVID-19 in New York City:

- Influenza-like illness (ILI) syndrome includes mention of fever, flu and cough or sore throat
- Respiratory includes mention of bronchitis, chest cold, chest congestion, chest

pain, cough, difficulty breathing, pneumonia, shortness of breath, and upper respiratory

Data on the number and proportion of each syndrome is publicly available and updated daily. This type of information can be used as an early signal for COVID-19 if an increase in the number or proportion of visits due to ILI and Respiratory syndromes is driven by symptomatic COVID-19 patients.

Influenza-like illness (ILI) overall emergency department visit count and ratio | 2/21/2020 to 4/3/2020



Looking back at ILI data from NYC from March 2020, the proportion of ED visits due to both ILI and Respiratory syndromes started to rise in early March, which is atypical when compared to seasonal averages and occurred in the context of falling influenza rates.

Face Masks in the Community

Respirators and surgical masks should be reserved for medical professionals. For the general public, there is no strong scientific evidence that facial coverings prevent transmission of disease. Expert groups are currently examining the risks and benefits of face mask use by the public, primarily out of concern for asymptomatic transmission. Regardless, face masks should not replace other measures currently in place to reduce the spread of infection.

[Click here](#) for the latest guidance on cloth face coverings from the US CDC.

Latest Articles

Epidemiology

Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults — Seattle, Washington, 2020 (MMWR 3 April 2020)

Main message: It is possible to prevent an outbreak of COVID-19, even in a senior assisted living community. Screening for COVID-19 symptoms only is insufficient to identify all COVID-19 cases. In the absence of frequent testing, it is especially important to adhere to stringent SARS-CoV-2 mitigation measures in independent and assisted living communities.

Response

Impact of school closures for COVID-19 on the US health-care workforce and net mortality: a modeling study (Lancet Public Health, 3 April 2020)

Main message: The decision to close schools is a difficult trade-off between closing schools to reduce further transmission and potential health-care worker absenteeism due to additional childcare needs that could ultimately increase mortality from COVID-19. We don't yet have enough information to estimate the overall impact of current school closures.

Question of the Week

How does COVID-19 relate to blood type?

It has been reported that certain blood types may be associated with an increased risk of COVID-19. This is based on a non-peer reviewed study of 2,173 patients in Wuhan, China which showed that blood group A was associated with a higher risk for acquiring COVID-19 compared with non-A blood groups, whereas blood group O was associated with a lower risk for the infection compared with non-O blood groups. More specifically, the proportion of blood group A in patients with COVID-19 was significantly higher than that in a group of 3,694 controls from a recent survey in Wuhan. the general population, being 38% in the former vs 32% in the later ($P < 0.001$) The observed higher risk for blood group A was not replicated in a similar comparison of 285 COVID-19 patients and 23,368 controls in Shenzhen, China. The authors of this study acknowledge that this is an early study with limitations and should not guide clinical practice. Others note that the authors did not provide an explanation for this observation and the findings should not change the behavior of people with certain blood types. Those with Type A or Type O blood should continue to follow guidance to prevent infection (as should those of any blood type).

[Read the full COVID-19 Weekly Science Review](#)

News Highlights from Last Week



March 31, 2020 - A series of errors with lab testing delayed the U.S. response to the Covid-19 pandemic. We need to be clear about what went wrong and how we can get things right. [Continue reading.](#)



April 1, 2020 - Coronavirus live blog: Dr. Tom Frieden, former CDC director, answers your questions. [Continue reading.](#)



April 1, 2020 - Dr. Tom Frieden, who served as CDC Director during the Ebola and Zika outbreaks, weighs in on the latest pandemic models and how Americans can stay healthy during an appearance on "CBS This Morning." [Watch here.](#)



April 2, 2020 - "This is a world war, and the enemy is not people, states or countries but a dangerous microbe. It's us against the microbes," Frieden told reporters during a Wednesday news briefing. He led the response to the Ebola outbreak in 2014. [Continue Reading.](#)

Social Media Highlights



MIT Technology Review ✓
@techreview



We're speaking with epidemiologist Dr. @CyrusShahpar about the "war" against covid-19. Join us for this live web show, and bring your questions.



Radio Corona: The War Against Covid-19

In this episode of Radio Corona, Gideon Lichfield, editor in chief of Technology Review, will speak with epidemiologist ...

[youtube.com](#)

4:12 PM · Apr 1, 2020 · Twitter Web App

17 Retweets 22 Likes



Dr. Tom Frieden ✓
@DrTomFrieden



If you missed my virtual press briefing and public health update on the #COVID19 pandemic, you can watch it below on my YouTube channel #coronavirus



Virtual Media Briefing with Dr. Tom Frieden
The former CDC Director and NYC Health Commissioner will provide a rigorous public health update on COVID-19 pandemic.

April 1, 2020
Zoom will begin at 12:00 PM ET

Dr. Tom Frieden
CEO of Resolve to Save Lives, an initiative of Vital Strategies



Resolve to Save Lives - Virtual Media Briefing on COVID-19 with Dr....

Resolve to Save Lives and Dr. Tom Frieden provide a Virtual Media Briefing and public health update on COVID-19, April 1, 2020

[youtube.com](#)

For more insights and updates, and to read this week's Science Review, visit:
www.preventepidemics.org



*Copyright © *2019* *Resolve to Save Lives*, All rights reserved.*

Our mailing address is:

[*preventepidemics@resolvetosavelives.org*](mailto:*preventepidemics@resolvetosavelives.org)

You can [update your preferences](#) or [unsubscribe from this list](#).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 12:31:05 +0000
To: Del Rio, Carlos; (b) (6)
Subject: RE: wanted to send you my most recent JAMA Viewpoint....hopefully useful for clinicians.

Carlos:

Terrific article! Thanks for sending it.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Del Rio, Carlos (b) (6)
Sent: Tuesday, April 7, 2020 8:11 AM
To: (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: wanted to send you my most recent JAMA Viewpoint....hopefully useful for clinicians.

<https://jamanetwork.com/journals/jama/fullarticle/2764366>

Carlos

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact

the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:07:45 +0000
To: Birx, Deborah L. (b) (6); Birx, Deborah L. EOP/NSC; Grogan, Joseph J. EOP/WHO (b) (6); Redfield, Robert R. (CDC/OD); Giroir, Brett (HHS/OASH); Hahn, Stephen; Kadlec, Robert (OS/ASPR/IO)
Subject: FW: The Contact Tracing Collaborative
Attachments: CTC_PIH Press Release_FINAL.pdf

See attached.

(b) (5)

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Yong Kim <Jim.Yong.Kim@global-infra.com>
Sent: Friday, April 3, 2020 3:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: The Contact Tracing Collaborative

Hi Tony,

Not sure you'll be able to take a look but we launched today. I attached the Partners In Health press release. Thanks so much for everything you're doing.

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 03:06:30 +0000
To: Grogan, Joseph J. EOP/WHO
Cc: Bonner, Maria K. EOP/WHO;Campana, Alexandra D.
EOP/WHO; (b) (6);Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [EXTERNAL] RE: Good news

Joe:

I would be happy to speak with him. However, it would have to wait until Thursday since tomorrow is impossible. I believe that we can work this out. Perhaps we can arrange for a call between me ,the CEO and some knowledgeable people in my program.

Best regards,

Tony

From: Grogan, Joseph J. EOP/WHO (b) (6)
Sent: Tuesday, April 7, 2020 10:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Bonner, Maria K. EOP/WHO (b) (6);Campana, Alexandra D. EOP/WHO (b) (6)
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond, (b) (5)

Sent from my iPhone

Begin forwarded message:

From: Shawn O'Neail (b) (6)
Date: April 7, 2020 at 10:07:37 PM EDT
To: "Grogan, Joseph J. EOP/WHO" (b) (6), "Bonner, Maria K. EOP/WHO" (b) (6)>
Subject: [EXTERNAL] RE: Good news

You bet.

Joe – Have an enormous request – for help or counsel.

(b) (4)

My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

=====

Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >www.lilly.com<



CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO (b) (6)
Sent: Tuesday, April 7, 2020 9:31 AM
To: Shawn O'Neail (b) (6); Bonner, Maria K. EOP/WHO
<(b) (6)>
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

From: Shawn O'Neail (b) (6)
Sent: Tuesday, April 7, 2020 9:26 AM
To: Grogan, Joseph J. EOP/WHO (b) (6); Bonner, Maria K. EOP/WHO
(b) (6)>
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for \$35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the \$35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you....

Shawn

=====

Shawn O'Neil
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) mobile)
(b) (6) | >>www.lilly.com<<



CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 10:36:49 +0000
To: Grogan, Joseph J. EOP/WHO
Subject: RE: pathogenesis and NIH surveillance

Joe:

Thanks for the note. I will discuss with you late today at the WH.

Best,

Tony

From: Grogan, Joseph J. EOP/WHO <(b) (6)>
Sent: Wednesday, April 8, 2020 6:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Bonner, Maria K. EOP/WHO <(b) (6)>; Campana, Alexandra D. EOP/WHO <(b) (6)>
Subject: pathogenesis and NIH surveillance

Feel free to have a staff member respond to this and let me know if there is anyone on your team I can cc:

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 17:27:54 +0000
To: Grogan, Joseph J. EOP/WHO
Cc: (b) (6) Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Autopsy Findings - as discussed
Attachments: COVID Autopsy 1.pptx, ATT00001.htm

These autopsy slide are in partial answer to your question from earlier today. I will explain when I see you.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 8, 2020 7:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Autopsy Findings - as discussed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 17:45:10 +0000
To: Birx, Deborah L. EOP/NSC; Tabak, Lawrence (NIH/OD) [E]
Cc: Dabbar, Paul; Brouillette, Dan; Schwetz, Tara (NIH/OD) [E]
Subject: RE: Insights from the DOE National Lab efforts

Ditto from me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Saturday, April 11, 2020 1:43 PM
To: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Cc: Dabbar, Paul (b) (6); Brouillette, Dan (b) (6); Schwetz, Tara (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Insights from the DOE National Lab efforts

Thank you. Excellent to see all the capacity. Dr Fauci and I appreciate seeing this. (b) (5)
(b) (5)

Sent from my iPhone

> On Apr 11, 2020, at 1:31 PM, Tabak, Lawrence (NIH/OD) [E] <(b) (6)> wrote:
>
> Thanks Paul,
> I will make certain that the key members of Tony's team get this.
> Best wishes,
> Larry
>
> Lawrence A. Tabak, DDS, PhD
> Principal Deputy Director, NIH
>
> On 4/11/20, 10:35 AM, "Dabbar, Paul" (b) (6) > wrote:
>
> Dear Dr's Fauci and Birx:
>
> Secretary Brouillette and I wanted to pass along to you a few items we have been working on with various

people on the Task Force and the White House. As you know we run the 17 National Labs (Oak Ridge, Lawrence Berkeley, Argonne, Los Alamos, etc.), and have various large capabilities including supercomputing, imaging, and biology.

>

> We know you are very busy, but we thought you should have visibility on the following three topics:

>

(b) (5)

- >
- > Please let us know if you would like to discuss further any of these topics.
- >
- > If the task force would like to amplify any of this work, our communications team stands ready to connect with the VP's office. Kelly Love is detailed to the White House from DOE so if there is a particular point above that you are interested in having talking points on, we are happy to make sure she has all of the relevant points for you.
- >
- >
- >
- > Paul M. Dabbar | Under Secretary for Science | U.S. Department of Energy |
- > James V. Forrestal Building | Department of Energy Headquarters |
- > 1000 Independence Ave, S.W., Washington D.C. 20585 USA |
- >
- > Executive Assistant: Sabrina Smith | T: [REDACTED] (b) (6)
- >
- >
- >
- >

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:50:28 +0000
To: Pottinger, Matthew F. EOP/WHO
Subject: RE: [EXTERNAL] For your confidential information

Thanks, Matt.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pottinger, Matthew F. EOP/WHO (b) (6)
Sent: Friday, April 10, 2020 1:18 PM
To: Carter, Hillary H. EOP/NSC (b) (6); Chafin, Kelly B. EOP/NSC (b) (6); Christ, Katelyn E. EOP/NSC (b) (6); Fabina, Lauren C. EOP/NSC <(b) (6)>; Ferro, Phil J. EOP/NSC (b) (6); Harrington, Kevin J. EOP/NSC (b) (6); Hennessey, Millicent S. EOP/NSC (b) (6); Holt, Brandon T. EOP/NSC (b) (6); Kratsios, Michael J. EOP/OSTP <(b) (6)>; Droegemeier, Kelvin K. EOP/OSTP (b) (6); Miles, Aaron R. EOP/OSTP (b) (6); Nesheiwat, Julia EOP/NSC (b) (6); Redd, Stephen C. EOP/NSC <(b) (6)>; Ruggiero, Anthony J. EOP/NSC (b) (6); Sinclair, Michael R. EOP/NSC (b) (6); Waterman, Paige E. EOP/OSTP (b) (6); Watson, Ian D. EOP/OSTP (b) (6); Wilson, Matt B. EOP/OSTP <(b) (6)>; Ferro, Phil J. EOP/NSC (b) (6); Ruggiero, Anthony J. EOP/NSC (b) (6); Bix, Deborah L. EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: [EXTERNAL] For your confidential information

Team,

This report is pre-publication, so please don't forward without my permission. The author was kind enough to send it. (b) (5)

(b) (5)

(b) (5)

Matt

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:48:21 +0000
To: Adams, Jerome (HHS/OASH); (b) (6); Joe Grogan; Birx, Deborah L. EOP/NSC
Cc: Smith, Ja'Ron K. EOP/WHO; Frazier, Nicole A. EOP/WHO; Rinat, Ory S. EOP/WHO; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: NAACP call

Jerome:

I would be happy to help in any way that I can.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Adams, Jerome (HHS/OASH) (b) (6) >
Sent: Wednesday, April 8, 2020 2:48 PM
To: (b) (6); Joe Grogan (b) (6) >; Birx, Deborah L. EOP/NSC (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Cc: Smith, Ja'Ron K. EOP/WHO <(b) (6)>; Frazier, Nicole A. EOP/WHO (b) (6); Rinat, Ory S. EOP/WHO <(b) (6)>
Subject: NAACP call

I just got off a phone call with NAACP President Johnson. He would like for us to launch a public awareness campaign targeting the black community ASAP. He says they can work on securing donated media time and celebrity influencers if we can provide a) Me and Dr. Fauci as the "docs" and b) We can do the production and provide the talking points. I have cced Ory

who's team filmed and produced the WH adds Drs. Fauci, Birx, and I did so far- they are amazing and can usually turn these around in 24-28 hours.

(b) (5)

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:09:42 +0000
To: Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Hahn, Stephen
Cc: (b) (6) MEDCOM WRAIR (USA)
Subject: RE: Working on testing strategy

There is no attachment with this.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Sunday, April 12, 2020 1:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD)
(b) (6); Hahn, Stephen (b) (6)
Cc: (b) (6) MEDCOM WRAIR (USA) <(b) (6)>
Subject: Working on testing strategy

Just a draft – all comments welcomed. (b) (5)
(b) (5)
(b) (5). Please review. Also Steve can you resend your AB
document to me. Deb

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 20:34:28 +0000
To: Short, Marc T. EOP/OVP; Adams, Jerome (HHS/OASH); Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Giroir, Brett (HHS/OASH)
Cc: Grogan, Joseph J. EOP/WHO
Subject: RE: Elective surgeries and testing

Jerome:

I appreciate your concern, which has some merit. (b) (5)

(b) (5)

(b) (5) I agree with Marc that this should be discussed at the next Task Force meeting.

Best,

Tony

From: Short, Marc T. EOP/OVP (b) (6) >
Sent: Tuesday, April 14, 2020 4:09 PM
To: Adams, Jerome (HHS/OASH) (b) (6); Birx, Deborah L. EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6); Giroir, Brett (HHS/OASH) (b) (6) >
Cc: Grogan, Joseph J. EOP/WHO (b) (6) >
Subject: RE: Elective surgeries and testing

Thanks, Jerome. (b) (5)
(b) (5)

From: Adams, Jerome (HHS/OASH) (b) (6) >
Sent: Tuesday, April 14, 2020 3:57 PM
To: Birx, Deborah L. EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6) >; Giroir, Brett (HHS/OASH) (b) (6) >
Cc: Short, Marc T. EOP/OVP (b) (6); Grogan, Joseph J. EOP/WHO (b) (6)
Subject: Elective surgeries and testing

Two quick points-

(b) (5)

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 02:05:36 +0000
To: Miller, Katie R. EOP/OVP
Subject: RE: Tweet by Anderson Cooper 360° on Twitter

(b) (5)

From: Miller, Katie R. EOP/OVP (b) (6) >
Sent: Tuesday, April 14, 2020 9:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Tweet by Anderson Cooper 360° on Twitter

(b) (5)



Anderson Cooper 360°
@AC360



NIH's lead scientist for coronavirus vaccine research Kizzmekia Corbett lays out the government's race to create a vaccine, saying they could be on track to have a vaccine from sequence to the general population within 8 months. cnn.it/34DnXnV pic.twitter.com/hlE34Wz64I
4/14/20, 9:06 PM

[Download](#) the Twitter app

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 10:45:28 +0000
To: Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC
Subject: RE: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

The issue also comes up when people are on certain drugs.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Wednesday, April 15, 2020 6:16 AM
To: Troye, Olivia EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Subject: Re: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

This one always comes up when we have differential responses to an infection and we do need to see if there is a genetic link – in HIV there are genetic links to better outcomes.

From: "Troye, Nsc" (b) (6) >
Date: Tuesday, April 14, 2020 at 11:03 PM
To: "Birx, Deborah L. EOP/NSC" <(b) (6)>, "Anthony Fauci [E]"
(b) (6) >
Subject: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

Follow up article to some previous emails. Just wanted to send this your way.

<https://www.medpagetoday.com/infectiousdisease/covid19/85929>

Olivia Troye
Special Advisor for Homeland Security and Counterterrorism
Office of the Vice President
White House Coronavirus Task Force
Office (b) (6)
Mobile: (b) (6) (Does not receive texts)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:00:39 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: WH Comms kept all of our words

Okay. Great. If [REDACTED] (b) (5)

From: Birx, Deborah L. EOP/NSC [REDACTED] (b) (6) >
Sent: Wednesday, April 15, 2020 9:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: WH Comms kept all of our words

[REDACTED] (b) (5)

Sent from my iPhone

On Apr 15, 2020, at 9:49 PM, Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) > wrote:

[REDACTED] (b) (5)

Thanks,
Tony

From: Birx, Deborah L. EOP/NSC [REDACTED] (b) (6) >
Sent: Wednesday, April 15, 2020 9:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: WH Comms kept all of our words

[REDACTED] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 02:28:05 +0000
To: Pottinger, Matthew F. EOP/WHO; Birx, Deborah L. EOP/NSC
Cc: (b) (6)
Subject: RE: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt:

(b) (5)

(b) (5). Let us discuss further.

Best regards,
Tony

From: Pottinger, Matthew F. EOP/WHO (b) (6) >
Sent: Thursday, April 16, 2020 7:54 PM
To: Birx, Deborah L. EOP/NSC (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: FW: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Deb, Tony,

(b) (5)

Best,
Matt

From: Skinner, James B. EOP/NSC (b) (6)
Sent: Thursday, April 16, 2020 6:53 PM
To: Pottinger, Matthew F. EOP/WHO (b) (6) >
Cc: (b) (6) >
Subject: FW: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt,

I spoke to Leland earlier this afternoon and he asked I pass this along to you.

James

From: Leland Schwartz (b) (6) >
Sent: Thursday, April 16, 2020 6:08 PM

To: Skinner, James B. EOP/NSC (b) (6) >

Cc: Ralph Crafts (b) (6) >; BARBARA SCHEIDE (b) (6) >; Ed Betts
(b) (6)

Subject: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt,

Oxygen therapy scientists can treat patients using the grounded airliners all over the country as mass treatment chambers.

Please watch this explanation from Extivita in Durham:

><https://www.youtube.com/watch?v=SWCHDuUQHSM&feature=youtu.be><

Please help us connect to the right people.

This could help save lives, get our economy restarted, and ensure continuity in the government.

Hope you're good. Catch up on the other side. Have figured out how to save local news.

Leland

(b) (6)

James,

Thanks very much for your help.

Leland



Leland Schwartz
Editor & Publisher
Fauquier Channel One
540 422 1376
editor@fauquierchannel.com
www.fauquierchannel.com

April 16, 2020

Matt Pottinger
Deputy National Security Advisor
The White House
1650 Pennsylvania Avenue, NW
Washington, DC 20502

Dear Sir,

Many of us in the hyperbaric medicine community believe that there exists a simple therapy to halt the inflammatory process and reverse the lung damage.

This process will also simultaneously provide many times over the amount of oxygenation offered by the coma-inducing intubation ventilator procedure.

We are reaching out to our network to make contact with the airlines to secure the use of an airplane with an onboard APU (Auxiliary Power Unit--used to pressurize the aircraft) for a month, to treat COVID-19 patients and show the effectiveness of the concept.

Initial testing indicates in one trial study 100% improvement while all others underway, although small scale, are showing great benefit at extremely low cost and patient risk.

So what is this new procedure? Hyperbaric Oxygen Therapy or HBOT; first used successfully in 1918 for Spanish Flu cases. HBOT is viable and appears to work well but we do not have the number of pressure vessels / HB chambers available to treat the possibly 100,000+ who need the therapy now.

Several of us in our small community have arrived at the same idea in several countries.

The idea is no longer new or unique.

Again, I am proposing use an aircraft as the pressure vessel. Every airplane with a pressurized cabin (i.e., all commercial airline aircraft) is routinely pressurized to around 9 psi (some go higher) while they are on the ground, as part of their normal airworthiness testing.

Myself and others have suggested that one or more of the hundreds of grounded aircraft be provided to complete the trial test.

737 Max are not flying but are a perfect pressure vessel for the procedure.

Could you help us contact Boeing, the airlines or the military?

No aircraft modification is required whatsoever so that is one of the issues off the table.

The aircraft remains parked on the ground with access for ambulatory patients via a stairway. No jetway is required unless we expand this in the future for non-ambulatory patients.

We would need to place standard DOT portable oxygen tanks in the cabin along with the associated manifold, pressure regulator, flow-meters and tubing.

Each patient will have his/her own anesthesia mask and breathing circuit.

There is no cross contamination between patients or the cabin environment atmosphere as each mask incorporates a Viral Filter Kit to help protect the technicians who are also breathing from a secure, clean source.

All safety issues are addressed in the plan.

The same process, once proven could be utilized by our military and of course our Navy who is experiencing possible outbreaks as we speak.

This is important to me personally (b) (6)

The Patriot Clinic in Oklahoma City is my personal charity where we have provided over 15,000 free HBOT treatments for our beloved vets and 30,000+ at cost or below.

We are not asking for money. Nor, am I selling anything in this effort. With the help of a small group of supporters, (Ralph Crafts & family) my company is willing to provide the equipment, training and technical support to begin the process.

Thank you for your ongoing service to our country, and thank you for reading and considering my proposal.

I sure would appreciate your help.

Semper Fi!

Sincerely,
Edward A. Betts

Edward A. Betts
ANDI American Nitrox Divers International
74 Woodcleft Avenue
Freeport, NY USA 11520

(b) (6)
><http://www.andihq.com/><

(b) (6)

Matt Pottinger
Deputy National Security Advisor
The White House
1650 Pennsylvania Ave., NW
Washington, DC 20502

Sir:

As one old Marine to another Marine, this letter contains the “straight scoop,” and is intended to provide information that can help stop the spread of COVID-19, and ensure the continuity of critical segments of government.

Hyperbaric Oxygen Therapy (HBOT) has been in use for over 100 years, and was the only effective treatment for the 1918 flu pandemic. HBOT is being used worldwide to treat a variety of serious diseases, and has been proven to be immediately effective in treating severe COVID-19 cases, with a success rate close to 100%.

HBOT is simply breathing high-purity oxygen (92% or higher) for 60-90 minutes in a pressurized environment (typically between 8 and 15psi—the higher pressure is about the same pressure as doing a SCUBA dive to 33 feet). HBOT chambers can be 1-2 person sizes and portable, up to 12-seat chambers which are used for Navy operations. (b) (6) I have a one-person chamber in our home, and we can attest to its effectiveness in treating severe breathing problems, like pneumonia, infections, and wounds.

The currently publicized and widely accepted statement that there is no effective treatment for COVID-19 is wrong. HBOT treatments, usually just a single one-hour session, provide immediate improvements in lung function, blood-oxygen levels, and organ recovery. Unlike respirators, which do more damage than good and are basically a death sentence, HBOT provides an immediate path for recovery and healing.

A team of very experienced scientists and HBOT experts have developed a concept that will enable the effective treatment of large numbers of people by using some of the thousands of grounded commercial aircraft as large HBOT chambers.

I'm an old Marine Corps jet pilot, and we use our (b) (6) so I have the professional contacts to confirm and verify the efficacy of the concept.

Every airplane with a pressurized cabin (i.e., all airline aircraft) is routinely pressurized to around 9psi (some go higher) while they are on the ground, as part of their normal airworthiness testing.

We have equipment staged and ready to go now, to treat 25 COVID-19 patients at a time—we need an airplane, and we can be treating people and saving lives in about 36 hours.

The aircraft we need remain parked on the ground, no modifications are needed—we will simply place portable oxygen tanks in the cabin with the associated tubing, manifold, and pressure regulators, and each patient will have his/her own anesthesia mask.

There is no cross contamination between patients, because everyone is breathing oxygen from their own personal mask.

We are reaching out to our contacts in the airlines to ask for the use of an airplane and APU (Auxiliary Power Unit—used to pressurize the aircraft) for a month, to treat COVID-19 patients and show the effectiveness of the concept.

We could do the same thing with a single military transport aircraft (many of which have been configured for medical use).

As a Marine, and with my knowledge of HBOT, the recent death of the Theodore Roosevelt sailor is particularly upsetting, knowing that a couple of Senior Chiefs or Marine Master Sergeants could have configured an aircraft in Guam in a couple of hours and be treating all the sailors from the carrier.

We are not asking for money—my wife and I are paying for all the required equipment and support personnel.

HBOT chambers are easily implemented and supported—you could have one in your office (ours is 8' long and 34" in diameter when pressurized) and it would only take a couple of hours to train your corpsmen to operate it. I don't know of a better guarantee of continuity in the current pandemic.

Please note that (b) (6) I have no financial or political interests in the HBOT treatment concept, companies, or manufacturers—we receive no benefits/rewards, other than helping to save many lives.

You will receive a letter from Ed Betts—he's a good man, really knows his stuff, and I trust him with my life—please take what he says seriously.

Thank you for your ongoing service to our country, and thank you for reading and considering the information in this letter.

Semper Fi!

Respectfully,

Ralph E. Crafts
Marshall, Virginia

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 15:00:21 +0000
To: Kadlec, Robert (OS/ASPR/IO); Birx, Deborah L. EOP/NSC
Cc: Redd, John (OS/ASPR/SPPR); Giroir, Brett (HHS/OASH); Verma, Seema (CMS/OA); Adams, Jerome (HHS/OASH); Hahn, Stephen; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID); Yeskey, Kevin (OS/ASPR/IO)
Subject: RE: Recommendation for a briefing by Dr. Dan Jernigan concerning Reopening Framework

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Saturday, April 18, 2020 10:47 AM
To: Birx, Deborah L. EOP/NSC (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redd, John (OS/ASPR/SPPR) (b) (6); Giroir, Brett (HHS/OASH) (b) (6); Verma, Seema (CMS/OA) (b) (6); Adams, Jerome (HHS/OASH) (b) (6); Hahn, Stephen (b) (6); Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6); Yeskey, Kevin (OS/ASPR/IO) (b) (6)
Subject: RE: Recommendation for a briefing by Dr. Dan Jernigan concerning Reopening Framework

Thank you we weren't sure and wanted to make sure that if you hadn't it would be made available. Please find attached the brief provided to the UCG.

From: Birx, Deborah L. EOP/NSC (b) (6)>
Sent: Saturday, April 18, 2020 10:38 AM

To: Kadlec, Robert (OS/ASPR/IO) <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Redd, John (OS/ASPR/SPPR)
<(b) (6)>; Giroir, Brett (HHS/OASH) (b) (6); Verma, Seema (CMS/OA)
<(b) (6)>; Adams, Jerome (HHS/OASH) (b) (6); Hahn, Stephen
<(b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6); Yeskey, Kevin
(OS/ASPR/IO) (b) (6)>

Subject: Re: Recommendation for a briefing by Dr. Dan Jernigan concerning Reopening Framework

I believe we were briefed on this before the guidelines but happy to hear it again.

Sent from my iPhone

On Apr 18, 2020, at 10:32 AM, Kadlec, Robert (OS/ASPR/IO) (b) (6)>
wrote:

(b) (5)

(b) (5) Best Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 18:30:03 +0000
To: Hahn, Stephen; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Kadlec, Robert (OS/ASPR/IO); [REDACTED] (b) (6)
Subject: FW: Boston Globe: Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Steve:

Here we go again! [REDACTED] (b) (5)

(b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
[REDACTED] (b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Saturday, April 18, 2020 1:54 PM
Subject: Boston Globe: Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Mass. General researcher says the results point to a 'raging epidemic,' but may also indicate the city is further along the disease curve than some other municipalities

By [Jonathan Saltzman](#) Globe Staff, Updated April 17, 2020, 6:26 p.m.



First responders loaded a patient into an

ambulance from a nursing home where multiple people have contracted COVID-19 in Chelsea, which has the highest concentration of COVID-19 infections in the state. Scott Eisen/Getty

Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this week tested positive for antibodies linked to COVID-19, a startling indication of how widespread infections have been in the densely populated city.

Sixty-four residents who had a finger pricked in Bellingham Square on Tuesday and Wednesday had antibodies that the immune system makes to fight off the coronavirus, according to Massachusetts General Hospital physicians who ran the pilot study.

The 200 participants generally appeared healthy, but about half told the doctors they had had at least one symptom of COVID-19 in the past four weeks.

Public health experts already knew Chelsea had the state's highest rate of confirmed COVID-19 cases and that the actual rate was probably higher. At least 39 residents have died from the virus, and 712 had tested positive as of Tuesday, a rate of about 1,900 cases per 100,000 residents, or almost 2 percent.

Get Talking Points in your inbox An afternoon recap of the day's most important business news, delivered Monday through Friday.

But the Mass. General researchers — who excluded anyone who had tested positive for the virus in the standard nasal swab test — found that 32 percent of participants have had COVID-19, and many didn't know it.

"I think it's both good news and bad news," said Dr. John Lafrate, vice chairman of MGH's pathology department and the study's principal investigator. "The bad news is that there's a raging epidemic in Chelsea, and many people walking on the street don't know that they're carrying the virus and that they may be exposing uninfected individuals in their families."

"On the good-news side, it suggests that Chelsea has made its way through a good part of the epidemic," he said. "They're probably further along than other towns."

Scientists suspect that people who recover from COVID-19 may be at least temporarily immune from catching it again. Several biotech and academic laboratories, in fact, are seeking blood donations from people who have recovered, in the hopes that their antibodies can help create a treatment or vaccine.

Chelsea's city manager, Thomas Ambrosino, said he learned the results of the pilot study Thursday in a conference call with the researchers. He was dismayed, but not shocked.

Related: Chelsea city manager sounds urgent alarm, calls for residents to stay home 24 hours a day

"We've long thought that the reported numbers are vastly under-counting what the actual infection is," said Ambrosino, who has called his city the epicenter of the crisis in Massachusetts. "Those reported numbers are based on positive COVID-19 tests, and we're all aware that a very, very small percentage of people in Chelsea and everywhere are getting COVID-19 tests."

“Still,” he added, “it’s kind of sobering that 30 percent of a random group of 200 people that are showing no symptoms are, in fact, infected. It’s all the more reason for everyone to be practicing physical distancing.”

Indeed, one of the doctors who tested volunteers in Bellingham Square said it’s possible that some of the people who had the antibodies are still contagious.

“Just because you have the antibodies doesn’t mean you’ve cleared the virus,” said Dr. Vivek Naranbhai, a clinical fellow in hematology and oncology.

Researchers said the test results, which had yet to be shared with state officials late Friday, couldn’t necessarily be extrapolated for the city’s roughly 40,000 residents. Still, the findings provided a valuable snapshot of a community that medical experts say is especially vulnerable to COVID-19.

Chelsea covers only about two square miles, across the Mystic River from Boston. For generations, it has attracted new immigrants, and about 65 percent of its residents are Latino. Many live in three-decker houses, Ambrosino said, where it’s hard for people to isolate themselves. Many work in the hospitality industry and health-related fields, where exposure to the virus is greater. And a lot of them must go to work during the pandemic.

To get Chelsea residents to participate in the study — which included a questionnaire that was available in English, Spanish, and Portuguese — investigators allowed them to remain anonymous. But that meant none of the participants received the results of the blood tests.

The doctors used a diagnostic device made by BioMedomics, of Morrisville, N.C., to analyze drops of blood. It resembled an over-the-counter pregnancy test and generated results on the street in about 10 minutes. Although the test hasn’t won the approval of the Food and Drug Administration, lafrate, the principal investigator, said Mass. General determined it’s reliable.

Within days, the physicians said, they hope to set up a medical tent outside the Mass. General Chelsea Healthcare Center to perform more antibodies tests with the device. The site will be located near a tent set up weeks ago to run standard PCR, or polymerase chain reaction, tests for people with active coronavirus symptoms. The latter uses nasal swabs to detect whether the virus is present at the time; the antibodies blood test reveals whether someone was infected in the past.

In addition to the new testing site, the researchers want to expand the study to other Massachusetts cities and towns. For all of those studies, Mass. General doctors plan to obtain the identities of participants so physicians can provide the results. But first the researchers need to come up with guidelines for what participants should do if they test positive for antibodies.

Dr. Dean Xerras, medical director of the Mass. General Chelsea Healthcare Center and a co-investigator in the study, said it illustrates why it’s essential for Chelsea and other communities to perform more tests, regardless of whether they detect antibodies or the virus itself.

“Knowing how many people are infected is critical,” said Xerras, a longtime member of the city’s board of health. “We need to get them isolated. We need to get masks delivered to the city. We need to launch more safe isolation sites. We need to be able to identify cases and then give people the things they need to prevent perpetuation of the spread.”

Chelsea and Revere officials, with help from the state Department of Public Health and the Massachusetts Emergency Management Agency, secured almost 150 rooms at a Quality Inn in Revere this week for residents who are recovering from COVID-19 and unable to isolate themselves at home, according to Ambrosino. So far, only a handful of those rooms are occupied.

Governor Charlie Baker on Thursday staunchly defended the state’s handling of the escalating outbreak in Chelsea, including asserting, without offering details, that city leaders have turned down help from his administration.

The governor's claim surprised officials in Chelsea who told the Globe this week that the state, and even health care providers, should have recognized the virus's rapid spread through the city sooner.

Jonathan Saltzman can be reached at jonathan.saltzman@globe.com

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 15:53:34 +0000
To: Miller, Katie R. EOP/OVP; Short, Marc T. EOP/OVP
Cc: Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Billet, Courtney (NIH/NIAID) [E]; Hall, Bill (HHS/ASPA); O'Malley, Devin M. EOP/OVP; Hahn, Stephen, (b) (6); Myles, Renate (NIH/OD) [E]
Subject: FYI - "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"
Attachments: Proactive Statement on Treatment Guidelines (002).docx

Katie/Marc:

Just as an FYI - "The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines" that were developed here at NIH, and a copy of which I provided to Deb Birx and ultimately to Mark Meadows is moving forward. (b) (5)

It is important to point out that this will be an NIH-sponsored document. It will not come from the Secretary of HHS, nor will it come from the White House Task Force. It is an NIH-sponsored document reflecting the work product of approximately 30 experts drawn from U.S. health care and academic organizations, federal agencies, and professional societies. It will be a "living online document" that will be updated regularly as additional information, including that from the results of clinical trials, becomes available. Press release will come from NIH with clearance through the appropriate channels (see attachment as an FYI). I anticipate that this will happen in the next day or two.

Thanks.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 19:42:03 +0000
To: Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield, Robert R. (CDC/OD)
Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

See below

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >

Sent: Monday, April 20, 2020 1:53 PM

Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

[China / Science](#)

Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

- The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the least potent type
- New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States



Stephen Chen in Beijing

Published: 10:41pm, 20 Apr, 2020

Updated: 1:33am, 21 Apr, 2020



A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible implications for the pandemic. Photo: EPA-EFE

A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has been vastly underestimated and different strains may account for different impacts of the disease in various parts of the world.

Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients many mutations not previously reported. These mutations included changes so rare that scientists had never considered they might occur.

They also confirmed for the first time with laboratory evidence that certain mutations could create strains deadlier than others.

"Sars-CoV-2 has acquired mutations capable of substantially changing its pathogenicity," Li and her collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday. Li's study provided the first hard evidence that mutation could affect how severely the virus caused disease or damage in its host.

Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and then tested how efficiently they could infect and kill cells.

The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe, while the milder strains were the predominant varieties found in parts of the United States, such as Washington state, according to their paper.

A separate study had found that New York strains had been imported from Europe. The death rate in New York was similar to that in many European countries, if not worse.

But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang, two patients in their 30s and 50s who contracted the weaker strain became severely ill. Although both survived in the end, the elder patient needed treatment in an intensive care unit.

This finding could shed light on differences in regional mortality. The pandemic's infection and death rates vary from one country to another, and many explanations have been proposed.

Genetic scientists had noticed that the dominant strains in different geographic regions were inherently different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations but they had no direct proof.

The issue was further complicated because survival rates depended on many factors, such as age, underlying health conditions or even blood type.

In hospitals, Covid-19 has been treated as one disease and patients have received the same treatment regardless of the strain they have. Li and her colleagues suggested that defining mutations in a region might determine actions to fight the virus.

"Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations ... into account to avoid potential pitfalls," they said.

Li was the first scientist to propose the Wuhan lockdown, according to state media reports. The government followed her advice and in late January, the city of more than 11 million residents was shut down overnight.

The sample size in this most recent study was remarkably small. Other studies tracking the virus mutation usually involved hundreds, or even thousands, of strains.

Li's team detected more than 30 mutations. Among them 19 mutations – or about 60 per cent – were new.

They found some of these mutations could lead to functional changes in the virus' spike protein, a unique structure over the viral envelope enabling the coronavirus to bind with human cells. Computer simulation predicted that these mutations would increase its infectivity.

To verify the theory, Li and colleagues infected cells with strains carrying different mutations. The most aggressive strains could generate 270 times as much viral load as the weakest type. These strains also killed the cells the fastest.

It was an unexpected result from fewer than a dozen patients, "indicating that the true diversity of the viral strains is still largely underappreciated," Li wrote in the paper.



Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua

The mutations were genes different from the earliest strain isolated in Wuhan, where the virus was first detected in late December last year.

The coronavirus changes at an average speed of about one mutation per month. By Monday, more than 10,000 strains had been sequenced by scientists around the globe, containing more than 4,300 mutations, according to the China National Centre for Bioinformation.

Most of these samples, though, were sequenced by a standard approach that could generate a result quickly. The genes were read just once, for instance, and there was room for mistakes.

Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the virus genome was read more than 100 times, allowing the researchers to see changes that could have been overlooked by the conventional approach.

The researchers also found three consecutive changes – known as tri-nucleotide mutations – in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces were infectious with living viral strains.

"Investigating the functional impact of this tri-nucleotide mutation would be highly interesting," Li and colleagues said in the paper.

Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective strategy to track the virus' mutation.

"It can produce some useful information," he said.

But this approach could be much more time consuming and costly. It was unlikely to be applied to all samples.

"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus came from, why it could kill some healthy young people while generating no detectable symptoms in many others still left scientists scratching their heads.

"If there is a discovery that overturns the prevailing perception, don't be surprised."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 19:45:11 +0000
To: Hahn, Stephen; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: RE: Viral Clades Brufsky 42020 Accepted Final.pdf

I am checking with Barney Graham here at NIAID who is one of the world's expert on this sort of thing.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6) >
Sent: Tuesday, April 21, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Birx, Deborah L. EOP/NSC (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >
Subject: RE: Viral Clades Brufsky 42020 Accepted Final.pdf

Thanks, Tony. I'll be sending another article that is to be submitted to Nature from the same US authors.

(b) (5)

Steve

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Date: April 21, 2020 at 3:41:13 PM EDT
To: Birx, Deborah L. EOP/NSC (b) (6), Hahn, Stephen <(b) (6)>, Redfield, Robert R (CDC) (b) (6)
Subject: RE: Viral Clades Brufsky 42020 Accepted Final.pdf

A Chinese study is apparently finding the same thing. I will send now by another e-mail a commentary on the Chinese study that is not peer-reviewed yet.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6) >

Sent: Tuesday, April 21, 2020 3:34 PM

To: Hahn, Stephen (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >;

Redfield, Robert R. (CDC/OD) (b) (6) >

Subject: Re: Viral Clades Brufsky 42020 Accepted Final.pdf

(b) (5)

From: "Hahn, Stephen" (b) (6) >

Date: Tuesday, April 21, 2020 at 3:29 PM

To: "Fauci, Anthony S (NIH)" (b) (6), "Redfield, Robert R (CDC)"

(b) (6) "Birx, Deborah L. EOP/NSC" (b) (6)

Subject: Viral Clades Brufsky 42020 Accepted Final.pdf

Sorry for all of the emails. I spoke to Adam who is an oncologist. I thought this might be of interest.
Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:14:18 +0000
To: Hahn, Stephen; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: RE: Viral Clades Brufsky 42020 Accepted Final.pdf

Just spoke with Barney Graham and he informed me (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen <(b) (6)>
Sent: Tuesday, April 21, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Birx, Deborah L. EOP/NSC
(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)
Subject: RE: Viral Clades Brufsky 42020 Accepted Final.pdf

Thanks, Tony. I'll be sending another article that is to be submitted to Nature from the same US authors.

(b) (5)

Steve

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Date: April 21, 2020 at 3:41:13 PM EDT
To: Birx, Deborah L. EOP/NSC (b) (6), Hahn, Stephen <(b) (6)>
Redfield, Robert R (CDC) (b) (6)>
Subject: RE: Viral Clades Brufsky 42020 Accepted Final.pdf

A Chinese study is apparently finding the same thing. I will send now by another e-mail a commentary on the Chinese study that is not peer-reviewed yet.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6) >

Sent: Tuesday, April 21, 2020 3:34 PM

To: Hahn, Stephen (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >;
Redfield, Robert R. (CDC/OD) (b) (6) >

Subject: Re: Viral Clades Brufsky 42020 Accepted Final.pdf

(b) (5)

From: "Hahn, Stephen" (b) (6) >

Date: Tuesday, April 21, 2020 at 3:29 PM

To: "Fauci, Anthony S (NIH)" (b) (6), "Redfield, Robert R (CDC)"
(b) (6) "Birx, Deborah L. EOP/NSC" <(b) (6)>

Subject: Viral Clades Brufsky 42020 Accepted Final.pdf

Sorry for all of the emails. I spoke to Adam who is an oncologist. I thought this might be of interest.
Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:29:10 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Serology Test Calculator

Amen for 2 tests!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Tuesday, April 21, 2020 4:06 PM
To: Hahn, Stephen (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6);
Redfield, Robert R. (CDC/OD) (b) (6); Giroir, Brett (OS) (b) (6)
Subject: Re: Serology Test Calculator

(b) (5) Deb

From: "Hahn, Stephen" (b) (6)
Date: Tuesday, April 21, 2020 at 3:23 PM
To: "Birx, Deborah L. EOP/NSC" (b) (6); "Fauci, Anthony S (NIH)"
(b) (6); "Redfield, Robert R (CDC)" (b) (6); "Giroir, Brett (OS)"
(b) (6)
Subject: Fwd: Serology Test Calculator

From: Shuren, Jeff (b) (6)>
Date: April 20, 2020 at 6:26:14 PM EDT
To: Hahn, Stephen (b) (6); Lenihan, Keagan (b) (6)>, Shah, Anand

(b) (6)>, Rom, Colin

(b) (6)

Subject: Serology Test Calculator

Attached is a very rudimentary calculator that you are welcome to share with the WHTF/HHS serology WG to calculate the positive predictive value and negative predictive value of individual serology tests and the use of two tests by plugging in the known or estimated sensitivity, specificity, and population prevalence of COVID-19. (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 16:23:24 +0000
To: Miller, Katie R. EOP/OVP
Subject: RE: can you explain this?

He is playing it very conservative. It is possible that it might take that long if the vaccines that we are testing have glitches in the various phases of testing. That is always possible, but I would not be concerned about what he says. I have said at least 1 to 1.5 years.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Miller, Katie R. EOP/OVP <(b) (6)>
Sent: Wednesday, April 22, 2020 11:52 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: can you explain this?

<https://twitter.com/adamparsons/status/1252865243442642946>

From: (b) (6)
Sent: Wed, 22 Apr 2020 13:49:49 -0400
To: Miller, Katie R. EOP/OVP
Cc: Birx, Deborah L. EOP/NSC
Subject: Re: [EXTERNAL] Re: WSJ, "scientists to stop covid"

Ed Skolnick

On Apr 22, 2020, at 1:48 PM, Miller, Katie R. EOP/OVP <(b) (6)> wrote:

Are either of you working with this group?

From: Copeland, Rob <rob.copeland@wsj.com>
Sent: Wednesday, April 22, 2020 1:41 PM
To: Miller, Katie R. EOP/OVP (b) (6)
Subject: Re: [EXTERNAL] Re: WSJ, "scientists to stop covid"

Dr. Thomas J. Cahill, MD, Ph.D. is the Founder and Managing Partner of Newpath Management, L.P. Dr. Cahill received both his M.D. and Ph.D. from Duke University. His Ph.D. work, with Professor Robert Lefkowitz (Nobel Laureate), focused on studying cellular receptors and their signaling to inform novel drug development and discovery.

Dr. Benjamin Cravatt, Ph.D. is a Professor of Chemistry at The Scripps Research Institute in La Jolla, California and a member of the National Academy of Sciences. He is a founder of Vividion Therapeutics, Abide Therapeutics, and ActiveX Biosciences. Considered a co-inventor of activity-based proteomics and a substantial contributor to research on the endocannabinoid system, Cravatt is a prominent figure in the field of chemical biology.

Lynn R. Goldman, M.D., M.S., M.P.H. is the Michael and Lori Milken Dean and Professor of Environmental and Occupational Health at the Milken Institute School of Public Health at the George Washington University. She is a member of the National Academy of Medicine, the National Research Council Strategic Planning Group, and the NIH National Advisory Environmental Health Sciences Council.

Dr. Akiko Iwasaki, Ph.D. is a Waldemar von Zedtwitz Professor of Immunobiology at Yale University School of Medicine, and a Howard Hughes Medical Institute Investigator. She is a member of the National Academy of Sciences, and a member of the National Academy of Medicine. She has discovered molecular mechanisms underlying innate and adaptive antiviral immunity and is a pioneer of novel vaccine strategies.

Dr. Michael Z. Lin, M.D., Ph.D. is Associate Professor of Neurobiology, Bioengineering, and Chemical and Systems Biology at Stanford University. A NIH Pioneer Award recipient, Dr. Lin develops protein- based tools for molecular imaging and control of gene and viral therapy.

Dr. David Liu, Ph.D. is Professor of Chemistry and Chemical Biology at Harvard University, Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, and a Howard Hughes Medical Institute Investigator. He is a founder of Editas Medicine, Beam Therapeutics, Pairwise Plants, Exo Therapeutics, and Prime Medicine. Liu is a pioneer in gene editing and protein engineering and developed both base editing and prime editing technologies.

Dr. Michael Rosbash, Ph.D. is the 2017 Nobel laureate in Physiology or Medicine, a member of the National Academy of Sciences, a Professor of Biology at Brandeis University, and a Howard Hughes Medical Institute Investigator. Rosbash is a pioneer of chronobiology, the study of how living systems sense and respond to time.

Dr. Stuart Schreiber, Ph.D. is a Professor of Chemistry and Chemical Biology at Harvard University and co-Founder of the Broad Institute. He is a member of the National Academy of Sciences, and a founder of Vertex Pharmaceuticals, Ariad Pharmaceuticals, Infinity Pharmaceuticals, Forma Therapeutics, H3 Biomedicine and Jnana Therapeutics. Schreiber co-pioneered the field of chemical biology.

Dr. Edward Scolnick, M.D. is the former Head of Research and Development at Merck and a core investigator at the Broad Institute of MIT and Harvard. While at Merck, Scolnick oversaw the development of 28 FDA-approved drugs and vaccines, including statins, HIV protease inhibitors, and Gardasil. He also made seminal discoveries on the nature of genes that cause cancer in humans before beginning his 22-year career at Merck.

Dr. Jonathan W. Simons, M.D. is the CEO and President of the Prostate Cancer Foundation. Simons a molecular oncologist who previously was the Founding Director of the Winship NCI Cancer Center at Emory University, and currently co-directs the PCF-Veterans Administration Precision Oncology Program for Prostate Cancer.

Dr. Ramnik Xavier, M.D., Ph.D. is Professor of Medicine at Harvard Medical School, former Chief of Gastroenterology at Massachusetts General Hospital, and a core institute member of the Broad Institute of MIT and Harvard. He has discovered molecular mechanisms underlying innate and adaptive immunity, as well as causes of Crohn's disease, ulcerative colitis, inflammatory bowel disease, and autoimmunity.

On Wed, Apr 22, 2020 at 10:32 AM Miller, Katie R. EOP/OVP

(b) (6) wrote:

Do you have their names so I can run this down please?

From: Copeland, Rob <rob.copeland@wsj.com>

Sent: Wednesday, April 22, 2020 12:50 PM

To: Miller, Katie R. EOP/OVP (b) (6)>

Subject: [EXTERNAL] Re: WSJ, "scientists to stop covid"

Hey Katie, just following up on this.

Thanks
Rob

On Mon, Apr 20, 2020 at 8:14 AM Copeland, Rob <rob.copeland@wsj.com>wrote:
Hey Katie, I'm working a WSJ feature about a group of very prominent scientists who are working behind the scenes with the federal government (including the task force)/several states to fight covid. They are organized by a young man named Tom Cahill in Boston, and the group name s "Scientists to Stop Covid."

I would love to talk to someone in the task force, and make sure we neither under nor overstate their importance. Everyone involved is participating in the feature.

My cell phone is below, feel free to call or text.

Thanks!
Rob

--

Rob Copeland
REPORTER

Office:

--

Rob Copeland
REPORTER

Office:

--

Rob Copeland
REPORTER

✕

Office:

From: (b) (6)
Sent: Wed, 22 Apr 2020 13:51:27 -0400
To: Miller, Katie R. EOP/OVP
Cc: Birx, Deborah L. EOP/NSC
Subject: Re: [EXTERNAL] Re: WSJ, "scientists to stop covid"

Ed Scolnick and I have been in communication. I will explain when I see you

On Apr 22, 2020, at 1:48 PM, Miller, Katie R. EOP/OVP <(b) (6)> wrote:

Are either of you working with this group?

From: Copeland, Rob <rob.copeland@wsj.com>
Sent: Wednesday, April 22, 2020 1:41 PM
To: Miller, Katie R. EOP/OVP <(b) (6)>
Subject: Re: [EXTERNAL] Re: WSJ, "scientists to stop covid"

Dr. Thomas J. Cahill, MD, Ph.D. is the Founder and Managing Partner of Newpath Management, L.P. Dr. Cahill received both his M.D. and Ph.D. from Duke University. His Ph.D. work, with Professor Robert Lefkowitz (Nobel Laureate), focused on studying cellular receptors and their signaling to inform novel drug development and discovery.

Dr. Benjamin Cravatt, Ph.D. is a Professor of Chemistry at The Scripps Research Institute in La Jolla, California and a member of the National Academy of Sciences. He is a founder of Vividion Therapeutics, Abide Therapeutics, and ActiveX Biosciences. Considered a co-inventor of activity-based proteomics and a substantial contributor to research on the endocannabinoid system, Cravatt is a prominent figure in the field of chemical biology.

Lynn R. Goldman, M.D., M.S., M.P.H. is the Michael and Lori Milken Dean and Professor of Environmental and Occupational Health at the Milken Institute School of Public Health at the George Washington University. She is a member of the National Academy of Medicine, the National Research Council Strategic Planning Group, and the NIH National Advisory Environmental Health Sciences Council.

Dr. Akiko Iwasaki, Ph.D. is a Waldemar von Zedtwitz Professor of Immunobiology at Yale University School of Medicine, and a Howard Hughes Medical Institute Investigator. She is a member of the National Academy of Sciences, and a member of the National Academy of Medicine. She has discovered molecular mechanisms underlying innate and adaptive antiviral immunity and is a pioneer of novel vaccine strategies.

Dr. Michael Z. Lin, M.D., Ph.D. is Associate Professor of Neurobiology, Bioengineering, and Chemical and Systems Biology at Stanford University. A NIH Pioneer Award recipient, Dr. Lin develops protein- based tools for molecular imaging and control of gene and viral therapy.

Dr. David Liu, Ph.D. is Professor of Chemistry and Chemical Biology at Harvard University, Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, and a Howard Hughes Medical Institute Investigator. He is a founder of Editas Medicine, Beam Therapeutics, Pairwise Plants, Exo Therapeutics, and Prime Medicine. Liu is a pioneer in gene editing and protein engineering and developed both base editing and prime editing technologies.

Dr. Michael Rosbash, Ph.D. is the 2017 Nobel laureate in Physiology or Medicine, a member of the National Academy of Sciences, a Professor of Biology at Brandeis University, and a Howard Hughes Medical Institute Investigator. Rosbash is a pioneer of chronobiology, the study of how living systems sense and respond to time.

Dr. Stuart Schreiber, Ph.D. is a Professor of Chemistry and Chemical Biology at Harvard University and co-Founder of the Broad Institute. He is a member of the National Academy of Sciences, and a founder of Vertex Pharmaceuticals, Ariad Pharmaceuticals, Infinity Pharmaceuticals, Forma Therapeutics, H3 Biomedicine and Jnana Therapeutics. Schreiber co-pioneered the field of chemical biology.

Dr. Edward Scolnick, M.D. is the former Head of Research and Development at Merck and a core investigator at the Broad Institute of MIT and Harvard. While at Merck, Scolnick oversaw the development of 28 FDA-approved drugs and vaccines, including statins, HIV protease inhibitors, and Gardasil. He also made seminal discoveries on the nature of genes that cause cancer in humans before beginning his 22-year career at Merck.

Dr. Jonathan W. Simons, M.D. is the CEO and President of the Prostate Cancer Foundation. Simons a molecular oncologist who previously was the Founding Director of the Winship NCI Cancer Center at Emory University, and currently co-directs the PCF-Veterans Administration Precision Oncology Program for Prostate Cancer.

Dr. Ramnik Xavier, M.D., Ph.D. is Professor of Medicine at Harvard Medical School, former Chief of Gastroenterology at Massachusetts General Hospital, and a core institute member of the Broad Institute of MIT and Harvard. He has discovered molecular mechanisms underlying innate and adaptive immunity, as well as causes of Crohn's disease, ulcerative colitis, inflammatory bowel disease, and autoimmunity.

On Wed, Apr 22, 2020 at 10:32 AM Miller, Katie R. EOP/OVP

(b) (6) wrote:

Do you have their names so I can run this down please?

From: Copeland, Rob <rob.copeland@wsj.com>

Sent: Wednesday, April 22, 2020 12:50 PM

To: Miller, Katie R. EOP/OVP (b) (6)>

Subject: [EXTERNAL] Re: WSJ, "scientists to stop covid"

Hey Katie, just following up on this.

Thanks
Rob

On Mon, Apr 20, 2020 at 8:14 AM Copeland, Rob <rob.copeland@wsj.com>wrote:
Hey Katie, I'm working a WSJ feature about a group of very prominent scientists who are working behind the scenes with the federal government (including the task force)/several states to fight covid. They are organized by a young man named Tom Cahill in Boston, and the group name s "Scientists to Stop Covid."

I would love to talk to someone in the task force, and make sure we neither under nor overstate their importance. Everyone involved is participating in the feature.

My cell phone is below, feel free to call or text.

Thanks!
Rob

--

Rob Copeland
REPORTER

Office:

--

Rob Copeland
REPORTER

Office:

--

Rob Copeland
REPORTER

✕

Office:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:59:59 +0000
To: Birx, Deborah L. EOP/NSC; Hahn, Stephen; (b) (6)
MEDCOM WRAIR (USA); Redfield, Robert R. (CDC/OD)
Subject: RE: if possible review in mins not hours

Agree. (b) (5)

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Thursday, April 23, 2020 4:41 PM
To: Hahn, Stephen (b) (6); (b) (6) MEDCOM WRAIR (USA)
(b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield,
Robert R. (CDC/OD) (b) (6)
Subject: Re: if possible review in mins not hours

Yes — (b) (5)

From: "Hahn, Stephen" (b) (6)
Date: Thursday, April 23, 2020 at 4:36 PM
To: "Birx, Deborah L. EOP/NSC" <(b) (6)>, (b) (6)
(b) (6) MEDCOM WRAIR (USA)" (b) (6), "Fauci, Anthony S (NIH)"
(b) (6)>, "Redfield, Robert R (CDC)" (b) (6)>
Subject: Re: if possible review in mins not hours

(b) (5)

From: Birx, Deborah L. EOP/NSC (b) (6)>
Date: April 23, 2020 at 4:32:54 PM EDT
To: Hahn, Stephen (b) (6) (b) (6) MEDCOM WRAIR (USA)
(b) (6)>, Fauci, Anthony S (NIH) (b) (6), Redfield, Robert R
(CDC) (b) (6)>
Subject: Re: if possible review in mins not hours

(b) (5)

From: "Hahn, Stephen" <(b) (6)>
Date: Thursday, April 23, 2020 at 4:30 PM
To: "Birx, Deborah L. EOP/NSC" (b) (6), (b) (6)
(b) (6) MEDCOM WRAIR (USA)" (b) (6)>, "Fauci, Anthony S (NIH)"
(b) (6) "Redfield, Robert R (CDC)" (b) (6)>
Subject: Re: if possible review in mins not hours

Looks good

(b) (5)

From: Birx, Deborah L. EOP/NSC <(b) (6)>

Date: April 23, 2020 at 2:14:58 PM EDT

To: (b) (6) MEDCOM WRAIR (USA) <(b) (6)>, Fauci, Anthony S (NIH) <(b) (6)>, Redfield, Robert R (CDC) (b) (6), Hahn, Stephen (b) (6)

Subject: if possible review in mins not hours

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Apr 2020 14:25:15 +0000
To: Birx, Deborah L. EOP/NSC; Giroir, Brett (HHS/OASH); Redfield, Robert R. (CDC/OD); Schuchat, Anne MD (CDC/OD); Hahn, Stephen; CMS (b) (6); Adams, Jerome (HHS/OASH)
Cc: McGuffee, Tyler Ann A. EOP/OVP
Subject: RE: If possible review with written responses by 1030 am
Attachments: 20200422 Testing Strategy UPDATE4db - with additional tracked edits.docx

Deb:

Nice job! I am attaching the document with some suggested edits that are tracked.

Thanks,

Tony

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Saturday, April 25, 2020 8:20 AM
To: Giroir, Brett (HHS/OASH) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Schuchat, Anne MD (CDC/OD) (b) (6); Hahn, Stephen (b) (6); CMS (b) (6); <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Adams, Jerome (HHS/OASH) (b) (6)
Cc: McGuffee, Tyler Ann A. EOP/OVP <(b) (6)>
Subject: If possible review with written responses by 1030 am

Thank you

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Apr 2020 22:35:55 +0000
To: Adams, Jerome (HHS/OASH); Birx, Deborah L. EOP/NSC
Cc: Short, Marc T. EOP/OVP
Subject: RE: Monday TF Agenda and Press Conference

Good point. [REDACTED] (b) (5)

From: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6)
Sent: Saturday, April 25, 2020 6:03 PM
To: Birx, Deborah L. EOP/NSC [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6)>
Cc: Short, Marc T. EOP/OVP [REDACTED] (b) (6)>
Subject: Monday TF Agenda and Press Conference

Regarding the Monday TF meeting, [REDACTED] (b) (5)
[REDACTED] (b) (5)

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 13:06:43 +0000
To: Birx, Deborah L. EOP/NSC; Hahn, Stephen; Redfield, Robert R. (CDC/OD)
Subject: RE: Testing Strategy
Attachments: 20200422 Testing Strategy SUNDAY2 (redline) - with additional Fauci edits.docx

See my tracked edits in the attached document. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Monday, April 27, 2020 7:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Hahn, Stephen (b) (6);
Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: FW: Testing Strategy

Please review redline word document. I did not participate in the PPT. Deb

From: "Lyons, Derek S. EOP/WHO" <(b) (6)>
Date: Sunday, April 26, 2020 at 8:06 PM
To: "Meadows, Mark R. EOP/WHO" (b) (6), "Kushner, Jared C. EOP/WHO" (b) (6), "Hicks, Hope C. EOP/WHO" (b) (6), "Gilmartin, Kayleigh M. EOP/WHO" <(b) (6)>, "Birx, Deborah L. EOP/NSC" <(b) (6)>, "Boehler, Adam" (b) (6), "Short, Marc T. EOP/OVP" <(b) (6)>, "Farah, Alyssa A. EOP/WHO" (b) (6), "Liddell, Christopher P. EOP/WHO" (b) (6), "Philbin, Patrick F. EOP/WHO" (b) (6), "Vought, Russell T. EOP/OMB" <(b) (6)>
Cc: "Kan, Derek T. EOP/OMB" (b) (6), (b) (6) "Rader, John N. EOP/NSC" (b) (6), "Storch,

Thomas H. EOP/NSC" <(b) (6)>, "Rinat, Ory S. EOP/WHO"
(b) (6)>, "Butterfield, Nicholas W. EOP/WHO"
(b) (6)>, "Dumbauld, Cassidy M. EOP/WHO"
(b) (6), "Miller, Ovp" (b) (6), "Keller, Catherine B.
EOP/WHO" (b) (6)>, "Porter, Madison F. EOP/WHO"
(b) (6)>

Subject: RE: Testing Strategy

All – Once again, thanks for your input. I've attached the latest documents. We had to implement quite a few comments from the last versions, particularly on the Word Document. My hope is that the changes did not affect the substance, but I've attached a redline for those who might need it. Please review and send any RED FLAGS no later than 700 am tomorrow.

Thanks,
Derek

From: Lyons, Derek S. EOP/WHO
Sent: Saturday, April 25, 2020 7:16 PM
To: Meadows, Mark R. EOP/WHO (b) (6)>; Kushner, Jared C. EOP/WHO
(b) (6)>; Hicks, Hope C. EOP/WHO (b) (6); Gilmartin, Kayleigh M. EOP/WHO
(b) (6)>; Birx, Deborah L. EOP/NSC (b) (6); 'Boehler,
Adam' <(b) (6)>; Short, Marc T. EOP/OVP (b) (6)>; Farah, Alyssa
A. EOP/WHO <(b) (6)>; Liddell, Christopher P. EOP/WHO
<(b) (6)>; Philbin, Patrick F. EOP/WHO (b) (6)>
Cc: Kan, Derek T. EOP/OMB (b) (6)>; (b) (6)
(b) (6)>; Rader, John N. EOP/NSC <(b) (6)>; Storch, Thomas H.
EOP/NSC <(b) (6)>; Rinat, Ory S. EOP/WHO (b) (6);
Butterfield, Nicholas W. EOP/WHO (b) (6)>; Dumbauld, Cassidy M.
EOP/WHO <(b) (6)>
Subject: RE: Testing Strategy

All – Thank you for your input over the past few days. Please find revised documents attached. We are still working on formatting, but the language should be firming up. Please let me know if you have additional comments or edits.

I've added Pat Philbin to this chain for legal review.

Derek

From: Lyons, Derek S. EOP/WHO
Sent: Friday, April 24, 2020 7:59 PM
To: Meadows, Mark R. EOP/WHO (b) (6)>; Kushner, Jared C. EOP/WHO
(b) (6); Hicks, Hope C. EOP/WHO (b) (6); Gilmartin, Kayleigh M. EOP/WHO
(b) (6)>; Birx, Deborah L. EOP/NSC (b) (6); Boehler,
Adam (b) (6); Short, Marc T. EOP/OVP (b) (6)>; Farah, Alyssa
A. EOP/WHO (b) (6)>; Liddell, Christopher P. EOP/WHO
<(b) (6)>

Cc: Kan, Derek T. EOP/OMB (b) (6);
(b) (6); Rader, John N. EOP/NSC (b) (6); Storch, Thomas H.
EOP/NSC (b) (6); Rinat, Ory S. EOP/WHO <(b) (6)>;
Butterfield, Nicholas W. EOP/WHO (b) (6); Dumbauld, Cassidy M.
EOP/WHO (b) (6)
Subject: Testing Strategy

All –

Please see the latest iteration of the testing documents for Monday. If possible, I would appreciate any comments/concerns about noon tomorrow so we can continue to progress. In addition to content, I believe we still need to do the following:

(b) (5)

I also think we probably need to reconvene at some point this weekend to ensure everyone is comfortable with the products before they go live on Monday. We'll work to find a time.

Derek

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:31:56 +0000
To: Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: For Discussion
Attachments: COVID Cases 4.27.20 powerpoint slides.pptx

Deb/Bob:

(b) (5)

Thanks,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 15:32:56 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redfield, Robert R. (CDC/OD)
Subject: RE: For Discussion

Deb:

(b) (5)

Thanks,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC <(b) (6)>

Sent: Monday, April 27, 2020 10:37 AM

To: Fauci, Anthony (NIH/NIAID) [E: (b) (6)]; Redfield, Robert R. (CDC/OD)

(b) (6)

Subject: Re: For Discussion

(b) (5)

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Date: Monday, April 27, 2020 at 10:32 AM

To: "Birx, Deborah L. EOP/NSC" (b) (6), "Redfield, Robert R. (CDC/OD)"

(b) (6)

Subject: For Discussion

Deb/Bob:

(b) (5)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:48:46 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redd, Stephen (CDC/DDPHSIS/OD); Hahn, Stephen
Subject: Flagging NIH Media Product for Release Tomorrow
Attachments: 2020-04-27_COVID-19WeeklyReport_NIBIB OD_tas.docx

Deb:

As an FYI. This is an initiative from NIBIB/NIH on development of POC diagnostics for SARS-CoV-2.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 00:46:11 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redd, Stephen (CDC/DDPHSIS/OD); Hahn, Stephen
Subject: RE: Flagging NIH Media Product for Release Tomorrow

Absolutely!

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Monday, April 27, 2020 8:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Redd, Stephen (CDC/DDPHSIS/OD) (b) (6); Hahn, Stephen (b) (6)
Subject: Re: Flagging NIH Media Product for Release Tomorrow

This is terrific. (b) (5).

Sent from my iPhone

On Apr 27, 2020, at 5:48 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Deb:

As an FYI. This is an initiative from NBIB/NIH on development of POC diagnostics for SARS-CoV-2.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<2020-04-27_COVID-19WeeklyReport_NIBIB OD_tas.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 02:42:59 +0000
To: CMS (b) (6); 'Feinberg, Rebecca P. EOP/NSC'; Charles, Julia (CDC/OD/OCS); Redd, Stephen C. EOP/NSC; (b) (6); Vitek, Charles (CDC/DDPHSIS/CGH/DGHT); McGuffee, Tyler Ann A. EOP/OVP; Redfield, Robert R. (CDC/OD); (b) (6); Adams, Jerome (HHS/OASH); Schuchat, Anne MD (CDC/OD); Jernigan, Daniel B. (CDC/DDID/NCIRD/ID); Grogan, Joseph J. EOP/WHO; Conway, Kellyanne E. EOP/WHO; Walke, Henry (CDC/DDID/NCEZID/DPEI); Payne, Rebecca L. (CDC/DDID/NCHHSTP/DASH); Greene, Carolyn M. (CDC/DDID/NCIRD/ID); Giroir, Brett (HHS/OASH); McQuiston, Jennifer H. (CDC/DDID/NCEZID/DHCPP); Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID); Butler, Jay C. (CDC/DDID/OD); Mead, Paul (CDC/DDID/NCEZID/DVBD); Fitter, David L. (CDC/DDPHSIS/CGH/GID)
Cc: Hoo, Elizabeth (CDC/OD/OCS); Warner, Agnes (CDC/OD/OCS); Gershman, Lynn E. (CDC/DDPHSIS/OD)
Subject: RE: Scheduling for Tuesday

I also have a conflict. We discuss with CDC folks after the meeting.

From: CMS (b) (6)>
Sent: Monday, April 27, 2020 9:49 PM
To: 'Feinberg, Rebecca P. EOP/NSC' <(b) (6)>; Charles, Julia (CDC/OD/OCS) (b) (6)>; Redd, Stephen C. EOP/NSC <(b) (6)>; (b) (6) (b) (6) Vitek, Charles (CDC/DDPHSIS/CGH/DGHT) <(b) (6)>; McGuffee, Tyler Ann A. EOP/OVP <(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6) (b) (6); Adams, Jerome (HHS/OASH) (b) (6)>; Schuchat, Anne MD (CDC/OD) (b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6); Grogan, Joseph J. EOP/WHO (b) (6)>; Conway, Kellyanne E. EOP/WHO <(b) (6)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <(b) (6)>; Payne, Rebecca L. (CDC/DDID/NCHHSTP/DASH) (b) (6)>; Greene, Carolyn M. (CDC/DDID/NCIRD/ID) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Giroir, Brett (HHS/OASH) (b) (6) McQuiston, Jennifer H. (CDC/DDID/NCEZID/DHCPP) (b) (6)>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) (b) (6); Butler, Jay C. (CDC/DDID/OD) (b) (6); Mead, Paul (CDC/DDID/NCEZID/DVBD) (b) (6)>; Fitter, David L. (CDC/DDPHSIS/CGH/GID) (b) (6)>
Cc: Hoo, Elizabeth (CDC/OD/OCS) (b) (6)>; Warner, Agnes (CDC/OD/OCS) (b) (6); Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6)
Subject: RE: Scheduling for Tuesday

I have a conflict, will be late.

From: Feinberg, Rebecca P. EOP/NSC (b) (6)
Sent: Monday, April 27, 2020 8:59 PM
To: Charles, Julia (CDC/OD/OCS) (b) (6)>; Redd, Stephen C. EOP/NSC <(b) (6)>; (b) (6) (b) (6)>; Vitek, Charles (CDC/DDPHSIS/CGH/DGHT) (b) (6)>; McGuffee, Tyler Ann A. EOP/OVP (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)

(b) (6); Adams, Jerome (HHS/OASH) (b) (6)>; CMS SV1 (b) (6)>; Schuchat, Anne MD (CDC/OD) (b) (6) Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6)>; Grogan, Joseph J. EOP/WHO (b) (6)>; Conway, Kellyanne E. EOP/WHO (b) (6); Walke, Henry (CDC/DDID/NCEZID/DPEI) (b) (6)>; Payne, Rebecca L. (CDC/DDID/NCHHSTP/DASH) (b) (6); Greene, Carolyn M. (CDC/DDID/NCIRD/ID) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Giroir, Brett (HHS/OASH) (b) (6); McQuiston, Jennifer H. (CDC/DDID/NCEZID/DHCPP) (b) (6); Meaney Delman, Dana M. (CDC/DDID/NCBDDD/DBDID) (b) (6); Butler, Jay C. (CDC/DDID/OD) (b) (6); Mead, Paul (CDC/DDID/NCEZID/DVBD) (b) (6)>; Fitter, David L. (CDC/DDPHSIS/CGH/GID) (b) (6)
Cc: Hoo, Elizabeth (CDC/OD/OCS) (b) (6) Warner, Agnes (CDC/OD/OCS) (b) (6) Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6)>

Subject: Re: Scheduling for Tuesday

All -

Apologies for another email on this meeting. The meeting will begin promptly at 9:15AM. Please note, the meeting room has been updated to EEOB 374 (SMS Large). This room is a SCIF and all electronic devices must be stored in the lockers outside the room. Please use the WAVES link I sent earlier to submit for building entry. I have updated the time on the back end of the system.

The dial in information remains the same. Please remember to mute your line at the start of the meeting.

Thanks,
Rebecca

Rebecca Feinberg
M: (b) (6)

On Apr 27, 2020, at 6:54 PM, Feinberg, Rebecca P. EOP/NSC (b) (6)> wrote:

All,

Please note this meeting will now be held from 9:15-10:15AM, tomorrow.

Thanks,
Rebecca

Rebecca Feinberg
M: (b) (6)

On Apr 27, 2020, at 2:46 PM, Feinberg, Rebecca P. EOP/NSC

(b) (6) > wrote:

Hi, all –

The CDC Activities Update is confirmed for tomorrow, April 28, from 10:00-11:00AM in the White House Situation Room.

Access information is listed below.

Thanks,
Rebecca

From: Charles, Julia (CDC/OD/OCS) (b) (6)
Sent: Monday, April 27, 2020 11:55 AM
To: Feinberg, Rebecca P. EOP/NSC <(b) (6)>; Redd, Stephen C. EOP/NSC (b) (6)>; (b) (6) <(b) (6)>; Vitek, Charles (CDC/DDPHSIS/CGH/DGHT) <(b) (6)>
Cc: Schuchat, Anne MD (CDC/OD) (b) (6)>; Hoo, Elizabeth (CDC/OD/OCS) <(b) (6)>; Warner, Agnes (CDC/OD/OCS) (b) (6)>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) (b) (6)>; Payne, Rebecca L. (CDC/DDID/NCHHSTP/DASH) (b) (6)>; Greene, Carolyn M. (CDC/DDID/NCIRD/ID) (b) (6)>; McQuiston, Jennifer H. (CDC/DDID/NCEZID/DHCPP) (b) (6)>; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) (b) (6)>; Butler, Jay C. (CDC/DDID/OD) (b) (6)>; Mead, Paul (CDC/DDID/NCEZID/DVBD) (b) (6)>; Fitter, David L. (CDC/DDPHSIS/CGH/GID) (b) (6)>; Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6)>
Subject: RE: Scheduling for Tuesday

Hi Rebecca,

The meeting will be held at an unclassified level and we will submit slides later today for tomorrow's meeting. Please find below a list of attendees and do let me know if you have any questions.

Thank you for your assistance!
Julia

In-person attendance:

Room: TBC

Please fill out the following WAVES Link by 8:00PM, Monday, April 27:

(b) (5)

- Dr. Birx (b) (6)
 - Dr. Redfield (b) (6)
 - Dr. Hahn (b) (6)
 - Surgeon General Adams (b) (6)
 - Administrator Verma (b) (6)
- Anne Schuchat, MD, CDC Principal Deputy Director and COVID-19 Incident Manager, (b) (6)
 - Daniel Jernigan, MD, MPH, CDC Liaison to NRCC, (b) (6)
 - Joe Grogan (b) (6)
 - Dr. Redd
 - Kellyanne Conway (b) (6)

Speaking mode:

Host Dial-In: (b) (6)

Leader Code: (b) (6)

- Henry Walke, MD, MPH, Deputy Incident Manager, (b) (6)
- Rebecca Payne, MPH, NRCC Community Mitigation Taskforce Lead, (b) (6)
- Carolyn Greene, MD, CDC representative on NRCC Community Mitigation Taskforce (b) (6)

Listen-only mode:

Participant Dial-In: (b) (6)

Participant Code: (b) (6)

- Jennifer McQuiston, DVM, MS, Principal Deputy Incident Manager, (b) (6)
- Dana Meaney-Delman, MD, Principal Deputy Incident Manager, (b) (6)
- Jay Butler, MD, CDC Deputy Director for Infectious Diseases, (b) (6)

- Paul Mead, MD, MPH, CDC-NRCC liaison, (b) (6)
- David Fitter, MD, Principal Deputy Incident Manager, (b) (6)

From: Feinberg, Rebecca P. EOP/NSC <(b) (6)>
Sent: Monday, April 27, 2020 10:57 AM
To: Charles, Julia (CDC/OD/OCS) (b) (6); Redd, Stephen C. EOP/NSC (b) (6)
Subject: RE: Scheduling for Tuesday

Hi,

Could you please send the names of attendees (both in person and by phone)? Will there be an AV requirement? At what level classification will this meeting be held?

I will generate the WAVES link and conference line and will send that out once I have the information.

Thanks,
Rebecca

From: Charles, Julia (CDC/OD/OCS) <(b) (6)>
Sent: Monday, April 27, 2020 10:53 AM
To: Redd, Stephen C. EOP/NSC (b) (6); Feinberg, Rebecca P. EOP/NSC <(b) (6)>
Subject: RE: Scheduling for Tuesday

Thank you, Steve and Rebecca.

Also, Tyler Ann said that the meeting can be a full hour (10:00 to 11:00). Will you be sending the WAVES links? I can send the names of the attendees (in-person, by phone).

From: Redd, Stephen C. EOP/NSC (b) (6)
Sent: Monday, April 27, 2020 10:48 AM
To: Feinberg, Rebecca P. EOP/NSC (b) (6)>
Cc: Charles, Julia (CDC/OD/OCS) (b) (6)
Subject: FW: Scheduling for Tuesday

Rebecca, can you set up this meeting for 172. Thanks..

For the principals, everyone who was invited last week should be included this week. . Should include Dr. Fauci, Joe Grogan, ADM Giroir, in addition to the CDC team and our team.

From: (b) (6) (b) (6) >
Sent: Monday, April 27, 2020 10:35
To: Redd, Stephen C. EOP/NSC <(b) (6)>
Subject: Fw: Scheduling for Tuesday

I think (b) (5)

From: McGuffee, Tyler Ann A. EOP/OVP <(b) (6)>
Sent: Monday, April 27, 2020 9:46 AM
To: Charles, Julia (CDC/OD/OCS)
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID); Schuchat, Anne MD (CDC/OD); Butler, Jay C. (CDC/DDID/OD); (b) (6); Redd, Stephen C. EOP/NSC; Vitek, Charles (CDC/DDPHSIS/CGH/DGHT); Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID); McQuiston, Jennifer H. (CDC/DDID/NCEZID/DHCPP); Fitter, David L. (CDC/DDPHSIS/CGH/GID); Mead, Paul (CDC/DDID/NCEZID/DVBD); Warner, Agnes (CDC/OD/OCS)
Subject: RE: Scheduling for Tuesday

Following up with Dr. Birx availability for Tuesday, (4/28) 10:00am-10:45am

I am going to let this group handle the meeting room, calendar invite to all attendees and IT requirements.

Last time I arranged the meeting, the President's IT support team's time was wasted due to a lack of communication.

You will need to ensure all principals that attended the last meeting are available to attend/invited to this meeting.

From: McGuffee, Tyler Ann A. EOP/OVP <(b) (6)>
Sent: Sunday, April 26, 2020 6:10 PM
To: Charles, Julia (CDC/OD/OCS) (b) (6) >
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6) >; Schuchat, Anne MD (CDC/OD) (b) (6) >; Butler, Jay C. (CDC/DDID/OD) (b) (6) >; (b) (6) (b) (6) >; Redd, Stephen C. EOP/NSC (b) (6); Vitek, Charles (CDC/DDPHSIS/CGH/DGHT) (b) (6) >; Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) (b) (6) >; McQuiston, Jennifer H. (CDC/DDID/NCEZID/DHCPP) (b) (6) >; Fitter, David L. (CDC/DDPHSIS/CGH/GID) <(b) (6)>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <(b) (6)>; Warner, Agnes (CDC/OD/OCS) (b) (6) >
Subject: Re: Scheduling for Tuesday

Request received. Will circle back tomorrow regarding exact time but yes, Tuesday.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office: (b) (6) | Mobile: (b) (6) [no text]

Email: (b) (6)

On Apr 26, 2020, at 5:31 PM, Charles, Julia (CDC/OD/OCS) (b) (6):

Hi Tyler Ann,

I hope you were able to take some semblance of a break over the weekend. We would like to schedule time with Dr. Birx to go over the package of CDC activities, which we have compiled per her request. Can you please help us find a time? (b) (6) suggested scheduling for an hour on Tuesday, if that helps.

Thank you,
Julia

Julia Charles, JD

CDC COVID-19 Response

o. (b) (6) | m. (b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 15:02:07 +0000
To: Short, Marc T. EOP/OVP; Miller, Katie R. EOP/OVP
Subject: Potential slides for Remdesivir presentation
Attachments: Remdesivir bullet slides - FAUCI - FINAL.pptx

Marc/Katie:

Here are 3 slides that I might use in the press briefing. If necessary, I could make the presentation without them, but it might be clearer to have them just in case.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 01:04:42 +0000
To: Szabat, Joel (OST); Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: RE: Two Strains

As Deb said in a prior e-mail. This would be easy to test for.

From: Szabat, Joel (OST) (b) (6) >
Sent: Wednesday, April 29, 2020 8:39 PM
To: Birx, Deborah L. EOP/NSC (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6)
Subject: Two Strains

Doctors,
I have read reports about different strains in the press... today was the first time I heard it discussed at the TF. (b) (5)
~Joel

Get [Outlook for iOS](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 01:10:33 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Why is CNN

Life in the fast lane.....

-----Original Message-----

From: Birx, Deborah L. EOP/NSC [REDACTED] (b) (6)
Sent: Wednesday, April 29, 2020 9:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Why is CNN

Trying to discredit the study as minimal.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:37:05 +0000
To: Hahn, Stephen;Debi Birx;Redfield, Robert R. (CDC/OD);Verma, Seema (CMS/OA)
Subject: RE: Serology Studies in Germany

Thanks, Steve!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)
Sent: Thursday, April 30, 2020 6:34 PM
To: Debi Birx (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Verma, Seema (CMS/OA) (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)

Subject: Fwd: Serology Studies in Germany

Interesting information from Germany

From: Shuren, Jeff (b) (6)
Date: April 30, 2020 at 5:46:27 PM EDT
To: Hahn, Stephen (b) (6), Shah, Anand <(b) (6)>, Lenihan, Keagan (b) (6), Guram, Jeet (b) (6), Rom, Colin (b) (6),
(b) (6)

Subject: Serology Studies in Germany

FYSA regarding serology studies being conducted in Germany, including status of tests to be used for those studies. This is the follow up to what I sent you last week. (b) (5)

(b) (5)

From: Hoshi, Ryan <(b) (6)>

Sent: Thursday, April 30, 2020 3:17 PM

To: Shuren, Jeff <(b) (6)>


Cc: Nalubola, Ritu <(b) (6)>; Louati, Claudia (FSN)* <(b) (6)>;


O'Leary, Brendan <(b) (6)>; Torres, Melissa A <(b) (6)>;

Stenzel, Timothy <(b) (6)>

Subject: FW: PLEASE REVIEW >> Meeting Notes - Call with Prof. Krause

(b) (5)





Thank you,
Ryan

Ryan A. Hoshi, Ph.D.

International Policy Analyst | Center for Devices and Radiological Health | (b) (6) | phone

(b) (6) | mobile (b) (6)



Excellent customer service is important to us.

Please take a moment to provide feedback regarding the customer service you have received:

[click here for survey](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:39:47 +0000
To: Birx, Deborah L. EOP/NSC; Adams, Jerome (HHS/OASH)
Cc: Short, Marc T. EOP/OVP; Redfield, Robert R. (CDC/OD)
Subject: RE: Task Force Data

Good idea!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Friday, May 1, 2020 6:14 PM
To: Adams, Jerome (HHS/OASH) (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Short, Marc T. EOP/OVP
(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>
Subject: Re: Task Force Data

If we can get the numbers. The numbers have been incomplete but I am happy to include.

Sent from my iPhone

On May 1, 2020, at 5:20 PM, Adams, Jerome (HHS/OASH) (b) (6) wrote:

Wasn't able to mention this at the meeting, but I have two requests for inclusion in the task force data.

(b) (5)

Any thoughts or concerns about these requests? I've included Dr. Redfield as CDC would be the most likely/ direct source of this data.

Thanks!

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 01:56:17 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Hahn, Stephen; Redfield, Robert R. (CDC/OD)
Subject: RE: New Understanding of Covid Infection

Amen.

-----Original Message-----

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Saturday, May 2, 2020 8:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Hahn, Stephen <(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)
Subject: Re: New Understanding of Covid Infection

Absolutely. (b) (5)

Sent from my iPhone

> On May 2, 2020, at 8:00 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

>

> We should discuss all of this on Monday

>

> -----Original Message-----

> From: Birx, Deborah L. EOP/NSC <(b) (6)>

> Sent: Saturday, May 2, 2020 7:05 PM

> To: Hahn, Stephen (b) (6)>

> Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)

> Subject: Re: New Understanding of Covid Infection

>

> Thank you. Between this and the pediatric cardiac complications it is not a good weekend.

>

> Sent from my iPhone

>

>> On May 2, 2020, at 6:59 PM, Hahn, Stephen (b) (6) wrote:

>>

>>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 13:29:53 +0000
To: Adams, Jerome (HHS/OASH); (b) (6); Giroir, Brett (HHS/OASH)
Cc: (b) (6)
Subject: RE: High touch points

(b) (5)

From: Adams, Jerome (HHS/OASH) <(b) (6)>
Sent: Sunday, May 3, 2020 7:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Giroir, Brett (HHS/OASH) (b) (6)>
Cc: (b) (6)
Subject: Fwd: High touch points

Please see short thread below. Senator Young reached out to me about this and I forwarded to CDC. As I mention, (b) (5)

(b) (5)

(b) (5) Thoughts?

Jerome

VADM Jerome Adams
20th US Surgeon General

Begin forwarded message:

From: "Adams, Jerome (HHS/OASH)" <(b) (6)>
Date: May 3, 2020 at 7:32:46 AM EDT
To: "Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)" (b) (6)>
Cc: "Schuchat, Anne MD (CDC/OD)" (b) (6)
Subject: Re: High touch points

Thank you.

(b) (5)

(b) (5)

Please keep me posted. And should I refer the senator to you or someone at CDC to close the loop?

Thanks!

J

VADM Jerome Adams
20th US Surgeon General

On May 2, 2020, at 7:08 PM, Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [REDACTED] (b) (6) wrote:

ADM Adams:

Thanks for sending this. There has been a lot of guidance on disinfection and cleaning, notably some very recent collaborative work we have done with EPA (<https://www.cdc.gov/coronavirus/2019-ncov/community/reopen-guidance.html>). Attached are two documents focused on re-opening America with emphasis on cleaning and disinfection, including high-touch surfaces. Also below are a number of websites that address cleaning and disinfection which point out the importance of disinfecting high-touch locations like doorknobs. They give guidance how to clean them, but they don't address methods for using a paper towel or Kleenex to first turn the knob and then discard the towel. [REDACTED] (b) (5)

Thanks
Dan.

Daniel B. Jernigan, MD MPH
Director, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 Response
Captain, USPHS (RET)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd NE, Atlanta, GA 30329
Phone [REDACTED] (b) (6), Cell [REDACTED] (b) (6)
[REDACTED] (b) (6) www.cdc.gov/flu

<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility.html>
<https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/disinfecting-your-home.html>
<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility-H.pdf>

From: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6)
Sent: Friday, May 1, 2020 5:35 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [REDACTED] (b) (6)>
Cc: Schuchat, Anne MD (CDC/OD) [REDACTED] (b) (6)
Subject: High touch points

Dr. Jernigan,

I got a message from a Senator asking why we didn't have specific reopening recommendations for "high touch" points like door knobs/ handles/ elevator buttons. The Senator stated that [REDACTED] (b) (5)

[REDACTED]
[REDACTED]
[REDACTED] I told him I'd follow up with CDC, [REDACTED] (b) (5)

[REDACTED] Would appreciate your feedback on this.

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

<Reopening_America_Guidance.pdf>

<ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 15:35:13 +0000
To: (b) (6) Redfield, Robert R. (CDC/OD)
Subject: FW: Update: White House Coronavirus Task Force PowerPoint - 5.3.20
Attachments: 3May2020Data.pptx

(b) (5)

From: Hurst, Natalie R. EOP/OVP <(b) (6)>
Sent: Sunday, May 3, 2020 11:02 AM
Cc: McGuffee, Tyler Ann A. EOP/OVP <(b) (6)>
Subject: Update: White House Coronavirus Task Force PowerPoint - 5.3.20
Importance: High

Good morning,

Dr. Birx wanted to share today's PowerPoint with members of the Task Force. Please see the attachment above.

Should you have any additional questions, please contact Tyler Ann (copied above).

Thank you,

Natalie Hurst
Operations Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice President
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:39:10 +0000
To: Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: RE: White House Coronavirus Task Force PowerPoint - 5.3.20

Got it. Let us discuss this, as you suggest, at an operational meeting.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Sunday, May 3, 2020 11:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6)
Subject: Re: White House Coronavirus Task Force PowerPoint - 5.3.20

(b) (5)

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, May 3, 2020 at 11:35 AM
To: "Birx, Deborah L. EOP/NSC" (b) (6) >, "Redfield, Robert R. (CDC/OD)" (b) (6) >
Subject: FW: Update: White House Coronavirus Task Force PowerPoint - 5.3.20

(b) (5)

From: Hurst, Natalie R. EOP/OVP <(b) (6)>
Sent: Sunday, May 3, 2020 11:02 AM
Cc: McGuffee, Tyler Ann A. EOP/OVP (b) (6)>
Subject: Update: White House Coronavirus Task Force PowerPoint - 5.3.20
Importance: High

Good morning,

Dr. Birx wanted to share today's PowerPoint with members of the Task Force. Please see the attachment above.

Should you have any additional questions, please contact Tyler Ann (copied above).

Thank you,

Natalie Hurst

Operations Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice President

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 8 May 2020 14:44:47 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redfield, Robert R. (CDC/OD); Hahn, Stephen; Adams, Jerome (HHS/OASH)
Subject: Remdesivir Recommendations and Inclusion-Exclusion criteria of the Protocol
Attachments: Remdesivir.docx, ACTT-1 Inclusion Exclusion.docx

Deb:

Below is a summary of what will be in the treatment guidelines revision coming out next week from the NIH Treatment Guidelines Panel;

Remdesivir

Recommendation:

- Based on preliminary clinical trial data the Panel recommends the investigational antiviral agent **remdesivir** for the treatment of COVID-19 in hospitalized patients with severe disease defined as $\text{SpO}_2 \leq 94\%$ on ambient air (at sea level), requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (**BI**).
- The Panel does not recommend remdesivir for treatment of mild or moderate COVID-19 outside of a clinical trial (**AIII**).

The attachment labelled “Remdesivir” is the full description of the recommendations. The attachment labelled “ACTT-1 inclusion Exclusion” is the actual language from the protocol.

Please let me know if you have any questions.

Thanks,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 9 May 2020 14:04:49 +0000
To: Birx, Deborah L. EOP/NSC; Conley, Sean P. CDR USN WHMO/WHMU
Cc: Redfield, Robert R. (CDC/OD)
Subject: RE: Contact Return

Ditto from my standpoint.

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Saturday, May 9, 2020 9:35 AM
To: Conley, Sean P. CDR USN WHMO/WHMU <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Subject: Re: Contact Return

We are here to help in anyway. (b) (5)

Sent from my iPhone

On May 9, 2020, at 9:31 AM, Conley, Sean P. CDR USN WHMO/WHMU (b) (6)> wrote:

I hear you all, and agree.

As you say Tony, (b) (5)
(b) (5)

Thanks for the backup everyone.
Sean

Sent from my iPhone

On May 9, 2020, at 8:45 AM, Redfield, Robert R. (CDC/OD) (b) (6) wrote:

I agree that (b) (5)
(b) (5)

Get Outlook for iOS

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Saturday, May 9, 2020 8:01:10 AM
To: Birx, Deborah L. EOP/NSC (b) (6); Conley, Sean P. CDR USN WHMO/WHMU <(b) (6)>
Cc: Redfield, Robert R. (CDC/OD) (b) (6)
Subject: RE: Contact Return

Sean/Deb:

I agree with Deb (b) (5)
(b) (5)

Thanks,
Tony

-----Original Message-----

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Saturday, May 9, 2020 6:22 AM
To: Conley, Sean P. CDR USN WHMO/WHMU <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: Re: Contact Return

A couple of things. (b) (5)
(b) (5)

(b) (5)

Just some thoughts and I defer to Bob and Tony. Deb

On 5/8/20, 10:00 PM, "Conley, Sean P. CDR USN WHMO/WHMU" (b) (6) wrote:

Tony,
Just wanted to close the loop w/ you on things.

After speaking w/ Ornato, the message is:

(b) (5)

Reasonable? Thanks everyone.

- Sean

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 9 May 2020 15:01:06 +0000
To: Hahn, Stephen; Conley, Sean P. CDR USN WHMO/WHMU; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Cc: Lane, Cliff (NIH/NIAID) [E]; Jones, James J. EOP/OA
Subject: RE: HCQ PEP?

Not that I am aware of.

From: Hahn, Stephen (b) (6) >
Sent: Saturday, May 9, 2020 10:26 AM
To: Conley, Sean P. CDR USN WHMO/WHMU (b) (6) >; Birx, Deborah L. EOP/NSC (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6) >
Cc: Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Jones, James J. EOP/OA <(b) (6)>
Subject: Re: HCQ PEP?

I'm not aware but I've pinged our Real World Evidence group and will get back to you.
Steve

From: Conley, Sean P. CDR USN WHMO/WHMU (b) (6) >
Date: May 7, 2020 at 7:16:05 PM EDT
To: Hahn, Stephen (b) (6), Birx, Deborah L. EOP/NSC (b) (6) >, Fauci, Anthony S (NIH) (b) (6), Redfield, Robert R (CDC) (b) (6)
Cc: Lane, Henry C (NIH) (b) (6), Jones, James J. EOP/OA (b) (6) >
Subject: HCQ PEP?

Doctors,
I just received a report referencing a large "placebo-controlled trial of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection after a discrete exposure".
Does anyone have insight or pre-publication data that they can share? Thanks!

Regards,
Sean

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 9 May 2020 17:14:42 +0000
To: Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: RE: Major League Soccer request for help on guidance

There was no attachment with this e-mail.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Saturday, May 9, 2020 1:00 PM
To: Troye, Olivia EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6)
Subject: Re: Major League Soccer request for help on guidance

(b) (5)

From: "Troye, Nsc" <(b) (6)>
Date: Saturday, May 9, 2020 at 12:55 PM
To: "Birx, Deborah L. EOP/NSC" <(b) (6)>, "Anthony Fauci [E]" (b) (6), Dr Bob Redfield (b) (6)
Subject: Major League Soccer request for help on guidance

Dr. Birx/All-

Please see below and attached. Any thoughts on how you all would like to approach this? I'm including the document that was sent and the context below. Is setting up a call better? If you all are willing to review and provide comments I can also consolidate them.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 9 May 2020 17:19:35 +0000
To: Troye, Olivia EOP/NSC; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD)
Subject: RE: Major League Soccer request for help on guidance

Now that I see the attachment, (b) (5)

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Troye, Olivia EOP/NSC <(b) (6)>
Sent: Saturday, May 9, 2020 12:55 PM
To: Birx, Deborah L. EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: Major League Soccer request for help on guidance

Dr. Birx/All-

Please see below and attached. Any thoughts on how you all would like to approach this? I'm including the document that was sent and the context below. Is setting up a call better? If you all are willing to review and provide comments I can also consolidate them.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 10 May 2020 22:20:35 +0000
To: Hahn, Stephen; Tyler McGuffee; Redfield, Robert R. (CDC/OD); Adams, Jerome (HHS/OASH); Debi Birx
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: testing, testing, testing

I do not see a Doctor's meeting on my calendar for tomorrow. Am I the only one that does not have it?

From: Hahn, Stephen (b) (6)
Sent: Sunday, May 10, 2020 6:17 PM
To: Tyler McGuffee (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Adams, Jerome (HHS/OASH)
(b) (6); Debi Birx (b) (6)
Subject: FW: testing, testing, testing

Tyler Ann,
Could we add Tony's email to our Doctor's meeting agenda tomorrow or Tuesday?
Thanks
Steve

From: Tony Fauci (b) (6)>
Date: Sunday, May 10, 2020 at 4:27 PM
To: Debi Birx (b) (6)>, Robert Redfield (b) (6)>, Stephen Hahn
(b) (6)>, Jerome Adams (b) (6), Brett Giroir
(b) (6)>, Robert Kadlec (b) (6)
Subject: testing, testing, testing

Folks:

The link below is an article by Harold Varmus representing the deliberations of 10 world-class scientists. (b) (5)

(b) (5)

Maybe we can discuss it the next time we meet, which might be virtual.

<https://www.theatlantic.com/ideas/archive/2020/05/lack-testing-holding-science-back/611422/>

Thanks,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 11 May 2020 00:41:02 +0000
To: Giroir, Brett (HHS/OASH); Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); (b) (6) Adams, Jerome (HHS/OASH); Kadlec, Robert (OS/ASPR/IO)
Cc: Collins, Francis (NIH/OD) [E]
Subject: RE: testing, testing, testing

Brett:

Thanks for the note. I look forward to discussing this with you.

Best regards,

Tony

From: Giroir, Brett (HHS/OASH) (b) (6) >
Sent: Sunday, May 10, 2020 5:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Birx, Deborah L. EOP/NSC (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Adams, Jerome (HHS/OASH) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6) >
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Giroir, Brett (HHS/OASH) (b) (6) >
Subject: RE: testing, testing, testing

Tony,

I am really surprised at your email.

(b) (5)



Happy to discuss next time we meet.

BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Sunday, May 10, 2020 4:28 PM
To: Birx, Deborah L. EOP/NSC (b) (6); Redfield, Robert R. (CDC/OD)
(b) (6) Adams, Jerome (HHS/OASH)
(b) (6); Giroir, Brett (HHS/OASH) (b) (6); Kadlec, Robert
(OS/ASPR/IO) (b) (6)
Subject: testing, testing, testing

Folks:

The link below is an article by Harold Varmus representing the deliberations of 10 world-class scientists. (b) (5)

(b) (5)

<https://www.theatlantic.com/ideas/archive/2020/05/lack-testing-holding-science-back/611422/>

Thanks,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 12 May 2020 12:25:03 +0000
To: Birx, Deborah L. EOP/NSC; Hahn, Stephen; Redfield, Robert R. (CDC/OD)
Subject: RE: CDC Guidelines

Ditto response as Steve. I have always considered my work at NIH and in the Task Force as essential for the COVID-19 effort. Therefore, I am following and have been following the critical infrastructure guidelines

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Tuesday, May 12, 2020 8:21 AM
To: Hahn, Stephen (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CDC Guidelines

Did not distinguish – the implication was they were needed to combat the epidemic on the front lines. I just want to make sure that we all understand the confusion this has created by each of us doing something different following different subelements of guidelines. I just need each of you to define which guideline you are following and why

From: "Hahn, Stephen" (b) (6)>
Date: Tuesday, May 12, 2020 at 8:14 AM
To: "Birx, Deborah L. EOP/NSC" (b) (6)>, "Redfield, Robert R (CDC)" (b) (6), "Fauci, Anthony S (NIH)" (b) (6)>
Subject: Re: CDC Guidelines

Thanks, Deb. These are guidelines for docs and nurses who are involved in patient care, right? I think we have reasonable wording for our response which is shown below.

"The Centers for Disease Control and Prevention and U.S. Department of Homeland Security have together determined that government entities working in support of the COVID-19 response efforts are providing essential services and the [current guidelines for critical infrastructure workers apply](#). Therefore, providing that they are asymptomatic, screened and monitored for fever and other symptoms, wear a face covering, and maintain a distance of at least six feet from others, Drs. Hahn, Fauci and Redfield can and will participate in meetings on the White House complex when their attendance is needed."

From: Debi Birx (b) (6)
Date: Tuesday, May 12, 2020 at 8:09 AM
To: Stephen Hahn (b) (6), Robert Redfield (b) (6), Tony Fauci

(b) (6) >

Subject: CDC Guidelines

I just want to note in case this comes up today that

(b) (5)

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 13 May 2020 17:22:34 +0000
To: CMS SV1; Short, Marc T. EOP/OVP; Redfield, Robert R. (CDC/OD) (b) (6);
(b) (6); Troye, Olivia (b) (6); Giroir, Brett (HHS/OASH); 'Birx, Deborah L. EOP/NSC'
Subject: RE: Flu & COVID-19 vaccines

Good idea. We should definitely make it a point of discussion on a future call/meeting

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: CMS (b) (6) >
Sent: Wednesday, May 13, 2020 1:18 PM
To: Short, Marc T. EOP/OVP <(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); (b) (6) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Troye, Olivia (b) (6) Giroir, Brett (HHS/OASH) (b) (6); 'Birx, Deborah L. EOP/NSC' (b) (6)
Subject: Flu & COVID-19 vaccines

Team,

(b) (5)

(b) (5)

Let me know your thoughts and would be good to brainstorm on next steps if there is agreement.
Thanks.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 14 May 2020 02:01:57 +0000
To: Ray, Paul J. EOP/OMB; Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC; Lyons, Derek S. EOP/WHO; Short, Marc T. EOP/OVP
Cc: Vought, Russell T. EOP/OMB; Redfield, Robert R. (CDC/OD); Kan, Derek T. EOP/OMB
Subject: RE: URGENT - CDC opening guidance for clearance tonight

I clear these 6 decision trees.

From: Ray, Paul J. EOP/OMB (b) (6)
Sent: Wednesday, May 13, 2020 9:56 PM
To: Birx, Deborah L. EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Troye, Olivia EOP/NSC (b) (6); Lyons, Derek S. EOP/WHO (b) (6); Short, Marc T. EOP/OVP (b) (6)
Cc: Vought, Russell T. EOP/OMB (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Kan, Derek T. EOP/OMB (b) (6)
Subject: URGENT - CDC opening guidance for clearance tonight

Good evening all,

Attached please find final versions of the six decision trees discussed in the TF earlier today for your clearance. The VP has set a deadline to clear these tonight, so we ask that you let us know tonight as soon as possible if you clear. Thank you.

Best,

Paul J. Ray
Administrator
Office of Information and Regulatory Affairs
Office of Management and Budget

PREDECISIONAL DELIBERATIVE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 14 May 2020 10:35:42 +0000
To: CMS (b) (6); Deborah Birx; (b) (6) Giroir, Brett (HHS/OASH); Redfield, Robert R. (CDC/OD)
Subject: RE: Nursing home reopening and testing guidance- draft. Confidential. Deliberative

Seema:

Unfortunately, I will miss part or all of the discussion today since I have a teleconference with Sec. Azar that overlaps with your meeting. I will catch up about this with you later.

Thanks,

Tony

From: CMS (b) (6) >
Sent: Wednesday, May 13, 2020 10:16 PM
To: Deborah Birx (b) (6) >; (b) (6) (b) (6); Giroir, Brett (HHS/OASH) (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Nursing home reopening and testing guidance- draft. Confidential. Deliberative

For discussion tomorrow.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 16 May 2020 11:52:51 +0000
To: Redfield, Robert R. (CDC/OD); Birx, Deborah L. EOP/NSC; Short, Marc T. EOP/OVP; Vought, Russell T. EOP/OMB
Subject: RE: guidance documents

Go for it!

From: Redfield, Robert R. (CDC/OD) (b) (6)
Sent: Saturday, May 16, 2020 7:38 AM
To: Birx, Deborah L. EOP/NSC (b) (6); Short, Marc T. EOP/OVP (b) (6); Vought, Russell T. EOP/OMB (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: guidance documents

Working to align with decision trees and post

Get [Outlook for iOS](#)

From: Birx, Deborah L. EOP/NSC (b) (6)>
Sent: Saturday, May 16, 2020 6:33:26 AM
To: Redfield, Robert R. (CDC/OD) (b) (6); Short, Marc T. EOP/OVP (b) (6); Vought, Russell T. EOP/OMB <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: guidance documents

I think these should be posted as soon as possible.

From: "Redfield, Robert R. (CDC/OD)" (b) (6)>
Date: Wednesday, May 13, 2020 at 2:37 PM
To: "Short, Marc T. EOP/OVP" (b) (6)
Cc: "Birx, Deborah L. EOP/NSC" (b) (6); "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: guidance documents

Dear Vice President,

Via Mark Short, I am sending you a copy of the guidance documents we developed. These documents back up and provide details to the decision trees that are being presented to the Task Force today. I provided a copy to Dr Birx and Dr Fauci as you requested and am happy to discuss if you have questions.

Peace,
r3

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 16 May 2020 22:08:30 +0000
To: Kan, Derek T. EOP/OMB; Birx, Deborah L. EOP/NSC
Subject: RE: BCG and COVID

Derek:

(b) (5)

Best regards,
Tony

From: Kan, Derek T. EOP/OMB (b) (6) >
Sent: Friday, May 15, 2020 4:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Birx, Deborah L. EOP/NSC
(b) (6)
Subject: BCG and COVID

Saw this paper from NIAID. Tony, what do you make of this?

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 17 May 2020 16:29:11 +0000
To: Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield, Robert R. (CDC/OD)
Subject: RE: First attempt
Attachments: Comprehensive use of COVID - with Fauci suggested edits.docx

A small start (see attached)

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Sunday, May 17, 2020 8:41 AM
To: Hahn, Stephen (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: First attempt

Sorry – its been a long morning

From: "Birx, Deborah L. EOP/NSC" (b) (6) >
Date: Sunday, May 17, 2020 at 8:40 AM
To: "Hahn, Stephen" (b) (6) >, "Redfield, Robert R. (CDC/OD)" (b) (6)
Anthony S Fauci (b) (6)
Subject: First attempt

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 18 May 2020 13:59:03 +0000
To: Birx, Deborah L. EOP/NSC; Kushner, Jared C. EOP/WHO
Subject: RE: great testing day yesterday!

Jared:

Deb's comment reflects what I was going to ask. (b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Monday, May 18, 2020 9:47 AM
To: Kushner, Jared C. EOP/WHO (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Subject: Re: great testing day yesterday!

Yep – incredible work by your team and (b) (5)

From: "Kushner, Jared C. EOP/WHO" (b) (6) >
Date: Monday, May 18, 2020 at 9:08 AM
To: (b) (6) "Birx, Deborah L. EOP/NSC"
<(b) (6)>
Subject: great testing day yesterday!

<https://covidtracking.com/data/us-daily>

US Daily Cumulative Totals - 4 pm ET

Date	States Tracked	New Tests	Positive	Negative	Pos + Neg	Pending	Deaths	Total Tests
Sun May 17 2020	56	422,024	1,479,856	10,019,347	11,499,203	3,449	83,854	11,499,203
Sat May 16 2020	56	356,994	1,458,787	9,618,92	11,077,179	3,788	83,015	11,077,179
Fri May 15 2020	56	378,410	1,433,696	9,286,89	10,720,185	2,457	81,729	10,720,185
Thu May 14 2020	56	366,944	1,407,507	8,934,68	10,341,775	2,673	80,084	10,341,775
Wed May 13 2020	56	324,426	1,382,304	8,592,27	9,974,31	1,983	78,343	9,974,31
Tue May 12 2020	56	301,947	1,361,884	8,288,21	9,650,05	1,803	76,650	9,650,05
Mon May 11 2020	56	388,296	1,340,412	8,008,46	9,348,58	1,989	75,107	9,348,58
Sun May 10 2020	56	273,662	1,322,807	7,637,55	8,960,62	3,095	74,270	8,960,62
Sat May 9 2020	56	296,494	1,301,095	7,385,05	8,686,00	3,054	73,291	8,686,00
Fri May 8 2020	56	299,145	1,275,916	7,114,90	8,390,06	3,307	71,762	8,390,06

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 27 May 2020 02:20:06 +0000
To: Butler, Jay C. (CDC/DDID/OD); CMS (b) (6) Birx, Deborah L. EOP/NSC
Cc: Redfield, Robert R. (CDC/OD); Giroir, Brett (HHS/OASH); Short, Marc T. EOP/OVP; Troye, Olivia (b) (6)
Subject: RE: Comprehensive use of COVID tests

Thanks, Jay

From: Butler, Jay C. (CDC/DDID/OD) (b) (6) >
Sent: Tuesday, May 26, 2020 10:12 PM
To: CMS (b) (6) >; (b) (6) Birx, Deborah L. EOP/NSC (b) (6) >
Cc: Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Giroir, Brett (HHS/OASH) (b) (6) >; Short, Marc T. EOP/OVP (b) (6) >; Troye, Olivia (b) (6) (b) (6)
Subject: RE: Comprehensive use of COVID tests

Updates on the various documents/workstreams you have outlined below:

(b) (5)



I hope that is helpful for clarification.

From: CMS (b) (6) >
Sent: Tuesday, May 26, 2020 9:42 PM

To: (b) (6)>; Birx, Deborah L. EOP/NSC (b) (6)>;
Butler, Jay C. (CDC/DDID/OD) <(b) (6)>
Cc: Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>; Giroir, Brett (HHS/OASH) (b) (6) Short, Marc T. EOP/OVP
(b) (6)>; Troye, Olivia (b) (6) (b) (6)
Subject: RE: Comprehensive use of COVID tests

(b) (5)

From: Hahn, Stephen (b) (6)>
Sent: Tuesday, May 26, 2020 4:18 PM
To: Birx, Deborah L. EOP/NSC (b) (6)>; Butler, Jay C. (CDC/DDID/OD)
(b) (6)
Cc: CMS (b) (6) Redfield, Robert R. (CDC/OD) <(b) (6)>; Fauci, Anthony
(NIH/NIAID) [E] (b) (6)>; Giroir, Brett (HHS/OASH) <(b) (6)>; Short, Marc
T. EOP/OVP (b) (6)>; Troye, Olivia (b) (6) <(b) (6)>
Subject: Re: Comprehensive use of COVID tests

Deb,
My comments
Glad to discuss further
Steve

From: Debi Birx (b) (6)>
Date: Tuesday, May 26, 2020 at 9:13 AM
To: "Butler, Jay C (CDC)" (b) (6)>
Cc: Seema Verma <(b) (6)>, Robert Redfield (b) (6)>, Stephen Hahn
(b) (6)>, Tony Fauci (b) (6)>, Brett Giroir (b) (6),
Marc Short (b) (6) Olivia Troye (b) (6)>
Subject: Comprehensive use of COVID tests

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 27 May 2020 11:55:05 +0000
To: Hahn, Stephen; CMS (b) (6); Birx, Deborah L. EOP/NSC; Butler, Jay C. (CDC/DDID/OD)
Cc: Redfield, Robert R. (CDC/OD); Giroir, Brett (OS); Short, Marc T. EOP/OVP; Troye, Olivia (b) (6)
Subject: RE: Comprehensive use of COVID tests

Looks really good!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Wednesday, May 27, 2020 7:38 AM
To: CMS (b) (6)>; Birx, Deborah L. EOP/NSC (b) (6)>; Butler, Jay C. (CDC/DDID/OD) (b) (6)>
Cc: Redfield, Robert R. (CDC/OD) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Giroir, Brett (OS) (b) (6)>; Short, Marc T. EOP/OVP (b) (6)>; Troye, Olivia (b) (6) (b) (6)>
Subject: Re: Comprehensive use of COVID tests

Seema,
The CDC guidance around serology went live.
Here it is featured on our landing page: <https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html>. Here are the guidelines: <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>

Steve

From: Seema Verma (b) (6)
Date: Tuesday, May 26, 2020 at 9:57 PM
To: Stephen Hahn (b) (6)>, Debi Birx (b) (6)>, "Butler, Jay C

(CDC)" (b) (6)

Cc: Robert Redfield (b) (6)>, Tony Fauci (b) (6), Brett Giroir
<(b) (6)>, Marc Short (b) (6)>, Olivia Troye
(b) (6)>

Subject: RE: Comprehensive use of COVID tests

(b) (5)

From: Hahn, Stephen <(b) (6)>

Sent: Tuesday, May 26, 2020 4:18 PM

To: Birx, Deborah L. EOP/NSC (b) (6); Butler, Jay C. (CDC/DDID/OD)
(b) (6)

Cc: CMS (b) (6) Redfield, Robert R. (CDC/OD) (b) (6)>; Fauci, Anthony
(NIH/NIAID) [E] (b) (6); Giroir, Brett (HHS/OASH) (b) (6); Short, Marc
T. EOP/OVP (b) (6)>; Troye, Olivia (b) (6) (b) (6)>

Subject: Re: Comprehensive use of COVID tests

Deb,
My comments
Glad to discuss further
Steve

From: Debi Birx (b) (6)>

Date: Tuesday, May 26, 2020 at 9:13 AM

To: "Butler, Jay C (CDC)" (b) (6)

Cc: Seema Verma (b) (6), Robert Redfield (b) (6)>, Stephen Hahn
(b) (6)>, Tony Fauci <(b) (6)>, Brett Giroir (b) (6)
Marc Short (b) (6)>, Olivia Troye (b) (6)>

Subject: Comprehensive use of COVID tests

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 27 May 2020 15:13:27 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Saw you on CNN - have they let you out?

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Wednesday, May 27, 2020 11:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: Saw you on CNN - have they let you out?

You looked great

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Wednesday, May 27, 2020 at 11:10 AM
To: "Birx, Deborah L. EOP/NSC" (b) (6)>
Subject: RE: Saw you on CNN - have they let you out?

Yes and no. Really crazy. First they said yes to CNN and then 20 minutes after I actually did the hit, HHS sent an e-mail saying that clearance was withdrawn. Too late, already did it.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)

Sent: Wednesday, May 27, 2020 11:06 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Saw you on CNN - have they let you out?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 28 May 2020 01:51:52 +0000
To: Hahn, Stephen; Redfield, Robert R. (CDC/OD); Debi Birx
Subject: RE: Bloomberg: Covid Patients Testing Positive After Recovery Aren't Infectious, Study Shows

Yes. Viral fragments can hang around for quite a while

From: Hahn, Stephen (b) (6) >
Sent: Wednesday, May 27, 2020 1:22 PM
To: Redfield, Robert R. (CDC/OD) (b) (6); Debi Birx (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Bloomberg: Covid Patients Testing Positive After Recovery Aren't Infectious, Study Shows

Are you all aware of this study?

From: Shah, Anand <(b) (6)>
Date: May 20, 2020 at 10:16:18 AM EDT
To: Hahn, Stephen (b) (6) >, Shuren, Jeff (b) (6), Stenzel, Timothy (b) (6) >
Subject: Bloomberg: Covid Patients Testing Positive After Recovery Aren't Infectious, Study Shows

<https://www.bloomberg.com/news/articles/2020-05-19/covid-patients-testing-positive-after-recovery-aren-t-infectious>



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 5 Jun 2020 18:31:29 +0000
To: Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield, Robert R. (CDC/OD)
Subject: FW: Covid is not winding down in the United States.


See below

To my friends and colleagues.

The number of those infected is not decreasing. Please scan the numbers of new cases detected per day below. The number newly diagnosed on June 2nd is similar that over two months ago, March 28th. The Times story highlights twelve states with rising numbers, some rising sharply. I have highlighted the day on which the numbers are similar to those of June 2 (red) as well as the peak daily numbers (in purple). The US has been hovering around 20,000 newly diagnosed cases per day for over two months. Contrast that with what is happening in China 9 low single-digit cases beginning May. This is in large part due to poor communication and public health management.

See this New York Times story describing the increase in the number of daily infection in sixteen states.

The number of confirmed cases is rising in 16 states



A volunteer controls traffic at a testing site in Central Los Angeles in May. Credit...Jae C. Hong/Associated Press

Police brutality, protests and unrest may have knocked the pandemic from the lead of many U.S. newscasts, but the outbreak is continuing to spread. Even as some Northeast states are seeing improvements, in others, daily case numbers are reaching new highs.

That is partly a consequence of the country's vastly expanded testing capacity. Earlier in the pandemic, when test kits were scarce, many people who contracted the virus were not tested and not included in official counts. Here is a look around the country.

In **California**, daily case reports exceeded 3,000 twice in the past week, a threshold the state had not crossed before. In **Northern California**, six chief health officers said in a statement that they were "encouraged by what we are seeing in some areas and concerned about what we are seeing in others." As more businesses were allowed to reopen, they said, "each decision we make involves difficult trade-offs."

Arizona, Wisconsin, Tennessee, at least 12 other states and Puerto Rico are also seeing an upward trend of newly reported cases, and some are reaching new highs.

In **Mississippi**, the 439 cases announced Saturday were the most yet on a single day. In **Alaska**,

which has so far avoided the worst of the virus, cases have soared to their highest levels in recent days.

With **New York City** still working toward lifting some virus-related restrictions on June 8 — despite a nightly curfew imposed to curb looting — Mayor Bill de Blasio called on the agency that runs the city’s subways and buses to limit capacity. “It is crucial that every other seat be blocked off so that it’s clear that you never end up sitting next to someone,” he said. The agency had said it would take some steps to encourage and enforce social distancing, including putting floor markings at all subway stations.

Mr. Trump’s high-stakes feud with Democratic officials in **North Carolina** is disrupting planning for the Republican National Convention. His speech will be moved out of Charlotte, party officials said Tuesday night, after indications that the entire event might be relocated.

In **Dallas County, Texas**, case numbers have continued to rise, and the 16 deaths announced Tuesday were the most of any day so far. Clay Jenkins, Dallas County’s chief elected official, said there was also no improvement in data on hospitalizations and intensive care unit admissions. He called for residents to use caution even though restrictions had eased.

Chicago moved to its third phase of reopening, which eases restrictions on businesses combined with new precautions. Child care centers are reopening, but children are screened for signs of illness, and parents and teachers must wear face coverings. Restaurants will reopen with outdoor dining only. And riders will be encouraged to wear face masks while using public transportation.

In New Jersey, restaurants and bars can offer outdoor dining on June 15, the governor said. There were an additional 112 virus-related deaths.

The US numbers of new Covid-19 per day

26 on Mar 4
64 on Mar 5
77 on Mar 6
101 on Mar 7
144 on Mar 8
148 on Mar 9
291 on Mar 10
269 on Mar 11
393 on Mar 12
565 on Mar 13
662 on Mar 14
676 on Mar 15
872 on Mar 16
1,291 on Mar 17
2,410 on Mar 18
3,948 on Mar 19
5,417 on Mar 20
6,271 on Mar 21

8,631 on Mar 22
10,410 on Mar 23
9,939 on Mar 24
12,226 on Mar 25
17,050 on Mar 26
19,046 on Mar 27
20,093 on Mar 28
19,118 on Mar 29
20,463 on Mar 30
25,305 on Mar 31
26,756 on Apr 1
28,879 on Apr 2
32,525 on Apr 3
33,725 on Apr 4
25,717 on Apr 5
29,359 on Apr 6
30,512 on Apr 7
32,282 on Apr 8
34,243 on Apr 9
33,578 on Apr 10
31,869 on Apr 11
28,057 on Apr 12
24,685 on Apr 13
25,987 on Apr 14
29,465 on Apr 15
32,076 on Apr 16
30,915 on Apr 17
28,084 on Apr 18
26,013 on Apr 19
25,132 on Apr 20
25,378 on Apr 21
29,046 on Apr 22
32,331 on Apr 23
36,137 on Apr 24
34,956 on Apr 25
26,884 on Apr 26
22,086 on Apr 27
24,429 on Apr 28
25,904 on Apr 29
29,674 on Apr 30
33,007 on May 1
30,568 on May 2
25,393 on May 3
21,278 on May 4
22,252 on May 5
24,859 on May 6

27,535 on May 7
27,114 on May 8
25,563 on May 9
20,697 on May 10
17,779 on May 11
21,486 on May 12
20,549 on May 13
26,762 on May 14
25,382 on May 15
24,527 on May 16
19,731 on May 17
21,107 on May 18
19,662 on May 19
22,368 on May 20
25,017 on May 21
23,923 on May 22
22,784 on May 23
20,286 on May 24
18,586 on May 25
16,700 on May 26
18,677 on May 27
23,051 on May 28
23,607 on May 29
23,836 on May 30
21,703 on May 31
16,070 on Jun 1
20,073 on Jun 2
Number of new cases per day China

59 on Jan 18
77 on Jan 19
93 on Jan 20
149 on Jan 21
131 on Jan 22
259 on Jan 23
457 on Jan 24
688 on Jan 25
769 on Jan 26
1,771 on Jan 27
1,459 on Jan 28
1,737 on Jan 29
1,981 on Jan 30
2,099 on Jan 31
2,589 on Feb 1
2,825 on Feb 2
3,233 on Feb 3
3,886 on Feb 4

3,694 on Feb 5
3,143 on Feb 6
3,385 on Feb 7
2,652 on Feb 8
2,973 on Feb 9
2,467 on Feb 10
2,015 on Feb 11
1,819 on Feb 12
1,995 on Feb 13
1,503 on Feb 14
1,121 on Feb 15
19,457 on Feb 16
1,888 on Feb 17
1,749 on Feb 18
817 on Feb 19
889 on Feb 20
397 on Feb 21
648 on Feb 22
214 on Feb 23
508 on Feb 24
406 on Feb 25
433 on Feb 26
327 on Feb 27
427 on Feb 28
573 on Feb 29
202 on Mar 1
125 on Mar 2
119 on Mar 3
139 on Mar 4
143 on Mar 5
99 on Mar 6
44 on Mar 7
40 on Mar 8
19 on Mar 9
24 on Mar 10
15 on Mar 11
20 on Mar 12
11 on Mar 13
20 on Mar 14
16 on Mar 15
21 on Mar 16
13 on Mar 17
34 on Mar 18
39 on Mar 19
41 on Mar 20
46 on Mar 21

39 on Mar 22
78 on Mar 23
47 on Mar 24
67 on Mar 25
55 on Mar 26
54 on Mar 27
45 on Mar 28
31 on Mar 29
48 on Mar 30
36 on Mar 31
35 on Apr 1
31 on Apr 2
19 on Apr 3
30 on Apr 4
39 on Apr 5
32 on Apr 6
62 on Apr 7
63 on Apr 8
42 on Apr 9
46 on Apr 10
99 on Apr 11
108 on Apr 12
89 on Apr 13
46 on Apr 14
46 on Apr 15
351 on Apr 16
27 on Apr 17
16 on Apr 18
12 on Apr 19
11 on Apr 20
30 on Apr 21
10 on Apr 22
6 on Apr 23
12 on Apr 24
11 on Apr 25
3 on Apr 26
6 on Apr 27
22 on Apr 28
4 on Apr 29
12 on Apr 30
1 on May 1
2 on May 2
3 on May 3
1 on May 4
2 on May 5
2 on May 6

1 on May 7
1 on May 8
14 on May 9
17 on May 10
1 on May 11
7 on May 12
3 on May 13
4 on May 14
8 on May 15
6 on May 16
7 on May 17
6 on May 18
5 on May 19
2 on May 20
4 on May 21
0 on May 22
3 on May 23
11 on May 24
7 on May 25
1 on May 26
2 on May 27
0 on May 28
4 on May 29
2 on May 30
16 on May 31
5 on Jun 1

Each day shows new cases reported since the previous day · Updated less than 30 mins ago ·

Source: [Wikipedia](#) ·

[About this data](#)

Total cases

Total



Mainland China

Confirmed

83,021

Recovered

78,314

Deaths

4,634

Location

Confirmed

Recovered

Deaths

Hubei

68,135

63,620

4,512

Guangdong Province

1,595

1,583

8

Henan

1,276

1,254

22

Zhejiang

1,268

1,267

1

Hunan

1,019

1,015

4

"+" shows new cases reported yesterday · Updated less than 30 mins ago ·

Source: [Wikipedia](#) ·

[About this data](#)

Each day shows

[About this data](#)

Total cases

(b)(5) - PCP



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 9 Jun 2020 22:55:56 +0000
To: Miller, Katie R. EOP/OVP; Short, Marc T. EOP/OVP
Subject: Another press misrepresentation

Katie/Marc:

I am sure that this article (see link) will come to the attention of the POTUS and VP. The title of the article completely misrepresents what I said in the article. I spoke about what has happened, not what will happen. If this title causes a disturbance, please make sure that they actually read the article and not just the title. Geeez.....

Thanks,

Tony

<https://www.nytimes.com/2020/06/09/health/fauci-vaccines-coronavirus.html>

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 15 Jun 2020 19:00:28 +0000
To: Pottinger, Matthew F. EOP/WHO
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Berg, Jeremy
Subject: Paper from China on human ACE2 knockin mice
Attachments: A Mouse Model of SARS-CoV-2 Infection and Pathogenesis _ Elsevier Enhanced Reader.html

Matt:

(b) (5)

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409


E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

JavaScript needs to be enabled for this application to run correctly





(b)(5) - PCP



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 20 Jun 2020 21:40:28 +0000
To: Birx, Deborah L. EOP/NSC
Subject: my concern
Attachments: Convalescent Plasma study - selected slides.pptx

Deb:

(b) (5)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any

other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 21 Jun 2020 17:48:34 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: my concern

(b) (5)

From: Birx, Deborah L. EOP/NSC (b) (6)>
Sent: Sunday, June 21, 2020 1:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: my concern

I understand your point but I think

(b) (5)

(b) (5)

Happy to discuss.

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Date: Sunday, June 21, 2020 at 12:58 PM
To: "Birx, Deborah L. EOP/NSC" <(b) (6)>
Subject: FW: my concern

Deb:

(b) (5)

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sunday, June 21, 2020 7:33 AM
To: Birx, Deborah L. EOP/NSC <(b) (6)>
Subject: RE: my concern

Cliff:

(b) (5)

Tony

From: Birx, Deborah L. EOP/NSC [REDACTED] (b) (6)
Sent: Sunday, June 21, 2020 6:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: my concern

Thank you Tony. This is the way I look at it. [REDACTED] (b) (5)

(b) (5)

From: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Date: Saturday, June 20, 2020 at 5:40 PM
To: "Birx, Deborah L. EOP/NSC" [REDACTED] (b) (6)>
Subject: my concern

Deb:

(b) (5)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 21 Jun 2020 18:40:06 +0000
To: Miller, Katie R. EOP/OVP
Cc: Miller, Stephen EOP/WHO
Subject: FW: CIDRAP: Chinese study: Antibodies in COVID-19 patients fade quickly

Katie:

As per our discussion

(b) (6)

(b) (6)


Best regards,
Tony

Chinese study: Antibodies in COVID-19 patients fade quickly

Robert Roos | News Writer | CIDRAP News

|

Jun 19, 2020



wildpixel / iStock

A new [study](#) from China showed that antibodies faded quickly in both asymptomatic and symptomatic COVID-19 patients during convalescence, raising questions about whether the illness leads to any lasting immunity to the virus afterward.

The study, which focused on 37 asymptomatic and 37 symptomatic patients, showed that more than 90% of both groups showed steep declines in levels of SARS-COV-2–specific immunoglobulin G (IgG) antibodies within 2 to 3 months after onset of infection, according to a report published yesterday in *Nature Medicine*. Further, 40% of the asymptomatic group tested negative for IgG antibodies 8 weeks after they were released from isolation.

The authors said the findings suggest that it could be risky to assume that recovered patients are immune to reinfection, which may have implications for how long to maintain physical distancing restrictions.

The patients included in the study were among 2,088 people who were tested for COVID-19 because they were close contacts of confirmed patients in China's Wanzhou district. Of those who tested positive, 60 had had no symptoms in the preceding 2 weeks but were hospitalized for isolation. Of those, 23 people who had mild symptoms on admission or soon afterward were excluded from the study, leaving 37.

For a control group, the investigators identified 37 mildly symptomatic COVID-19 patients matched with the asymptomatic group by age, sex, and comorbidity. For additional comparisons, they also selected 37 sex- and age-matched persons who tested negative. The median age of asymptomatic patients was 41, and 22 were female.

Antibody levels dropped 70%

Among the main findings was that IgG levels in 93% (28/30) of the asymptomatic group and 97% (30/31) of the symptomatic group declined greatly during the early convalescent phase (by 8 weeks after release from the hospital). Antibody levels dropped by 71.1% in asymptomatic patients and 76.2% in the symptomatic group.

"Moreover, 40.0% (12/30) of asymptomatic individuals, but only 12.9% (4/31) of symptomatic individuals, became seronegative for IgG" during that time, the report says.

The researchers also found declines in specific neutralizing antibodies (antibodies that can neutralize a pathogen on their own, without help from other elements of the immune system), but the declines were not nearly as large as with IgG.

Decreases in the neutralizing antibodies were seen in 81% (30/37) of the asymptomatic group and 62% (23/37) of the symptomatic group. The median decreases in antibody level were 8.3% in the asymptomatic group and 11.7% in the symptomatic patients.

The report also notes that IgG levels were significantly higher in the symptomatic patients than the asymptomatic ones in both the acute and convalescent phases of infection.

Longer shedding in asymptomatic group

In other findings, the researchers said the asymptomatic patients shed the virus significantly longer than the symptomatic patients—a median of 19 days versus 14 days. But they cautioned that detectable viral shedding does not necessarily mean that the viral particles shed were infectious.

The investigators also measured the levels of a number of cytokines and chemokines in the patients and concluded that "the asymptomatic individuals had a reduced inflammatory response characterized by low circulating concentrations of cytokines and chemokines."

The authors observe that their findings contrast with what's known about the duration of antibodies to two other key coronaviruses, SARS-CoV, which causes severe acute respiratory syndrome (SARS) and MERS-CoV (Middle East respiratory syndrome coronavirus). Previous findings indicate that antibodies to those viruses last at least a year and often longer, they said.

In combination with certain previous findings on COVID-19 antibodies, the researchers concluded that their results "might indicate the risks of using COVID-19 'immunity passports' and support the prolongation of public health interventions, including social distancing, hygiene, isolation of high-risk groups and widespread testing."

The study did not address cellular immunity to COVID-19—that is, immune responses involving T-cells rather than antibodies. Some previous [studies](#) have found SARS-CoV-specific T-cells in high percentages of convalescent COVID-19 patients.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 23 Jun 2020 13:14:50 +0000
To: Troye, Olivia EOP/NSC; Birx, Deborah L. EOP/NSC
Subject: RE: Memo from DOD for your review
Attachments: SD ROM revised draft - with Fauci edits.docx

Olivia:

Looks fine.

(b) (5)

(b) (5)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Troye, Olivia EOP/NSC (b) (6) >

Sent: Tuesday, June 23, 2020 8:39 AM

To: Birx, Deborah L. EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E]

(b) (6)

Subject: Memo from DOD for your review

Dr. Birx and Dr. Fauci,

DOD sent this over and asked if you both could review it. It would really help them. Attached is the draft memo, (b) (5)

(b) (5)

(b) (5)

(b) (5)

(b) (5)

Thank you,

Olivia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 23 Jun 2020 22:57:25 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Great jobs today - looked long

Thanks. 5 hours and 50 minutes. 😞

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Tuesday, June 23, 2020 6:43 PM
To: Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>; Hahn, Stephen (b) (6)>
Subject: Great jobs today - looked long

Just a tiny bit of encouraging news. NC test pos has been dropping the past few days and now cases are dropping. (b) (5) CA continues to escalate. Sending today's data and the reports going to States tonight. This is our first of these and they will go out before Governor's call each week. Deb

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 24 Jun 2020 23:17:59 +0000
To: Miller, Katie R. EOP/OVP
Subject: RE: Tweet by Patricia Mazzei on Twitter

Thanks. "For the first time..." (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Miller, Katie R. EOP/OVP (b) (6)
Sent: Wednesday, June 24, 2020 7:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Brett Giroir (b) (6); Birx, Deborah L. EOP/NSC <(b) (6)>
Subject: Tweet by Patricia Mazzei on Twitter



Patricia Mazzei

[@PatriciaMazzei](#)



For the first time, Miami-Dade County will send teams to neighborhoods with the highest number of coronavirus cases to educate people about social distancing and masking and distribute hand sanitizer and mask. The county is also providing hotel rooms for people to self-isolate.

6/24/20, 4:52 PM

[Download](#) the Twitter app

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 27 Jun 2020 21:38:34 +0000
To: Birx, Deborah L. EOP/NSC
Cc: (b) (6) Follmann, Dean (NIH/NIAID) [E]
Subject: Pooled testing
Attachments: Pooled Testing - JID in press.pdf

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 29 Jun 2020 17:58:53 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Good to see you.

Yes. We did not hear anything you were saying to the governor in between your speaking with us.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Monday, June 29, 2020 12:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Good to see you.

Making progress. I was on mute right in between?

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 29 Jun 2020 23:54:12 +0000
To: Birx, Deborah L. EOP/NSC
Cc: (b) (6); Follmann, Dean (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pooling of PCR samples for SARS-CoV-2
Attachments: PCR Pooling final.pptx, ATT00001.htm, PCR Pooling Executive Summary.docx, ATT00002.htm

Deb:

Attached is the analysis of the pooling issue by our top statistician/data analysis person, Dean Follmann. I left his contact information below, in case you or your team want to contact him.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Sent: Monday, June 29, 2020 6:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Pooling of PCR samples for SARS-CoV-2

Analysis by Dean Follmann.

Begin forwarded message:

From: "Follmann, Dean (NIH/NIAID) [E]" (b) (6) >
Date: June 29, 2020 at 6:19:13 PM EDT

To: "Lane, Cliff (NIH/NIAID) [E]" (b) (6)

Subject: Pooling of PCR samples for SARS-CoV-2

Hi Cliff,

I've looked at some papers and written up some thoughts (attached). The power point has backup slides which includes an evaluation of the one-stage multiple pool method of Hertz which AMB Birx forwarded.

Happy to engage further as needed.

Best,

Dean

Dean Follmann
Assistant Director for Biostatistics, NIAID
Chief Biostatistics Research Branch
BRB/ DCR
5601 Fishers Lane, Room 4C11
Rockville, MD 20852

For FedEx/UPS use:
Rockville, MD 20852
For US Mail use:
Bethesda, MD 20892
Mail Stop Code: 9820
Phone (b) (6)

From: [Birx, Deborah L. EOP/NSC](#)
To: [Fauci, Anthony \(NIH/NIAID\) \[E\]](#); [Hahn, Stephen](#); [Redfield, Robert R. \(CDC/OD\)](#)
Subject: Today's data - close hold the hottest list
Date: Tuesday, June 30, 2020 8:19:14 AM
Attachments: [Hottest States and Metros.pptx](#)
[30June2020DataSummary.pptx](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 30 Jun 2020 19:32:29 +0000
To: Birx, Deborah L. EOP/NSC
Subject: Final 28-day mortality data from ACTT-1
Attachments: actt1_28_day_mortality_update_30june2020_final3.docx

Deb:

Here are the final 28 day mortality data for the Remdesivir study.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, June 30, 2020 11:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Final 28-day mortality data from ACTT-1

As requested by Dr. Birx.

Cliff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Jul 2020 11:43:01 +0000
To: Birx, Deborah L. EOP/NSC; Adams, Jerome (HHS/OASH)
Cc: McGuffee, Tyler Ann A. EOP/OVP; Redfield, Robert R. (CDC/OD); Short, Marc T. EOP/OVP; Abel, Vadm Daniel (HHS/IOS); Harrison, Brian (HHS/IOS)
Subject: RE: Information for the Surgeon General

Thanks, Jerome. I had not seen this before now.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)>
Sent: Tuesday, July 7, 2020 7:12 AM
To: Adams, Jerome (HHS/OASH) (b) (6)>
Cc: McGuffee, Tyler Ann A. EOP/OVP (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Short, Marc T. EOP/OVP (b) (6)>; Abel, Vadm Daniel (HHS/IOS) (b) (6)>; Harrison, Brian (HHS/IOS) (b) (6)>
Subject: Re: Information for the Surgeon General

This is very helpful. I don't think I got it before

From: "Adams, Jerome (HHS/OASH)" (b) (6)
Date: Tuesday, July 7, 2020 at 6:21 AM
To: "Birx, Deborah L. EOP/NSC" (b) (6)>
Cc: Tyler McGuffee (b) (6), Robert Redfield (b) (6)
"Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>, "Short, Marc T. EOP/OVP" (b) (6)>, "Abel, Vadm Daniel (HHS/IOS)" (b) (6)>,"

"Harrison, Brian (HHS/IOS)" (b) (6)

Subject: Fwd: Information for the Surgeon General

Did you get the response I sent from the Georgia Governor yesterday? Here is an additional one from the Gwinnett health officer.

VADM Jerome Adams
20th US Surgeon General

From: Audrey Arona <(b) (6)>

Date: July 6, 2020 at 6:09:08 PM EDT

To: "Adams, Jerome (HHS/OASH)"

Following our discussion, please see the recommendations, requests, and concerns below. We greatly appreciate the ability to provide feedback and input into this ongoing response.

Recommendations:

- Due to the ever increasing volume of cases, prioritization of investigation needs to be on those that are high risk and/or may impact a congregate setting. We are unable to investigate all cases fully and despite educating cases and contacts about isolation and quarantine, as appropriate, there is no capacity to ensure that these disease control measures are maintained. If efforts were able to be prioritized to control spread in high risk settings in congregate settings (LTCs, jails, schools, shelters, etc.) and among high risk individuals (work in congregate setting, clinical capacity, school etc.), this would ensure a better use of resources.
- Outbreak management should also be prioritized in high risk, congregate settings. Our program is being flooded with business location outbreaks due to the increasing numbers of cases in the general population. We treat and follow these outbreaks similar to our congregate facilities, but this is unsustainable and pulls resources and focus away from those outbreaks in facilities where we will likely see increased morbidity and mortality.
- There needs to be a concerted effort to engage more partners in testing to better handle the astronomical demand.
- We would like to see an effort at the national level to engage labs on how to increase their capacity, lower turnaround time, as well as to improve the process on the back end by "connecting the dots" more in terms of notification of results. Ensuring the systems capturing, transmitting, and storing the electronic data are appropriately linked is important. The process can be clunky and time-consuming.

Requests:

- Please carry the message about prioritization of case and outbreak investigation. See recommendations above. Despite having a steady stream of contact tracers that are being hired to assist with investigation and disease control, they are all inexperienced

and do not recognize the nuances of investigations and what situations may result in a significant risk (i.e. a nurse in a long term care, a judge, a county commissioner, a volunteer at a shelter, etc.). This level of inexperience can result in catastrophic issues from a political standpoint. In addition, most experienced Epidemiologists are spending their time trying to manage and lead hordes of inexperienced staff conducting the investigations and contact tracing.

- Please also help to develop a nationwide education campaign for individual that are contacts to a case. We would like to educate individuals that getting a test immediately following the exposure is not recommended. All contacts are recommended to quarantine for 14 days after their last exposure to the case, monitor themselves for signs and symptoms of COVID-19, wear a surgical mask (not a cloth face covering), and schedule testing around day 10 of their quarantine period. Individuals are flooding in to get tested immediately following their exposure and when they test negative, they feel that they don't need to comply with quarantine requirements. Educating them to test later in their quarantine period will give a more accurate assessment of their true disease status and reduce unnecessary testing. This will free up resources (staffing, testing supplies, etc.) to prioritize those that truly need testing.
- If Public Health is tasked to continue the aggressive testing efforts, we suggest that you consider extending National Guard presence to prioritize testing and cleaning in congregate facilities. While the Public Health infrastructure is impacted by the National Guard response (required to provide all test results and conduct all disease follow-up and mitigation), the National Guard's presence does increase testing capacity, specifically for those facilities that have no internal ability to test staff and residents. It is incredibly important, however, that effective communication occur between National Guard and Public Health so that staffing resources can be allocated as appropriate to manage all after-testing functionality. Alternatively, consider deploying Federal Teams to conduct targeted testing events, ensuring, however, that included in the their plan is the ability to provide all test results and allow for prompt communication and reporting to Public Health.

Concerns:

- This response is unsustainable, from a testing capacity, from a disease investigation and control functionality, and ever increasing from an outbreak capacity. We should be following a sustainable model such as how we respond to flu: monitor ILI, investigate outbreaks (specifically in congregate facilities), and communicate general community based recommendations on what to do when you are ill and if you have been a contact. We need to begin to return to a manageable approach where Public Health fills the gaps and focuses efforts on protecting our most vulnerable populations.
- The strain that this is placing on our Public Health workforce is significant. Many staff have been working 6 and 7 days a week since late February/early March. If we burn out our

workforce continuing to respond in an unsustainable way, we will have significant issues when we move to the next phase of this response, or we have the next response.

- At what point do we say that this disease is here and it becomes a normal infection that we respond to as we respond to all of the other Notifiable Diseases, again, focusing our efforts for the most impact for the community and realistic to the resources we have available.
- In order for PH to be effective, we should be filling in the gaps for those that are most vulnerable, but we are often tasked with doing everything for everybody. This puts undue pressure and exceedingly long work hours on PH departments which may risk losing key staff. This could put a vaccination campaign and handling all other PH threats (which continue unabated) in serious jeopardy

Gwinnett, Newton, and Rockdale County Health Departments

Like us on Facebook: <https://protect2.fireeye.com/url?k=5cfdb93a-00a8b0ea-5cfd8805-0cc47a6a52de-0549945a783a75a3&u=http://www.facebook.com/GNRHD>

Follow us on Twitter: [www.twitter.com/GNRHealth](https://twitter.com/GNRHealth)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Jul 2020 14:10:42 +0000
To: Birx, Deborah L. EOP/NSC; Hahn, Stephen; Redfield, Robert R. (CDC/OD)
Cc: (b) (6); McGuffee, Tyler Ann A. EOP/OVP
Subject: RE: closehold

Deb:

Thanks for sending this. Nice job!

(b) (5)

(b) (5)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Tuesday, July 7, 2020 6:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Hahn, Stephen (b) (6)
Redfield, Robert R. (CDC/OD) (b) (6)
Cc: (b) (6) <(b) (6)>; McGuffee, Tyler Ann A. EOP/OVP
(b) (6) >
Subject: closehold

All edits welcomed – for WH website. Would like to get this done this week.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Jul 2020 17:23:44 +0000
To: Birx, Deborah L. EOP/NSC; (b) (6); Hahn, Stephen; Redfield, Robert R. (CDC/OD)
Subject: RE: closehold

Looks good.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Tuesday, July 7, 2020 10:50 AM
To: (b) (6); (b) (6); Hahn, Stephen (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: closehold

Newest version – I think I have all your comments – please review once more. (b) (5)
– if yes happy to link. Deb

From: (b) (6) (b) (6)>
Date: Tuesday, July 7, 2020 at 10:34 AM
To: "Birx, Deborah L. EOP/NSC" <(b) (6)>
Subject: Re: closehold

(b) (5)

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Tuesday, July 7, 2020 10:12 AM
To: Redfield, Robert R. (CDC/OD) (b) (6); Hahn, Stephen (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6) (b) (6); McGuffee, Tyler Ann A. EOP/OVP

(b) (6)>

Subject: Re: closehold

(b) (5)

From: Robert Redfield (b) (6)>

Date: Tuesday, July 7, 2020 at 10:11 AM

To: "Hahn, Stephen" (b) (6), "Birx, Deborah L. EOP/NSC"

(b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6),

Robert Redfield (b) (6)>

Cc: (b) (6) (b) (6)>, Tyler McGuffee

(b) (6)>

Subject: RE: closehold

Here are my edits and comments – I had my assistant's computer do the edits. I agree with Steve on the

(b) (5).

Thanks all

From: Hahn, Stephen (b) (6)>

Sent: Tuesday, July 7, 2020 8:36 AM

To: Birx, Deborah L. EOP/NSC (b) (6); Fauci, Anthony (NIH/NIAID) [E]

(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)

Cc: (b) (6) (b) (6)>; McGuffee, Tyler Ann A. EOP/OVP

(b) (6)

Subject: Re: closehold

(b) (5). My comments are attached. Really well done.

steve

From: Debi Birx <(b) (6)>

Date: Tuesday, July 7, 2020 at 4:20 AM

To: Tony Fauci (b) (6)>, Stephen Hahn (b) (6)>, Robert Redfield

(b) (6)

Cc: (b) (6) (b) (6)>, Tyler McGuffee

(b) (6)

Subject: closehold

All edits welcomed – for WH website. Would like to get this done this week.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Jul 2020 17:16:13 +0000
To: Birx, Deborah L. EOP/NSC; Farah, Alyssa A. EOP/WHO
Subject: RE: messaging around COVID

Alyssa:

Thanks for the note.

(b) (5)

(b) (5)

(b) (5). Again, thanks

for your note. I do appreciate it.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6) >

Sent: Thursday, July 9, 2020 12:47 PM

To: Farah, Alyssa A. EOP/WHO (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]

(b) (6)

Subject: Re: messaging around COVID

Incredibly helpful

From: "Farah, Alyssa A. EOP/WHO" (b) (6) >

Date: Thursday, July 9, 2020 at 12:17 PM

To: "Birx, Deborah L. EOP/NSC" (b) (6) >, "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Subject: messaging around COVID

Dr. Birx & Dr. Fauci –

(b) (5)

(b) (5)

You both are heroes and doing incredible work. Let me know how I can help.

Alyssa Farah

Assistant to the President

Director of Strategic Communications

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Jul 2020 18:25:35 +0000
To: Debi Birx
Cc: Redfield, Robert R. (CDC/OD); Stephen Hahn (b) (6)
Subject: FW: Mortality and Remdesivir in ACTT-1
Attachments: actt1_28_day_mortality_update_30june2020_final3_LD.docx

Deb:

(b) (5)



I hope this clarifies what I meant today at the Task Force meeting. Again, sorry for any confusion.

Thanks,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)
National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Jul 2020 19:38:43 +0000
To: Birx, Deborah L. EOP/NSC
Bcc: (b) (6)
Subject: RE: Mortality and Remdesivir in ACTT-1

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)
Sent: Friday, July 10, 2020 2:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Mortality and Remdesivir in ACTT-1

(b) (5)

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Friday, July 10, 2020 at 2:25 PM
To: "Birx, Deborah L. EOP/NSC" <(b) (6)>
Cc: Robert Redfield (b) (6), Stephen Hahn <(b) (6)> Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: FW: Mortality and Remdesivir in ACTT-1

Deb:

I hope this clarifies what I meant today at the Task Force meeting. Again, sorry for any confusion.

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Jul 2020 19:40:14 +0000
To: Debi Birx; Redfield, Robert R. (CDC/OD)
Cc: [REDACTED] (b) (6)
Bcc: [REDACTED] (b) (6); Rick Klausner
Subject: Rockefeller Foundation

Deb/Bob:

(b) (5)

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

[REDACTED] (b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: [REDACTED] (b) (6)

FAX: (301) 496-4409

E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Jul 2020 19:23:04 +0000
To: Hahn, Stephen; Redfield, Robert R. (CDC/OD); Debi Birx
Subject: RE: Interesting observational data BCG vaccination and risk of COVID-19

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6) >
Sent: Saturday, July 11, 2020 11:09 AM
To: Redfield, Robert R. (CDC/OD) (b) (6); Debi Birx <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Interesting observational data BCG vaccination and risk of COVID-19

Morning colleagues,
What are your thoughts about this?

<https://www.dailymail.co.uk/sciencetech/article-8509655/BCG-DOES-protect-against-Covid-19-study-confirms.html>

Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Jul 2020 01:01:08 +0000
To: Redfield, Robert R. (CDC/OD); Birx, Deborah L. EOP/NSC; Hahn, Stephen
Subject: RE: Texas example

Very well done!

From: Redfield, Robert R. (CDC/OD) (b) (6) >
Sent: Sunday, July 12, 2020 8:38 PM
To: Birx, Deborah L. EOP/NSC (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >; Hahn, Stephen (b) (6)
Subject: Re: Texas example

Great job

Get [Outlook for iOS](#)

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Sunday, July 12, 2020 7:01:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD)
(b) (6); Hahn, Stephen (b) (6) >
Subject: Texas example

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Jul 2020 02:12:54 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Can you give my report tomorrow in TF

Sure. No problem. Happy to help. Any particular item you want me to emphasize?

-----Original Message-----

From: Birx, Deborah L. EOP/NSC <(b) (6)>
Sent: Tuesday, July 14, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Can you give my report tomorrow in TF

I will send TPs. I will be on flight to AL to MS.

Sent from my iPhone